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Abstract
Glucocorticoids are steroid hormones that exert profound effects on virtually all
tissues. The principal determinant of cellular sensitivity to glucocorticoids is the
level of glucocorticoid receptor (GR). Despite near-ubiquitous expression, GR levels
vary widely between tissues. A complete lack of GR is lethal at birth and even mild
dysregulation has significant pathophysiological consequences. The rat GR gene
includes a complex 5' promoter region encoding at least eleven untranslated alternate
exons 1, eight of which lie in a ~3kb CpG island region close to exon 2. The subject
for this investigation has been the association between the alternate exons 1 of the
GR promoter and the tissue-specific, constitutive and auto-regulation of GR.
Cell-specific alternate exon 1 expression was analysed by RT-PCR in various rodent
cell lines. All 'CpG island' exons 1 examined (I4, I5, 16, I7, 110 andln) were
expressed in all cell lines tested, while expression of exon 11, which lies outside the
CpG island region, ~30.2kb upstream of exon 2, was restricted to cells of the
immune system. Promoter activity was analysed by transient transfection in B103
(rat neural), C6 (rat glioma) and H4IIE (rat liver) cell lines, using constructs forming
both a 3' and 5' deletion series of the CpG island region fused to a luciferase reporter
gene. 'P2' contains the entire promoter and was the most active construct in all cell
lines tested. Transfections using the 3' deletion series, which assesses individual
exon 1-associated promoter activity, demonstrated that only 'PI7' showed high
tissue-specific activity restricted to the neural cell lines B103 and C6. Further
transfections with constructs based on Pl7 identified a 134bp region required for high
promoter activity in neural cells, which was orientation-specific and did not show
properties associated with a classical enhancer. This directionality was mirrored in
DNasel protection studies in which a footprint was identified on only one strand of
the 134bp fragment. While gel mobility shift assays showed evidence of Spl binding
over the region, the physiological significance of this remains unclear. It may be the
case that this fragment represents a region at which directional transcription is
initiated. Transfections in B103 cells using the 5' deletion series identified two
regions important for high promoter activity. Further analysis showed that the
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activity of these regions was position-dependent within the context of the whole
promoter. It appears, therefore, that alternate GR exons 1 are not associated with
individual promoters that are selectively regulated in different cell types. Rather,
tissue-specific levels of GR arise through a complex arrangement of interacting
regulatory elements over the whole promoter region.
The role of individual exon 1 splice donor sites was investigated by site-directed
mutagenesis of splice donor sites at exons U, lio and In within P2. Following
transient transfection in B103 cells, none of the mutant constructs showed a loss in
promoter activity relative to intact P2. RT-PCR identified longer transcripts
associated with the mutant exons, reflecting the use of downstream 'cryptic' splice
donor sites. There appears to be redundancy between alternate exons 1, which can
therefore be seen to form a robust promoter mechanism that ensures constitutive GR
expression. DNasel hypersensitive site mapping in H4IIE cells showed that a ~3kb
fragment, encompassing the entire CpG island region, is bounded by hypersensitive
sites and shows general sensitivity to nuclease digestion, consistent with an extended
region of transcriptionally active chromatin.
The role of individual exons 1 in the autoregulation of GR was investigated by
transient transfection of the 3' and 5' deletion series of the GR promoter into B103
cells treated with the synthetic glucocorticoid, dexamethasone. Results showed that
the mechanism of autoregulation does not operate selectively on individual exons 1,
but instead down-regulates the transcriptional activity of the whole GR CpG island
region.
Results were therefore consistent with a model of GR transcriptional regulation in
which exons 1 are not associated with individual promoters that are selectively
regulated by tissue-specific or auto-regulatory signals; rather, regulation occurs
through position-dependent interactions of elements arranged over the whole CpG
island promoter 'region'. However, while selection of alternate exon 1 transcription
initiation sites may not be of primary importance to the tissue-specific or auto¬
regulation of GR, the multiple exon 1 structure does ensure that promoter activity is
18





Glucocorticoids are steroid hormones that are secreted by the adrenal glands and are
known to regulate a large and varied range of physiological processes. They are
principally involved in restoring physiological homeostasis after stress, but also play
key roles in intermediary metabolism, development, central nervous system function
and the immune response. Dysregulation of circulating glucocorticoid levels is
associated with a number ofpathologies, most notably Addison's disease and
Cushing's syndrome. In cases of the former, primary adrenal insufficiency leads to
deficient glucocorticoid production which is characterised by weakness, fatigue,
weight loss and gastrointestinal complaints (Orth et al., 1992). In the latter, excessive
glucocorticoid secretion causes a range of symptoms including central obesity,
muscle atrophy, hypertension, diabetes, osteoporosis, depression and memory loss
(Orth et ah, 1992).
Glucocorticoids, like all steroid hormones, exert their effects on target cells by
interacting with intracellular receptor proteins. Two types of receptors are known to
bind to glucocorticoids; the mineralocorticoid receptor (MR), which binds ligand
with high affinity and the glucocorticoid receptor (GR), which binds with lower
affinity (Orth et ah, 1992). Both receptors are members of the ligand-activated
transcription factor super-family and therefore regulate a large number of target
genes by a variety of mechanisms (reviewed in Beato et al., 1996).
Obviously, the involvement of glucocorticoids in such a large and diverse array of
physiological processes means that regulation of their actions must be both tight and
complex. The following chapter therefore describes how glucocorticoid action is
regulated, with particular emphasis on the role of the glucocorticoid receptor.
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1.1.1 Glucocorticoid production and secretion
Glucocorticoids are primarily synthesised in the zona fasiculata and zona reticularis
of the adrenal cortex and, like all other steroid hormones, are derived from
cholesterol. The first stage in the biosynthetic pathway of all steroid hormones
involves a rate-limiting step in which the cholesterol side chain is removed by a
dedicated cytochrome P-450 enzyme (P-450Scc) to produce pregnenolone (fig. 1.1).
Subsequent reactions result in the production of two glucocorticoids; Cortisol and
corticosterone. In rodents, corticosterone is the major glucocorticoid due to their lack
of adrenal P-450ci7 enzyme, while Cortisol predominates in humans and other
mammals. Glucocorticoids are not stored by the adrenals, but are released
immediately into the circulation (Orth et ah, 1992).
Glucocorticoid secretion is regulated by hormonal interactions between the
hypothalamus, pituitary and adrenals (the 'HPA axis'), and also by neural and other
stimuli (fig 1.2). Specifically, neural stimuli cause the parvocellular paraventricular
neurons of the hypothalamus to release corticotrophin-releasing hormone (CRH),
arginine vasopressin (AVP) and other peptides into the hypophyseal portal
circulation. These peptides are then delivered to the anterior pituitary, where they
stimulate the production ofpro-opiomelanocortin (POMC), the precursor for
adrenocorticotrophic hormone (ACTH), which is subsequently secreted into the
systemic blood. ACTH acts by binding to specific cell-surface receptors of the
adrenal cortex, where most, ifnot all, of its effects are mediated through cyclic
adenosine monophosphate (cAMP). ACTH exerts an acute effect (occurring within
minutes) on glucocorticoid biosynthesis by increasing the rate at which cholesterol is
converted to pregnenalone by P-450Scc- The chronic effects of ACTH occur over
hours and days and involve increased synthesis of most of the enzymes of the
steroidogenic pathway, as well as more general actions on adrenocortical protein and
RNA synthesis and cell growth (Orth et al., 1992).
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Figure 1.1 Steroid biosynthetic pathways ofCortisol and corticosterone in the
adrenal cortex.
Diagram showing the pathways for Cortisol and corticosterone production and the
structures of these steroids and their biosynthetic precursors. Biosynthetic enzymes









1.1.2 Regulation of glucocorticoid secretion
An endogenous pacemaker, most probably located in the suprachiasmatic nucleus of
the hypothalamus, generates a circadian rhythm in a variety ofphysiological
processes, including HPA axis activity (Orth et ah, 1992). As such, levels of ACTH
and glucocorticoid secretion reach a peak just prior to the daily period of activity
(morning in humans and evening in rats) and decline to their nadir an hour or two
after sleep begins. Most importantly, acute physical or psychological stress activates
the HPA axis, increasing both ACTH and glucocorticoid secretion (Orth et ah, 1992).
However, glucocorticoid secretion is autoregulated via a negative feedback loop that
occurs at both the pituitary and hypothalamic level. In the pituitary, glucocorticoids
inhibit POMC gene transcription and hence ACTH production. In the hypothalamic
paraventricular nuclei, glucocorticoids decrease CRH and AVP mRNA and protein
levels, as well as blocking the stimulatory effect of CRH on POMC expression and
acute ACTH release (Orth et ah, 1992).
The hippocampus has also been implicated in the regulation of HPA axis activity.
Excitatory neurons project from the hippocampus to the lateral bed nucleus of the
stria terminalis (BST), which, in turn, exerts an inhibitory effect on the hypothalamus
(Raber, 1998). However, maintenance of basal HPA activity appears to be mediated
by MR, rather than GR, although under conditions of elevated glucocorticoid
secretion (e.g. after stress or during the circadian peak in glucocorticoid secretion),
GR become progressively occupied (De Kloet et ah, 1998). It appears that GR and
MR have opposing effects on neuronal excitability and hippocampal 'outflow' and
that hippocampal GR activation disinhibits tonic maintenance of HPA axis activity
by MR (De Kloet et ah, 1998). In contrast, the amygdala appears to exert a
stimulatory effect on HPA axis activity, principally through inhibition of outflow
from the BST, but also through the projection of excitatory neurons directly onto the
hypothalamus (Raber, 1998). The involvement of the amygdala in anxiety and fear-
related memory are intrinsically relevant to the stress response; after stress, the
amygdala increases HPA axis activity and fear memory is strengthened (Raber,
1998)
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Figure 1.2 Regulation ofglucocorticoid secretion by the hypothalamic-pituitaiy-
adrenal axis.
Diagram showing the excitatory (represented by arrows) and inhibitory (represented
by blunt arrows) interactions involved in regulation of glucocorticoid secretion by
the hypothalamic-pituitary-adrenal axis. The central nervous system (CNS) is shown
in grey. Physiological structures are represented by boxes. Secreted peptides and

















1.1.3 Modulation of glucocorticoid actions
There are several mechanisms by which the actions of glucocorticoids are
modulated. Firstly, the amount of glucocorticoids secreted by the adrenal gland can
vary according to HPA axis activity (section 1.1.2). Secondly, availability of
circulating glucocorticoids is modulated by the corticosteroid binding globulin
(CBG) protein (Dunn et ah, 1981). In vivo, approximately 90% of circulating
glucocorticoids are bound to CBG, with the majority of the remainder bound to
albumin (Dunn et ah, 1981). While it has been assumed that CBG acts as a 'sink',
there is also evidence indicating that glucocorticoids only enter cells upon
dissociation from CBG (Pardridge, 1987), suggesting that it may be part of a system
designed to deliver glucocorticoids to target cells. For instance, high activity
receptors for CBG have been found on target cell membranes and cleavage of CBG
by a serine protease has been shown to result in release of bound glucocorticoid
(Singer et ah, 1988; Flammond, 1988). After reaching the plasma membrane of
target cells, lipid-soluble glucocorticoids enter cells principally by diffusion,
although it is possible that some active transport may occur (Orth et al., 1992).
Thirdly, the availability of glucocorticoids is modulated by their metabolism and
excretion. In particular, the 11 P-hydroxysteroid dehydrogenase 2 (1 lpHSD2)
enzyme converts active Cortisol (corticosterone in rats) to inactive cortisone (11-
dehydrocorticosterone in rats), while the 11PHSD1 enzyme catalyses the reverse
reaction to generate active glucocorticoids (reviewed in Seckl et al, 2002). In
aldosterone target tissues such as the kidney, MR is co-localised with 11PHSD2,
with evidence showing that the two molecules can physically interact (Odermatt et
al, 2001). In this way, MR, as a high affinity glucocorticoid receptor, is protected
from exposure to high glucocorticoid levels, thus allowing it to bind aldosterone
(Stewart, et al., 1995). In addition, during development, 1 ipHSD2 is widely
expressed in the both the placenta and foetus during early to mid gestation where it
protects the developing foetus from potentially harmful levels of maternal
glucocorticoids (Stewart et al., 1995; Seckl et al, 2002). In contrast, 1 lpHSDl
reactivates inactive glucocorticoids in classical glucocorticoid target tissues such as
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liver, brain and adipose fat (Kotelevtsev et al., 1997; Seckl et al, 2002). Excretion of
glucocorticoids in the urine and faeces occurs following a variety of reduction,
oxidation and hydroxylation reactions (Orth et al., 1992).
1.1.4 Physiological effects of glucocorticoids
1.1.4.1 The stress response
Glucocorticoids affect a variety ofphysiological processes, but perhaps their most
important role is exerted during the stress response. Acute physical or psychological
stress increases HPA activity and consequently glucocorticoid secretion (Orth et al.,
1992). In the short term, the effects of glucocorticoids promote survival in the face of
a stressor by enhancing energy availability and inhibiting non-essential processes
such as inflammation, growth and reproduction (McEwen, 2000). However, the
negative feedback actions of glucocorticoids are vital in restoring homeostasis
following a stressful event (Dallman et al., 1995). This autoregulatory mechanism
prevents the pathologies associated with prolonged exposure to elevated
glucocorticoid levels, which can include myopathy, osteoporosis, hypertension and
diabetes (characteristics of Cushing's syndrome) (McEwen, 2000). In this
homeostatic role, glucocorticoids also act to protect the body from over-reactivity of
the immune system during illness (section 1.1.4.3).
1.1.4.2 Intermediary metabolism
Glucocorticoids derive their name from their role in glucose metabolism, but they
can be seen to regulate virtually all metabolic processes. Following food intake, they
promote energy storage in the form of glycogen by activating glycogen synthase and
inactivating the glycogen-mobilising enzyme glycogen phosphorylase (Orth et al.,
1992). Conversely, glucocorticoids can also increase energy availability during
fasting by directly activating key hepatic gluconeogenic enzymes, such as glucose-6-
phosphatase (Garland et al., 1986) and phosphoenolpyruvate carboxykinase
(PEPCK) (Hanson & Reshef, 1997). They also act to inhibit glucose uptake and
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utilisation in peripheral tissues, in part by direct inhibition of glucose transport into
these cells (Orth et al., 1992). Finally, glucocorticoids are intrinsically involved in
lipid metabolism, where they activate lipolysis in adipose tissue, enhancing free fatty
acid release (Orth et al., 1992; Brindley, 1995).
1.1.4.3 Immune system
Glucocorticoids are known to exert gross effects on thymus size in both developing
and adult animals (Akana et al., 1985). An experiment carried out in 1924 first
showed that adrenalectomy caused significant thymus growth (Jaffe, 1924). More
recent studies in which adrenalectomised rats were given replacement corticosterone
at various concentrations showed that the range of plasma glucocorticoids
compatible with normal thymus mass is very narrow, indicating that thymocytes are
extremely sensitive to the apoptotic effects of glucocorticoids (Akana et al., 1985).
Further work has shown that, at pharmocological levels, glucocorticoids induce
apoptosis in immature thymocytes, but not in mature T cells (Miller et al., 1998).
This apoptotic effect is important in the selection of T cells bearing TCRs that
recognise self antigens with low-to-moderate avidity, rather than those with near-nil
avidity (which would be immunologically useless) or high avidity (which would pose
autoimmune problems). While the mechanism mediating this effect is outside the
scope of this thesis, it has been the subject of several reviews (see Ashwell et al.,
2000 and references therein). However, the effects of glucocorticoids on T cell
development and selection in the thymus has been a matter considerable controversy
since it was reported that transgenic mice in which GR is completely abolished are
born with a normal thymus and normal thymocyte populations (Godfrey et al., 2000;
Godfrey et al., 2001; Purton et al., 2000; Jondal et al., 2001; Pazirandeh et al., 2002).
The clinical significance of glucocorticoids lies in their role as powerful
immunosuppressors and, as such, they are among the most widely prescribed drugs
in the world. One of the principal effects of glucocorticoids is on the traffic of
immune cells to and from peripheral circulation. In particular, glucocorticoids are
associated with depletion of peripheral lymphocytes, with a greater reduction
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observed in T cells than B cells. Peripheral levels of both monocytes and neutrophils
are also reduced, leading to suppression of local inflammatory responses (reviewed
in McEwen et al., 1997). Most importantly, glucocorticoids inhibit the actions of
both nuclear factor kappa B (NF-kB) and AP-1, transcription factors that play key
pro-immflammatory roles in both B- and T-cells (Elenkov & Chrousos, 1999; Barnes
& Adcock, 1998). NF-kB induces the expression of a wide range of cytokines and
chemokines, including IL-1, IL-2, IL-6, TNFa, (3- and y-interferons, as well as TCRs
a and p (reviewed in McKay & Cidlowski, 1999) while API is known to induce
genes involved in inflammatory diseases such as asthma (Barnes & Adcock, 1998).
The mechanisms behind the inhibitory actions of glucocorticoids on both NF-kB and
AP-1 remain, to a large extent, unresolved. Flowever, the transrepression mechanism
is mediated by GR, and has been postulated to involve direct interactions with NF-
kB and AP-1, effects on I-kB or through the recruitment of co-activators (discussed
in further detail in section 1.2.1.5).
1.1.4.4. Developmental effects
While glucocorticoids are known to promote the development ofmany tissues, one
of their most critical functions involves lung maturation, in which they induce
morphological changes and surfactant production in type II pneumocytes (Orth et al.,
1992). In fact, transgenic mice in which GR is completely abolished die within a few
minutes ofbirth due to atalectasis of the lungs (Tronche et al., 1998) (see section
1.2.2.2). The mechanisms by which glucocorticoids induce lung maturation remain
obscure. Initial evidence suggested that glucocorticoid-induced effects on lipid
metabolism caused the release ofphosphatidyl and fatty acids which, in turn,
activated a key enzyme in surfactant synthesis, cholinephosphate cytidyltransferase
(Mallampalli et al., 1994). However, more recent studies in GR knock out mice have
indicated that deficient surfactant production is not the cause of their lethal
phenotype (Kellendonk et al., 1999).
In the nervous system glucocorticoids regulate the differentiation of neural crest
epithelial cells into chromaffin cells (Anderson et al., 1993). Under the influence of
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glucocorticoids, neural crest precursor cells invade the embryonic adrenal gland and
cease to express neuron-specific gene products such as neurofilaments and instead
acquire the characteristics of adrenomedullary chromaffin cells (Anderson, 1993).
The most notable of these characteristics is the ability of differentiated chromaffin
cells to synthesise phenylethanolamine-N-methyl transferase (PNMT), the enzyme
that converts noradrenaline to adrenaline (Anderson et al., 1993). This model was
supported by initial analysis of GR-deficient mice in which GR appeared to be
necessary for the formation of adrenal chromaffin cells (Cole et ah, 1995). However,
subsequent investigations showed that mice carrying targeted GR mutations
possessed normal chromaffin cell numbers, but were unable to produce PNMT
(Finotto et ah, 1999).
1.1.4.5 Neuropsychiatric and behavioural effects
Most brain regions, including the cerebellum, amygdala, cortex, thalamus and
hypothalamus, express GR and are therefore sensitive to glucocorticoids (Herman et
ah, 1989). However, the highest levels of GR expression are seen in the
hippocampus, where the lack of 11PHSD2 means that hippocampal MRs also
effectively function as glucocorticoid receptors (Arriza et ah, 1988; De Kloet et ah,
1998). The hippocampus plays key roles in memory, mood and behaviour, all of
which are affected by local glucocorticoid exposure (Lupien & McEwen, 1997). For
instance, while low levels of glucocorticoids (sufficient to activate MR but not GR)
have been shown to enhance memory (De Kloet et ah, 1998), stress-induced
elevation of glucocorticoids and GR agonists appears to attenuate memory (Seckl &
Olsson, 1995). In addition, patients with major depressive disorders tend to
hypersecrete Cortisol and normalisation of HPA axis activity through anti-depressant
treatment has been shown to significantly improve outcome (Seckl & Olsson, 1995).
The involvement of the amygdala in behavioural responses to fear and anxiety are
mediated, at least in part, by CRH, which is secreted by both the amygdala itself and
the hypothalamus (Raber, 1998). Glucocorticoids increase CRH expression in the
amygdala thereby enhancing anxiety (Hsu et ah, 1998), while adrenalectomy
decreases CRH expression (Palkovits et ah, 1998).
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1.2The Glucocorticoid Receptor
The physiological effects of glucocorticoids and indeed, the negative feedback loop
that regulates their secretion are all mediated by GR. As such, both the mechanism
and regulation of GR action are crucial in determining cellular responses to
circulating glucocorticoids.
In virtually all species examined to date, only a single GR gene has been identified.
In the human, the GR gene is located on chromosome 5 (Gehring et al., 1985) and
consists of nine exons (fig 1.3) spread over ~124kb of DNA (Encio & Detera-
Wadleigh, 1991). All ligand activated transcription factors, including GR, possess a
modular structure consisting of a ligand-binding domain (LBD), a DNA-binding
domain (DBD) and one or more activation domains (reviewed in Beato et ah, 1995).
These functional domains are transposed onto the genomic structure of the GR locus.
Exon 1 and the first part of exon 2 contain the 5'-leader sequence, exon 2 encodes
the amino-terminal portion, exons 3 and 4 separately encode the two putative zinc
fingers that form the DBD, and exons 5-9 combine to form the LBD (Encio &
Detera-Wadleigh, 1991). Studies in mouse (Strahle et ah, 1992) and rat (Gearing et
ah, 1993), as well as over a dozen species including several non-human primates,
guinea pig, African frog, rainbow trout, flounder, chicken, sheep, pig and others (see
http://nrr.georgetown.edu/GRR/GRR.html and references therein), have shown that
this structure is highly conserved across species.
1.2.1 Mechanism of GR action
1.2.1.1 Ligand binding and dissociation from heat shock proteins
In the absence of ligand, GR forms a large heteromeric complex with several other
proteins, from which it dissociates upon ligand binding (reviewed in Pratt & Toft,
1997). One of the most important components of this complex is hsp90, which
associates with the LBD and keeps the receptor in a conformation that is able to bind
steroid but is transcriptionally inactive (Cadepond et al., 1991). Studies have also
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identified factors including p23, p60, hsp40, hsp70, as well as immunophilins such as
hsp56, in the stable GR-hsp90 heterocomplex (reviewed in Schaaf & Cidlowski,
2003).
The crystal structure of the human GR ligand binding domain (LBD) bound to
dexamethasone and a coactivator motif derived from the transcriptional intermediary
factor 2 has been elucidated (Bledsoe et ah, 2002). Despite structural similarity to
other steroid receptors, the GR LBD adopts a surprising dimer configuration
involving formation of an intermolecular beta sheet (Bledsoe et ah, 2002). The
structure also reveals an additional charge clamp that determines the binding
selectivity of a coactivator and a distinct ligand binding pocket that explains the
selectivity of GR for endogenous steroid hormones (Bledsoe et ah, 2002). The
functional importance of the LBD structure has been demonstrated by studies in
which mutation of single amino acid residues induce both decreases and increases in
binding affinity, as well as changing the specificity for different ligands (Hurley et
ah, 1991) (see Schaaf & Cidlowski, 2003 and references therein). Similarly, clinical
studies have shown that patients carrying mutations in the GR LBD exhibit marked
symptoms of glucocorticoid resistance (table 1.1)
Polymorphism Manifestation Reference
A D641V (LBD) Familial glucocorticoid resistance (Karl & Chrousos, 1993)
B 4bp deletion at
exon/intron 6
splice site (LBD)
Glucocorticoid resistance (Karl et ah, 1993)
C L753F (LBD) Glucocorticoid resistance; human
leukaemic CCRF-CEM cells
(Powers et ah, 1993)
(Palmer & Harmon, 1991)
F D559I, V729I
(LBD)
Familial glucocorticoid resistance (Hurley et ah, 1991)
Table 1.1 Summary ofGR polymorphisms in the LBD
Single amino acid nomenclature; D, aspartic acid; V, valine; L, leucine; F,
phenylalanine; I, isoleucine. Adapted from (Yudt & Cidlowski, 2002).
The relationship between the GR LBD structure and glucocorticoid-resistance is
further exemplified by the guinea-pig. The guinea-pig is a well-documented cortico-
resistant species, a characteristic that is caused by differences within the amino-
terminal portion of the GR LBD (Keightley et ah, 1998). However, it should be
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noted that the GR LBD has not been implicated in the glucocorticoid-resistance
exhibited by several New World primates, including the squirrel monkey and the
marmoset (Brandon et ah, 1995). In these species, resistance has been linked to a
cytosolic factor that somehow reduces sensitivity to circulating glucocorticoids
(Brandon et al., 1995).
1.2.1.2 Phosphorylation and nuclear translocation
GR is phosphorylated in the absence of hormone and becomes hyperphosphorylated
after binding of an agonist, but not an antagonist (Orti et al., 1989) (see section
1.2.2.1.3). The phosphorylated GR subsequently translocates to the nucleus.
However, receptor phosphorylation is not necessary for nuclear translocation since
results show that a mouse GR lacking all phosphorylation sites still undergoes
nuclear translocation upon ligand activation (Webster et al., 1997). Two domains of
GR have been implicated in nuclear translocation; the first (NL1) is located in the C-
terminal portion of the DBD and is 100% conserved between human and rat; the
exact location of the second (NL2) is unknown, although it has been mapped to the
LBD (Picard & Yamamoto, 1987).
1.2.1.3 Dimerisation and DNA binding
The effects of GR on gene transcription are mediated in most cases through binding
to specific DNA sequences that form glucocorticoid response elements (GREs)
(Beato et al., 1989). This interaction was originally thought to be dependent upon the
GR DNA binding domain (DBD), which consists of two protein loops co-ordinated
by a zinc ion, resulting in two zinc fingers that are each followed by an amphipathic
helix (Luisi et al., 1991). Under the traditional model, a GRE, comprised of a
partially/completely palindromic pair of DNA 'half-sites', binds GR as an obligate
homodimer (Luisi et al., 1991). This appears to occur through initial binding of a GR
monomer to the higher-affinity half-site, followed by co-operative binding of a
second monomer, which is stabilised by protein-protein interactions through a
'dimerisation interface' within the second zinc finger of the DBD (Dahlman-Wright
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et al., 1991). Further stability is achieved when GREs are multimerised, which
probably provides the basis for the transcriptional synergy observed in GR (Strahle et
al., 1988; Schmid et al., 1989).
However, very recent work has shown that the model described above does not apply
to a subset of GREs, at which dimerisation appears to be unnecessary (Adams et al.,
2003). The implications of DNA dimerisation deficiency are discussed in more detail
in section 1.2.1.6.
1.2.1.4 Transactivation
Transactivation of target genes has been shown to be dependent upon two domains of
GR; xl and t2 (Hollenberg & Evans, 1988). The first is located in the N-terminal
region of the receptor and its function is hormone-independent, while the second
maps to the LBD and requires hormone binding for optimal activity (Giguere et al.,
1986). The exact mechanism of how binding of GR to a GRE leads to transcription
initiation is unknown, although GR itself is capable of recruiting and stabilising the
transcriptional pre-initiation complex (Freedman, 1999). In addition, GR has been
shown to make contacts with numerous components of the transcriptional machinery
in vitro (Robyr et al., 2000). However, transactivation by GR is also known to be
dependent upon co-activators that facilitate either the recruitment of basal
transcription machinery or the remodelling of chromatin.
Investigation of the mouse mammary tumour virus long terminal repeat (MMTV
LTR), which contains several GREs, has shown that transcriptional activation by GR
requires DNA binding, disruption of local chromatin structure and assembly of the
initiation complex at a TATA box (Hebbar & Archer, 2003). The GR homodimer
recognises adjacent major grooves on only one face of the DNA and, as such, GR
binding to nucleosomal DNA is less affected by steric hindrance that other
transcription factors (Deroo & Archer, 2001). GR has been shown to associate with
BRG-1, a key component of the BRG-1/BAF complex (homologous to the yeast
SWFSNF complex) that acts as an ATP-dependent chromatin-remodelling machine
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(Fryer & Archer, 1998). BRG-1 removes histone HI from the chromatin, thus
allowing general transcription factors, including nuclear factor (NF)-1 and TBP, to
access their binding sites (Fryer & Archer, 1998).
Interestingly, the interaction between GR and the MMTV LTR locus is consistent
with a dynamic model ('hit and run'), in which GR first binds to the chromatin after
ligand activation, recruits remodelling activity and is then lost from the template
(Hager et al., 2000) (McNally et al., 2000). However, studies in which GR induces
the formation of nuclease-sensitive chromatin at an enhancer of the rat tyrosine
aminotransferase (TAT) gene show that ongoing enhancer activity requires continued
interaction between GR and its agonist (Reik et al., 1991). However, while chromatin
remodelling appears to be reversible after hormone withdrawal, more recent work
has shown that GR-induced DNA demethylation at the enhancer provides a
'memory' of a glucocorticoid regulatory event during development (Thomassin et
al., 2001).
1.2.1.5 Transrepression
In addition to its role as an activator of transcription, GR can also repress the
expression of specific target genes by at least three putative mechanisms. Firstly, it
can bind to DNA sequences called negative GREs (nGREs), which are present in the
promoters of genes such as osteocalcin and prolactin (see Schaaf & Cidlowski, 2003
and references therein). While the sequences of nGREs are too heterogeneous to
determine a consensus, binding of GR presumably replaces and/or prevents binding
of a transactivation transcription factor (Drouin et al., 1989). Of particular note is the
nGRE in the POMC promoter, on which a complex of three GR molecules induces
transrepression (Drouin et al., 1989). Specifically, a GR homodimer binds to one side
of the element while a GR monomer binds to the other (Drouin et al., 1989).
Secondly, GR can bind to DNA elements consisting of a non-overlapping GRE and a
binding site for a different transcription factor (known as composite GREs). This is
the case for the proliferin promoter, where the composite GRE includes an API
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binding site (Malkovski et al., 1999). Interestingly, GR can enhance or repress AP1-
induced transactivation depending upon cell type and composition of the API dimer
(Pearce & Yamamoto, 1993).
The final mechanism of transrepression occurs without the involvement of DNA
binding by GR. For example, API-induced activation of the collagenase promoter is
inhibited by ligand-activated GR, probably through a protein-protein interaction. The
API binding site is recognised by Jun homodimers and Jun/Fos heterodimers and GR
can interact directly, via its DBD, to both (although Fos appears to be the preferred
target) (Yang-Yen et al., 1990). In this way, API and GR can be seen to reciprocally
antagonise the transactivity of each other (Yang-Yen et al., 1990). In addition,
activated GR has been shown to repress activity of NK-kB, specifically through
direct interaction of its DBD with the p65/RelA subunit (McKay & Cidlowski,
1999). These examples of reciprocal antagonism may well be related to the opposing
effects of AP1/NF-kB and GR upon inflammatory responses (McKay & Cidlowski,
1999). Furthermore, an additional mechanism has been proposed based on the
observation that in some cells, glucocorticoids are known to induce expression of
members of the I-kB family, which sequester NF-kB in the cytoplasm and thus
prevent activation of the NF-kB target genes (Auphan et al., 1995).
1.2.1.6 Protein-protein versus protein-DNA interactions by GR
Elucidation of the DNA binding versus the protein-protein interaction roles of GR
has been investigated using transgenic mice carrying a point mutation in the DBD.
Specifically, (}Rdini/dirn mice were generated in which the D-loop of the second zinc
finger (which forms the dimerisation interface) carried a point mutation, thus
impairing dimerisation and thus binding to DNA targets (Reichardt et al., 1998). The
most striking phenotypic characteristic of GRdim/dirn mice was their survival past
birth, causing the authors of the report to declare that 'DNA binding is not essential
for survival' (Reichardt et al., 1998). These mice showed impaired GR-dependent
activation of transcription, as demonstrated by the lack of responsiveness of TAT
(which carries a GRE) to glucocorticoid exposure (Reichardt et al., 1998). In
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contrast, the glucocorticoid-dependent protein-protein interactions known to repress
AP-1 activity were unaffected (Reichardt et al., 1998). Furthermore, GRdlm/dim mice
revealed that feedback control of the HPA axis is dependent upon both the DNA-
binding and protein-protein actions of GR (Reichardt et ah, 1998). As such, CRF
expression was not-upregulated in transgenic mice, indicating that repression of CRF
synthesis by GR does not require DNA binding, but POMC (the gene encoding
ACTH) expression was strongly increased and is therefore dependent upon GR DNA
binding activity (Reichardt et al., 1998).
However, as mentioned previously (section 1.2.1.3), very recent work has indicated
that the GRdim mutation only abolishes GR binding at a subset, and not all, of GREs
(Adams et al., 2003). Results showed that GR binding and transactivation at
'simple', single GREs, including those found in the promoters of the TAT and
MMTV LTR genes, are indeed dependent upon an intact dimer interface. However,
promoters containing more complex arrangements of GRE consensus half- and
partial- sites, including that of PNMT, can be both bound and activated by GRdim
(Adams et al., 2003). Under this model, the GR-dependent functions that are intact in
GRdim/dim mice depend upon the formation of 'concerted GR multimers' on target
promoters, which interact at complex arrays of GREs and are supported by various
protein-DNA and protein-protein interactions (Adams et al., 2003). It is therefore
conceivable that DNA binding by GR might indeed be essential for survival. Further
transgenic models, in which GR is unable bind to DNA at all, must be developed to
further investigate this intriguing problem.
1.2.2. Regulation of GR action
1.2.2.1 IsoformsofGR
It is evident that GR exerts a complex range of actions on a variety of target genes.
This complexity arises, in part, through diversity of GR isoforms. While until very
recently only a single GR gene had been identified in all species examined, studies in
carried out in a cichlid fish, Haplochromis burtoni, have identified two GR isoforms,
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termed HbGRl and HbGR2, which are encoded by separate genes (Greenwood et al.,
2003). Phylogenetic analysis indicates that the two GR paralogues are unique to fish
and are the result of a gene or genome duplication event (Greenwood et al., 2003).
The difference between the isoforms occurs at the 3'-UTR, which is shorter in
HbGRl than in HbGR2. Interestingly, the transactivation properties of the two
isoforms were shown to differ when tested on a promoter containing three classical
GREs in tandem, with HbGRl eliciting a higher level of reporter gene expression
than HbGR2 (Greenwood et al., 2003). However, in all tissues tested, including
brain, heart, gill, kidney, liver and spleen, levels ofHbGR2 mRNA exceed those of
HbGRl (Greenwood et al., 2003). It is possible that the shortened 3'-UTR of HbGRl
mRNA renders it less stable, which may account for its decreased presence in all
tissues examined. As such, it remains to be seen if the increased transactivation
properties of HbGRl are functionally significant.
1.2.2.1.1 GRa and GRp
When a human GR cDNA was first cloned in 1985, two gene splicing products were
identified and termed hGRa and hGRp (reviewed in Schaaf & Cidlowski, 2003).
Immediately, hGRa was recognised as the classical GR, composed of a single
polypeptide chain of 777 amino acids and the primary mediator of glucocorticoid
action (Hollenberg et al., 1985). hGRp is generated through alternative splicing of
the ninth and final exon (fig 1.3), resulting in a protein sequence divergent only at the
carboxy terminal (Oakley et al., 1996). As such, while hGRa and hGRp are identical
through to amino acid 727, the 15 carboxy-terminal amino acids of hGRp are unique
and replace the carboxy-terminal 50 amino acids in hGRa. In all systems tested to
date, hGRp is transcriptionally inactive and is unable to bind either agonists or
antagonists (Oakley et al., 1996; Yudt & Cidlowski, 2002). Furthermore, unlike
hGRa, the hGRp isoform is located in the nucleus in the absence of ligand (Oakley
et al., 1996; Yudt & Cidlowski, 2002). These features led hGRp to originally be
dismissed as physiologically irrelevant. However, more recent studies have indicated
that the isoform may exert a dominant-negative effect on hGRa-mediateu
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Figure 1.3 Isoforms ofhuman GR.
Diagram (not to scale) showing the exonic structure of human GR and the generation
of various isofonns. Approximate phosphorylation sites are represented by 'P';
'SUMO' and 'U' represent the actions of sumoylation and ubiquitination
respectively. Met, methionine; DBD, DNA binding domain; LBD, ligand binding
domain. Adapted from Yudt & Cidlowski, 2003.
40
5'UTR








Met 1 — 9a
hGRaA
Met 1 — 9(3
hGRpA
41
transactivation (Bamberger et ah, 1995). Studies into the mechanism of this
dominant-negative activity suggest that it is the formation of hGRa/hGRP
heterodimers, incapable of binding co-activators in the same way as ligand activated
hGRa homodimers, that causes the observed attenuated hGRa response (Oakley et
ah, 1999).
Data suggesting a pathophysiological role for hGRp includes the association of
several inflammatory conditions with elevated expression of hGRp in particular cells
(Leung et ah, 1997; Christodoulopoulos et ah, 2000; Honda et ah, 2000). In addition,
a polymorphism in the hGRp 3'UTR, which stabilises the mRNA and increases
hGRp protein levels, has been found in patients suffering from rheumatoid arthritis
(DeRijk et ah, 2002). However, it should be noted that the physiological relevance of
hGRP is still a matter of some controversy. Firstly, transient transfection studies have
suggested that levels of hGRp must be in excess by at least 5-fold relative to hGRa
in order to achieve a significant dominant negative effect, yet all tissues examined
express much higher levels of endogenous hGRa (Oakley et ah, 1997). Secondly,
several groups have been unable to replicate the dominant negative activity of hGRP
(Hecht et ah, 1997; de Lange et ah, 1999). Finally, although the presence of hGRp
has recently been demonstrated in rat (Korn et ah, 1998) no mouse homologue has
been identified (Otto et ah, 1997).
1.2.2.1.2 GR-Aand GR-B
Alternative translation initiation also generates two distinct GR translational
isoforms, termed GR-A and GR-B (Yudt & Cidlowski, 2001) (fig. 1.3). The major
protein product, with an apparent molecular mass of 94kDa, represents translation
from the first initiator AUG codon and is designated GR-A. However, this start
codon lies within a weak Kozak sequence, resulting in leaky ribosomal scanning and
translation from a downstream start codon (met 27 in human or met 28 in rodents),
which generates a 91kDa protein termed GR-B (Yudt & Cidlowski, 2001). Evidence
suggests that the shorter GR-B species is nearly twice as efficient in GRE-mediated
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transactivation as the longer GR-A, although the biological significance of this
finding is still unclear (Yudt & Cidlowski, 2001).
1.2.2.1.3 Post-translational modifications of GR
GR is a substrate for several kinases and phosphatases and is poly-phosphorylated on
serine and threonine residues in the amino-terminal region of the protein (Bodwell et
al., 1991; fig. 1.3). GR phosphorylation appears to be strongly cell-cycle dependent
(Bodwell et al., 1998) and although the precise role of each specific phosphorylation
event remains unclear, mutation ofmultiple phosphorylation sites has been shown to
profoundly affect receptor stability, protein half-life and signalling (Webster et al.,
1997). There is also data suggesting that mouse GR is a target for both post-
translational ubiquitination (which targets the receptor for proteosomal degradation)
and sumoylation (which modulates transcriptional regulation) (reviewed in Yudt &
Cidlowski, 2002) (fig. 1.3).
1.2.2.1.4 Non-genome-active isoforms of GR
A notable paradox of glucocorticoid biology is the rapid release of glucocorticoid
hormone during a stress response (seconds) and the perceived delay (hours) in
eliciting a genomic response consistent with the classical action of steroid and other
nuclear hormone receptors. In recent years, there has been increased interest in
potential non-genomic and/or membrane-associated actions of glucocorticoids and
GR. One hypothesis involves a membrane-bound/associated form of GR, termed
mGR, which is postulated to be a modified form of the classical GR (Gametchu et
al., 1991), although this remains a major point of contention. Interestingly, studies
have shown that mGR is more strongly correlated with GC-evoked lymphocytosis
than the classical GR (Sackey et al., 1997).
Other work has proposed that the non-genomic effects of glucocorticoids are
transduced by the same biochemical effector pathways responsible for mediating
rapid responses to neurotransmitters (Borski, 2000) and implicated second messenger
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cascades involving phospholipase C, phosphoinositide turnover, intracellular pH and
calcium, protein kinase C, and tyrosine kinases (Wehling, 1997). Considerably more
work is required to resolve this paradox, particularly with regard to the proposed
mGR mechanism.
1.2.2.2 Regulation of GR levels
Obviously, the most important regulator of cellular sensitivity to glucocorticoids and
subsequent GR action is the level of GR itself. This has been demonstrated in vitro
using rat hepatoma-derived cell lines expressing different levels of GR (Vanderbilt et
al., 1987). Results showed that the extent of structural chromatin alteration at a
MMTV GRE and the magnitude of several transcriptional responses elicited by the
receptor (including those of TAT and a-1-acidic glycoprotein) are roughly
proportional to the number of GR molecules per cell (Miesfeld et al., 1986;
Vanderbilt et al., 1987).
Furthermore, several groups have developed genetic tools to study GR function in
vivo. Near-ubiquitous expression of a GR antisense mRNA (under the control of a
neurofilament promoter) in mouse tissues caused a 40-60% reduction of GR protein
in vivo and resulted in increased HPA axis activity (Pepin et al., 1995). In addition,
these transgenic animals showed a greatly increased adipose fat deposition (Pepin et
al., 1995). However, this approach is limited due to the fact that gene function is only
partially inactivated and the precise degree of GR loss at a cellular level is difficult to
assess.
Gene targeting approaches have generated two distinct disruptions of the GR gene.
The first involved the insertion of a neomycin cassette into the second GR exon and
resulted in a hypomorphic allele, GRhypo (Cole et al., 1995). The persistence of
mRNA species encoding an amino-terminal truncated protein containing the DBD
and LBD meant that this transgenic model was not a complete GR knock out (Cole et
al., 2001). The second involved a deletion of the third exon (encoding the first zinc
finger of the DBD) and caused complete inactivation of the GR gene, GRnu"
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(Tronche et al., 1998). Both GRhypo/hypo an(j Q^nuii/nuii mjce reportedly show similar
phenotypic changes, although those exhibited in the latter appear to be more severe
(Tronche et ah, 1998). While both types ofmutant mice die shortly after birth due to
atalectasis of the lungs, further changes have also been identified. These include the
impaired induction of gluconeogenic enzymes, the abolishment of T-cell apoptosis
and the reduced proliferation of erythroid progenitor cells (Bauer et al., 1999).
Furthermore, while the HPA axis is not fully functional at birth, GRnull/nu11 mutant
mice showed a significant increase in glucocorticoid (3-fold) and ACTH (15-fold)
levels (Tronche et al., 1998). These increases were due to enhanced transcription of
the CRF and POMC genes in the hypothalamus and anterior lobes of the pituitary
respectively (Cole et al., 1995; Tronche et al., 1998). It appears, therefore, that the
HPA axis is already responsive at birth and that GR levels are important in mediating
transcriptional repression associated with glucocorticoid negative feedback.
To circumvent the early lethality of GRnull/nu11 mice and the associated difficulty in
analysing GR function in adult animals, tissue-specific GR mutant mice were
generated. Conditional mutations of the GR gene were obtained by employing the
Cre/loxP system and have been used to evaluate the role of GR in the nervous system
(Tronche et al., 1999; Kellendonk et al., 2002), liver and thymus of adult animals
(unpublished data). The targeted absence of GR in the nervous system was not lethal,
but the lack of glucocorticoid feedback profoundly altered HPA axis equilibrium
(Tronche et al., 1999). The increased circulating glucocorticoid levels in these
animals caused them to display symptoms associated with Cushing's disease, i.e.
growth retardation, reduced size, osteoporosis and a characteristic 'buffalo hump' fat
deposition (Tronche et al., 1999), although further work showed that fat deposits
decreased after weaning (Kellendonk et al., 2002). Interestingly, these mice also
appear to be less anxious (Tronche et al., 1999; reviewed in Gass, 2001).
While the studies described above investigated the effects of hypomorphic or null
GR expression, the effects of increased GR gene dosage have also been studied.
These investigations involved mice in which a yeast artificial chromosome was used
to generate animals carrying two additional copies of the GR gene. As might be
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expected, these mice show altered basal regulation of the HPA axis, resulting in
reduced expression of CRH and ACTH and a fourfold reduction in circulating
glucocorticoids (Reichardt et al., 2000). These mice showed a weaker response to
restraint stress than wild type controls (Reichardt et al., 2000), possibly due to
increased sensitivity and thus more rapid attenuation of the HPA axis. In addition,
primary thymocytes taken from these transgenic mice showed an enhanced
sensitivity to glucocorticoid-induced apoptosis (Reichardt et al., 2000).
1.2.2.2.1 Homologous down-regulation of GR
Levels of GR are widely recognised to undergo down-regulation after exposure to
glucocorticoids in most cells and tissues (see Burnstein et al., 1991 and references
therein). While this mechanism once again serves to protect the body from over-
reactivity of the glucocorticoid response, this reduction in cellular GR levels also
leads to insensitivity to subsequent hormone administration and, as such, has
important clinical implications. The mechanisms of autoregulation have been studied
extensively both in vitro and in vivo, and, although reports have drawn conflicting
conclusions, results consistently indicate that both GR mRNA and protein levels are
affected.
Nuclear run-on experiments have demonstrated a dexamethasone-induced reduction
in GR transcription rate in H4IIE cells and liver (Dong et al., 1988) as well as in IM-
9 (human B cell), AR42J (rat pancreatic acinar) (Rosewicz et al., 1988) and in
transfected COS-1 (green monkey kidney) cells (Burnstein et al., 1994). The most
obvious explanation for this ligand-induced reduction in transcription would be
repression of the activity of the GR promoter. Indeed, a region of the human GR
promoter, shown to bind the novel transcription factor GRF-1, has been implicated in
down-regulation of a transiently transfected hGR-CAT reporter construct (Govindan
et al., 1991; Leclerc et al., 1991a; Leclerc et al., 1991b). Furthermore, GRF-1 mRNA
was shown to be up-regulated in rat liver following dexamethasone treatment
(Leclerc et al, 1991b), indicating that increased levels of GRF-1 protein bind to the
human GR promoter and consequently repress transcription. However, this result is
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contradicted by several studies showing that homologous down-regulation of GR
mRNA and protein appears to be independent of protein synthesis, since it occurs in
the presence of cylcohexamide (Okret et al., 1986; Burnstein et al., 1994).
Several studies also suggest that repression of GR expression may occur
independently of the GR promoter. Transfection studies in which GR expression
vectors were under the control of either the Rous sarcoma virus (Burnstein et al.,
1991) or human metallothionein-IIa (Alksnis et al., 1991) promoters, also showed a
decrease in GR mRNA after steroid treatment. Therefore, it was suggested that
sequences outside the GR promoter might also be involved in homologous down-
regulation. Accordingly, investigations have shown that GR can bind to both a 2.6kb
fragment of the 3'-UTR of GR cDNA (Okret et al., 1986) and a region encoding
amino acids 550-697 of the ligand binding domain of GR cDNA (Burnstein et al.,
1994). However, these results must be considered with the caveat that cDNA does
not physiologically exist in cells.
With regard to the effect of glucocorticoids on GR mRNA stability, several groups
report no effect in human lymphocytes (Rosewicz et al., 1988) or rat hepatoma cells
(Dong et al., 1988), while others describe a greater than 2-fold increase in GR
mRNA degradation in transfected COS-1 cells (Burnstein et al., 1994). Finally, there
is conflicting evidence on the effect of glucocorticoids on the half-life of the GR
protein; reports describe a marked decrease in rat hepatoma derived cell lines, rat
liver (Dong et al., 1988) and GH1 cells (Mclntyre & Samuels, 1985), while other
groups observed no effect in IM-9 human lymphocytes, rat pancreatic acinar AR42J
cells (Rosewicz et al., 1988) or NIH3T3 cells (Hoeck et al., 1989).
Previous studies have presented conflicting evidence of the short, medium and long-
term effects of glucocorticoids on GR expression levels. Studies in rat hepatoma
cells, show a small, initial increase in GR mRNA after 6h of dexamethasone
treatment, followed by a 50-95% decrease after 24h, with initial levels restored after
72h (Okret et al., 1986). However, the significance of the observed initial up-
regulation in GR mRNA following dexamethasone treatment has been reduced by in
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vivo experiments in rat liver that did not show any early increase in either GR mRNA
or protein levels (Dong et ah, 1988). Similarly, another report described a continued
reduction in GR mRNA levels in a variety of rat tissues for up to 72 hours, after
which there was no further decrease, indicating a 'plateau effect' (Kalinyak et ah,
1987).
Autoregulation of GR levels in vivo is demonstrated by transgenic mice carrying two
additional copies of the GR gene (using a yeast artificial chromosome) which did not
show the predicted two-fold elevation of GR expression levels (Reichardt et al.,
2000). Instead, the highest levels of over-expression were observed in the brain and
the pituitary (60% and 43% respectively), whereas in the spleen, thymus and liver,
GR was over-expressed by only 20-24%. Mice carrying only one copy of the GR
gene also express GR at levels greater than 50%, with levels of between 70 and
100% observed in most tissues (Cole et al., 2001). This is perhaps the strongest
evidence that GR levels are autoregulated and also indicates that, in the long term,
autoregulation exerts differential effects between tissues.
Finally, while in most cells and tissues, GR levels have been observed to decrease
following glucocorticoid exposure, a few cell types, mostly T-lymphoma cells, show
up-regulation of GR expression in response to ligand. For example, the human
leukaemic T-cell lines CEM-C7 (Eisen et al., 1988) and 6TG1.1 (Denton et al., 1993)
as well as the human myeloma cell line OPM-2 (Gomi et al., 1990) and the mouse
thymoma cell line WEHI-7 (Gruol et al., 1989) show an increase in GR expression
after treatment with a GR agonist. It may therefore be the case, that up-regulation of
GR in T-cells, which are sensitive to glucocorticoid-induced apoptosis, is a tissue-
specific response related to the biological effect of glucocorticoids in regulating T
cell homeostasis.
In the adult animal, autoregulatory mechanisms therefore exert potent and dynamic
control of GR expression in a tissue-specific manner. However, there is also
evidence that the perinatal environment can permanently and specifically
'programme' GR levels; a phenomenon in which this laboratory has a particular
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interest (Seckl, 1997; Seckl et al., 1999). In this way, any dynamic regulation of GR
that occurs in response to glucocorticoids or other stimuli fluctuates around a set,
'programmed' level.
1.2.2.2.2 Perinatal programming of GR levels
The foetal origins of disease hypothesis states that early life events can permanently
'programme' the development of tissues and organs thus influencing adult
physiology and later pathophysiology (Barker, 1990). In particular, maternal
nutrition contributing to low foetal birth weight correlates very strongly with the
development of hypertension, non-insulin dependent diabetes mellitus and death
from ischaemic heart disease in adulthood (Barker et al., 1990; Barker, 1997).
Significantly, antenatal glucocorticoid therapy (for example as a treatment for babies
at risk of congenital adrenal hyperplasia) results in offspring with reduced birth
weight (reviewed in Seckl, 2000). In this laboratory, a rat model of this programming
effect was developed in which pregnant females were exposed to the synthetic
glucocorticoid dexamethasone in the third week of pregnancy (Nyirenda et al.,
1998). The offspring of dexamethasone-treated rats showed reduced birth weight and
both fasting and post-glucose hyperglycaemia as adults (Nyirenda et al., 1998).
Furthermore, levels of GR and PEPCK were permanently elevated in the periportal
region of the liver, which is the major site of hepatic gluconeogenesis (Nyirenda et
al., 1998).
Interestingly, while rat hepatic GR levels are increased after dexamethasone
exposure in utero, hippocampal GR levels are decreased (Holmes et al., 1997). In
behavioural tests these animals show impaired learning and increased anxiety,
probably due to increased HPA axis activity (Holmes et al, 1997). Furthermore, adult
rats exposed to stressful stimuli show permanently decreased GR mRNA levels in
several brain regions including the hippocampus and cerebellum (Kitraki et al.,
1999). Conversely, a post-natal increase in 'maternal care' up-regulates GR
expression in the hippocampus, leading to greater hippocampal sensitivity to
glucocorticoids and enhanced negative HPA feedback efficacy (Meaney et al., 1988).
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The paradigm for maternal care has been neonatal handling, in which pups are
separated from mothers for short (15 minute) intervals during the first three weeks of
life. This separation results in altered maternal behaviours upon reuniting, including
increased licking and grooming of pups (Liu et ah, 2000). Handled animals show
blunted ACTH and corticosterone responses to stress and hence more effective shut¬
down of HPA activity following stress. In addition, the increased hippocampal GR
levels present in handled rats are correlated with reduced hippocampal cell loss and
improved spatial memory in old age (Meaney et al., 1988). As such, neonatal
handling appears to offer protection against the chronic detrimental effects of stress-
activation of the HPA axis.
The mechanisms underlying the permanent programming of GR levels by early life
events is poorly understood. While work discussed previously in this chapter
suggests that GR can induce chronic effects on the DNA methylation status and
chromatin conformation of target genes, and that GR levels are subject to
autoregulation, the divergent responses of the liver and hippocampus to
glucocorticoid exposure in utero is still a source of confusion. With regards to the
selective up-regulation ofhippocampal GR after neonatal handling, a pathway in
which thyroxine, 5-HT and cAMP act to up-regulate GR expression has been
proposed (Mitchell et al., 1992; Meaney et al., 2000). In addition, chronic
environmental enrichment has been shown to up-regulate expression of the (NGF-
induced) immediate early gene NGFI-A and GR in rat hippocampus, once again
demonstrating that chronic environmental manipulations can alter hippocampal GR
expression in adult rats (Olsson et al., 1994).
1.2.2.2.3 Transcriptional regulation of GR
Genetic manipulation in both in vitro and in vivo studies have therefore demonstrated
that maintaining appropriate levels of GR expression is crucial in maintaining normal
physiology. Similarly, studies have shown that tissue-specific levels of GR
expression are both autoregulated and subject to perinatal programming.
Furthermore, while analyses of GR in various tissues have shown it to be
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ubiquitously expressed (Ballard et al., 1974), GR levels appear to vary widely
between tissues (Funder, 1992). For example, Northern blot analysis of GR mRNA
in rat tissues showed that levels were greatest in the lung, with the relative levels in
other tissues as follows: spleen, 70%; brain, 55%; liver, 50%; kidney, 43%; heart,
35%; adrenal, 13%; and testis only 8% (Kalinyak et al., 1987). In addition, GR
mRNA levels have been shown to vary within tissues, most demonstrably in
subfields of the hippocampus (Herman & Spencer, 1998). The question therefore
arises of how such complex and tissue-specific regulation of GR levels is achieved.
Investigation into this question has naturally focused on the GR promoter. The
structure of the GR promoter has been partially elucidated in the human (Zong et al.,
1990; Encio & Detera-Wadleigh, 1991; Govindan et al., 1991), mouse (Strahle et ah,
1992; Chen et al., 1999) and rat (Gearing et al., 1993; McCormick et al, 2000). In all
species so far investigated, the promoter region of GR contains no obvious TATA or
CAAT elements and comprises multiple exons 1 that are alternatively spliced onto a
common exon 2. However, an in-frame translational stop codon downstream of the
splice acceptor site in exon 2 means that the sequence of the translated protein is
unaffected by the first exon. As such, all alternate exon 1 GR transcripts encode a
common protein but differ in their 5' leader sequence.
At least five alternate exons 1, termed 1A, IB, 1C, ID and IE, have been described
for the mouse GR gene (Strahle et al., 1992; Chen et al., 1999; fig 1.4). Human
homologues to 1A, IB and 1C have also been identified (Nunez & Vedeckis, 2002),
with further evidence suggesting that alternative splicing events generate three
different hGR 1 A-containing transcripts, termed 1A1, 1A2 and 1A3 (Breslin et al.,
2001; fig. 1.4). Evidence from this laboratory has demonstrated the existence of at
least eleven potential alternate GR exons 1 in the rat; 11, G, I3, I4, Is, U, I7, Is, I9,
110 and In (McCormick et al., 2000; McCormick, 2000). Sequence analysis has
shown that exons 11, 15, 1$, 110 and In are homologous to mouse and human exons
1A, ID, IB, 1C and IE respectively (McCormick et al., 2000; McCormick, 2000;
fig. 1.4). In addition, further data from this laboratory have identified homologues to
all rat alternate exons 1 in several human tissues (Reynolds, 2002). Interestingly, in
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Figure 1.4 5heterogeneity ofGR mRNA is conserved across species.
Schematic representation of alternate exons 1 identified in rat, mouse and human to
date (see text for details and references). Homologous exons are shown in the same
colour. The approximate locations of exons 1 are shown relative to the translation
start (ATG) in exon 2. The 5' extents of alternate exons 1 show considerable


















all species so far investigated, most alternate exons 1 are located within ~3.5kb of
each other just upstream from exon 2, however, exon 1 \/\A is located ~30.2kb
upstream of the translation start site in exon 2 (Strahle et ah, 1992; McCormick et ah,
2000; McCormick, 2000; Breslin et ah, 2001)
1.2.2.2.3.1 The GR promoter occupies a region containing two putative CpG
islands.
Analysis of the rat GR promoter with a CpG island predictor program
(http://www.ebi.ac.uk/emboss/cpgplot) strongly predicts two CpG islands extending
from -4557 to -3847 (CpGi) and from -3667 to -1651 (CpG2), relative to the
translation start at +1. As such, exon 14 lies within CpGi, while exons I5, 16, I7, Is,
I9 and 110 are located within CpG2 (fig 1.5). In contrast, exon 11, which is located
~30.2kb upstream of the translation start in exon 2, is not located in a CpG island.
CpG islands are known to be associated with several characteristics that may have
important implications for the transcriptional activity of the GR promoter. CpG
islands are stretches of non-methylated DNA rich in CpG dinucleotides, that are
found at the promoters of all 'housekeeping' genes and at about half of genes
showing tissue-restricted expression patterns (reviewed in Antequera & Bird, 1993).
CpG is normally a target for DNA methylation and is under-represented in the
genome due to the high mutation rate at 5-methylcytosine (Bird, 1986). The striking
immunity of CpG island sequences to methylation has therefore been the subject of
considerable investigation.
The current model is based on the association between CpG islands and promoters
that also serve as origins of replication (Delgado et al., 1998; Ponger et al., 2001). As
such, it is proposed that the transcriptional status of a promoter early in development
is 'memorised' by the DNA methylation pattern (Antequera & Bird, 1999). In this
way, promoters that are active early in development exclude methylation by
recruiting the molecules that initiate DNA replication, a status that is transmitted to
all somatic cells by maintenance methylation (Antequera & Bird, 1999).
There is an important relationship between DNA methylation, chromatin
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Figure 1.5 The rat GR promoter contains two CpG islands.
All locations are given relative to the translation start (ATG) in exon 2.
A: Schematic representation of the location of two CpG islands on the rat GR
promoter.
B: Output of a CpG island prediction program, shown to scale (see text for details).
CpG dinucleotides are represented by a red vertical line. A blue line shows the extent
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modification and gene expression. Experiments have demonstrated that artificially
methylated DNA can adopt a distinctive chromatin structure upon integration into the
genome that is associated with repression of gene activity (Keshet et al., 1986; Kass
et ah, 1997). Conversely, unmethylated CpG islands possess a nuclease-sensitive
chromatin structure distinct from bulk methylated chromatin and are strongly
correlated with transcriptional activity (Tazi & Bird, 1990). Acetylation of
chromatin-associated histone proteins appears to be an important factor in
maintaining the 'open' chromatin structure at CpG islands; studies have shown that
the transcriptional repression exerted by the methyl-CpG binding protein MeCP2
occurs through its interaction with the Sin3/histone deacetylase co-repressor complex
(Ng & Bird, 1999).
Thus, the presence of two CpG islands in the GR promoter is consistent with both its
activity early in development and its role as a 'housekeeping' gene, as well as
predicting that the chromatin in this region is in an 'open' conformation. Analysis of
the promoter regions of other members of the steroid hormone receptor family using
a CpG island predictor program (http://www.ebi.ac.uk/emboss/cpgplot) shows that
they also contain CpG islands of varying sizes. The human oestrogen and
progesterone receptor (ER and PR respectively) promoter regions each contain a
~500bp CpG island just upstream from the translation start. The human thyroid
receptor p (THP) also contains a -lOOObp CpG island that lies ~400bp upstream
from the ATG codon. Finally, the promoter of the human MR gene is most
similar to that of GR, containing two CpG islands which stretch over a ~3.5kb
region. Given the aforementioned association between CpG islands and both
housekeeping and tissue-specifically expressed genes, perhaps the presence of CpG
islands in the promoters of these genes is unsurprising. However, it is interesting that
the presence of multiple transcription start sites, encoding multiple alternate exons 1,
is also conserved between members of the steroid hormone receptor family.
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1.2.2.2.3.2 GR is one of many genes that are transcribed from multiple start
sites.
The use of multiple promoters and transcription starts appears to be a frequently used
mechanism of exerting complex control of gene expression. Alternative promoter
usage that results in alternative leader exons, as exemplified by GR, can be seen to
affect gene expression in a variety of ways (reviewed in Ayoubi & Van De Ven,
1996). These include the developmental stage-specific (temporal) expression of a
gene, the overall level of expression, the tissue-specific expression, the specific
capacity to respond to particular cellular or metabolic conditions, the stability of the
mRNA, the translation efficiency of the mRNA and the structure of the amino
terminus of the protein encoded by the gene. Many genes containing multiple
promoters, including GR, lack consensus TATA or CAAT boxes, a feature that is
usually associated with heterogeneous transcription initiation (reviewed in Ayoubi &
VanDe Ven, 1996).
In several cases, genes contain both a promoter with ubiquitous expression and an
alternative promoter with a more restricted spatial or temporal pattern. For example,
the human phorphobilinogen deaminase gene (PBGD) possesses an upstream
promoter that is active in all tissues, while a second promoter, located 3kb
downstream, is active only in erythroid cells (Grandchamp et al., 1987; Chretien et
al., 1988). Constitutive expression of the mouse cAMP-dependent protein kinase
subunit RIa gene is driven by transcription from two untranslated exons 1, while
three further alternate exons 1 show a tissue-specific expression pattern (Barradeau et
al., 2000). Similarly, an upstream region of the mouse P1,4-galactosyltransferase
gene functions as a housekeeping promoter, while a region adjacent to the translation
start site serves as a mammary gland-specific promoter (Rajput et al., 1996). Finally,
the human STAT5B gene (a member of the Signal Transducer and Activators of
Transcription family) possesses two promoters, one of which is embedded in a CpG
island and drives constitutive expression, while the other shows a tissue specific
pattern of expression (Ambrosio et al., 2002).
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There are also several examples in which regulation of overall levels of gene
expression in different tissues is controlled by promoters of different strengths. For
example, the a-amylase gene contains a weak (downstream) promoter that is active
in liver, while a strong (upstream) promoter is active in the parotid gland, causing a
more than 100-fold difference in a-amylase expression between the two tissues
(Schibler et ah, 1983). There are therefore numerous precedents in which
transcription from multiple initiation sites is associated with tissue-specific gene
regulation, either through promoters that are 'on' or 'off in selected tissues, or
through promoters that display differential activity between tissues.
There are also several examples whereby alternative promoters are used to regulate
gene expression levels according to various extra-cellular signals. For instance, only
one promoter of the human SRC gene is regulated by hepatic nuclear factor-la
(Bonham et al., 2000). This has particular relevance for members of the steroid
hormone receptor family, which are known to contain alternate promoters that are
differentially responsive to hormonal and other stimuli (see below).
Transcription from multiple promoters can also generate multiple mRNAs that can
potentially be regulated at the post-transcriptional level. There is substantial evidence
showing that transcripts containing long GC-rich leader exons and/or 5' leader
sequences with low free energy cannot be translated efficiently (Kozak, 1991). In
addition, the presence of short open reading frames (sORFs) within leader sequences
have also been shown to profoundly affect translation, whereby differences in
initiation efficiency at upstream sORFs lead to differences in translational efficiency
between mRNAs (reviewed in Morris & Geballe, 2000). Indeed, recent evidence has
shown that translation from a sORF present in mouse GR exon 1A is crucial for GR
synthesis, as mutation of its ATG codon completely abolishes GR expression from
the downstream translation start (Diba et al., 2001).
It is interesting that, in addition to GR, several other members of the steroid hormone
receptor family show evidence of alternate promoter usage. Two forms of human
progesterone receptor, hPRA and hPRB, are transcribed from two distinct promoters
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that generate overlapping leader sequences (Kastner et al., 1990). Furthermore,
transcripts initiating at the upstream promoter A encode an additional translation start
codon, giving rise to a protein with an N-terminal extension (Kastner et ah, 1990).
Importantly, transcription from PR-responsive genes (e.g. human GnRH receptor)
has been shown to be differentially activated by the two isoforms (Cheung et al.,
2000). Furthermore, the ratio ofhPRA to hPRB has been shown to vary widely
between human cell lines (Richer et al., 2002) suggesting that tissue-specific
regulation of the two isoforms has profound effects on the expression patterns of PR-
responsive genes.
A total of six human oestrogen receptor-a (hERa) mRNA isoforms have been
identified, with all transcripts encoding a common protein, but differing in their 5'
leader sequence (reviewed in Kos et al., 2001). Again, results show a differential
pattern of hERa mRNA isoforms in a variety of human tissues and cell types
(Flouriot et al., 1998). Similarly, the human mineralocorticoid receptor (hMR) is
transcribed from at least two alternate promoters giving rise to three alternate
untranslated exons 1; la, 1(3 and ly (Kwak et al., 1993; Zennaro et al., 1995; Listwak
et al., 1996). While results show that both promoters are glucocorticoid-inducible,
only the distal promoter (driving 1 (3 expression) is stimulated by aldosterone in a
dose and hMR-dependent manner (Zennaro et al., 1996). Results also show that the
three MR mRNA variants are differentially distributed within subfields of the
hippocampus (a major aldosterone target tissue) (Kwak et al., 1993), with evidence
suggesting that they may be differentially regulated during development according to
glucocorticoid exposure (Vazquez et al., 1998).
The thyroid hormone receptor (3 (TH(3) also possesses an interesting genomic
structure. In Xenopus laevis, two TH(3 genes each possess at least eight alternatively
spliced exons 1 in the 5' leader sequence (Shi et al., 1992). Significantly, while three
of the alternate exons 1 are present in all TH(3 transcripts, the two most distal exons,
termed a and b, are not found on the same molecule, suggesting that transcription is
driven from at least two distinct promoters (Shi et al., 1992). Furthermore, only
transcripts containing exon b are up-regulated following exposure to thyroid
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hormone (Shi et al., 1992). At least seven retinoic acid receptor a (RARa) isoforms
have been isolated and characterised in the mouse (Leroy et al., 1991). All of these
isoforms differ in their 5' leader sequences and, in the case of two variants (mRAR-
al and mRAR-a2), also in the sequences encoding the N-terminal region (Leroy et
al., 1991), which is known to be important for trans-activation by other members of
the nuclear receptor superfamily. Interestingly, mRAR-a2 and mRAR-al, were
found to be differentially expressed in mouse adult and foetal tissues and only one
isoform, mRAR-a2, could be induced by retinoic acid (Leroy et al., 1991). The
mouse RAR-(3 shows a similar genomic structure, with three isoforms generated
from the same gene by differential promoter usage and alternative splicing, which
also show varying levels in selected tissues (Zelent et al., 1991).
It is therefore apparent that many members of the steroid hormone receptor family
are transcribed from multiple promoters that are differentially regulated in a tissue-
specific manner, both during development and in response to external stimuli,
particularly their own ligands. In this way, we can hypothesise that the multiple exon
1 structure of the GR promoter is involved in its evidently complex and tissue-
specific regulation.
1.2.2.2.3.3 Role of the GR promoter
This hypothesis implies that alternate GR exons 1 are regulated in response to cell-
specific factors and external stimuli. Work carried out in this laboratory identified six
alternate GR exons 1 expressed in a range of rat tissues (McCormick et al., 2000;
McCormick, 2000). Table 1.2 summarises the results of RNase protection assays
(RPAs) carried out on rat hippocampus, liver and thymus, using probes
complementary to each specific exon 1. In hippocampus, liver and thymus, as well as
heart, kidney, lung and testis, transcripts containing exon lio predominated
(McCormick et al., 2000; McCormick, 2000). Exon 1$ -containing transcripts were
also observed in all three tissues. Interestingly, exons 15 and 17 were both present in
hippocampal GR mRNA but were below the limit of detection in liver and thymus.
Transcripts containing exon 111 were relatively higher in hippocampus than liver but
61
were below the limit of detection in thymus. Finally, transcripts containing exon 11
were only detected in thymus, representing -25% of total GR mRNA (McCormick et
al., 2000; McCormick, 2000).
Exon Hippocampus Liver Thymus
1. 0 0 25.6%, 27.1%
I2 0 0 0
14 0 0 0
15 8.1%, 7.4% 0 0
U 17.0%, 20.7% 10.0±1.3% (6) 21.9%, 19.9%
I7 8.0%±3.7% (3) 0 0
110 61.3%, 63.8% 74.8%, 77.5% 52.7%, 58.9%
In 12.5%, 7.9% 2.2%, 1.7% 0
Table 1.2 Relative abundance ofalternative exon 1-containing GR mRNA in rat
hippocampus, liver and thymus.
Summary of RPAs in which the amount of exon 1 is expressed as a percentage of the
total amount of GR mRNA in a particular tissue. Where individual values are shown,
the results for each of two independent experiments are given. Where the experiment
was carried out more than twice, values shown represent the mean ±SEM (n). Levels
of exon I4- and 12-containing transcripts were below the limits of detection (-1-5%
of total GR mRNA) in the three tissues examined. Taken from (McCormick et ah,
2000).
RT-PCR studies carried out in a range of mouse tissues have shown that all alternate
GR exons 1, including 1A, IB, 1C, ID and IE (homologous to rat exons 11, 16, 110,
15 and In respectively), are ubiquitously expressed (Chen et ah, 1999). RPA analysis
provided a more quantitative technique and showed that while mouse GR exons IB
and 1C were ubiquitously expressed, exon 1A was only detected in the T lymphocyte
lines S49 and WEHI-7 (Strahle et ah, 1992). The relative levels of IB and 1C
expression within tissues was not assessed in the study performed by Strahle et al,
although comparison between tissues showed that levels of both IB and 1C mRNA
were higher in mouse liver than in mouse brain, S49 or WEHI-7 cells (Strahle et ah,
1992). More recent RT-PCR studies showed that human GR exons IB and 1C (16
and 110) were expressed in all human cell lines investigated, including IM-9 (B-cell
lymphoma), CEM-C7 (T-cell lymphoblast), Jurkat (T-cell ALL), HL-60 (myeloid
leukaemia), HeLa (cervical carcinoma), HepG2 (hepatoma), MCF-7 (breast
carcinoma), 786-0 (kidney carcinoma), SJSA (osteosarcoma), H1299 (lung
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carcinoma) and WI-38 (normal diploid fibroblasts) (Breslin et al., 2001). Of the
three 1A splice variants detected by RT-PCR analysis of human GR, only expression
of 1 A3 was restricted to cells derived from the immune system (IM-9, CEM-C7,
Jurkat and HL-60), while transcripts containing exons 1 Al and 1A2 were identified
in all other cell lines (Breslin et al., 2001). Once again, quantitative studies did not
assess the relative levels of human GR exon IB and 1C expression within cell lines
(Breslin et al., 2001). However, comparison between cell lines showed that levels of
exon IB expression were not significantly different in IM-9, CEM-C7, Jurkat, or
HeLa cells, with slightly higher levels observed in WI-38 relative to IM-9 cells
(Breslin et al., 2001). In addition, levels of exon 1C expression in CEM-C7, Jurkat,
HeLa and WI-38 were shown to be <50% of those detected in IM-9 cells (Breslin et
al., 2001).
The hypothesis that patterns of alternate GR exon 1 expression are regulated in a
tissue-specific manner implies that multiple exons 1 are driven by multiple
associated promoters that are differentially active between tissues. Results from this
laboratory have shown that transiently transfected constructs associated with rat GR
exon % activated a reporter gene in a neural cell-specific manner (McCormick et al.,
2000; McCormick, 2000). Other studies have also shown that sequences associated
with human exons IB and/or 1C activate reporter genes in transiently transfected
systems in a cell-specific manner (Nobukuni et al., 1995; Breslin et al., 2001; Nunez
& Vedeckis, 2002). Specifically, while there was no difference in activity between
constructs associated with IB and 1C in HeLa or Jurkat cells, the promoter activity
of 1C was significantly higher than IB in HepG2 cells (Nunez & Vedeckis, 2002).
With regard to the IB promoter, footprints have been reported at one GATA, three
YY1 and four Spl transcription factor binding sites (Breslin & Vedeckis 1998;
Nunez & Vedeckis, 2002). A putative NF-kB binding site has also been identified in
the IB promoter, although the functional significance of this remains unresolved
(Webster et al., 2001). While EMSAs have not provided evidence of GATA-3
binding to the GATA footprint, experiments have confirmed binding of Spl and
YY1 at their respective sites (Breslin & Vedeckis, 1998; Nunez & Vedeckis, 2002).
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In addition, the relative contribution of these binding sites has been shown to be
tissue-dependent. Specifically, deletion of the three YY1 sites has been shown to
lead to a decrease in promoter activity in HepG2 and Jurkat cells, but not in HeLa
cells (Nunez & Vedeckis, 2002). Conversely, deletion of all four Spl sites caused a
significant down-regulation in promoter activity in HeLa cells, but not in HepG2 or
Jurkat cells (Nunez & Vedeckis, 2002).
With regard to promoter 1C, previous studies have identified five putative Spl sites,
although their contribution to overall and tissue-specific GR regulation has not been
investigated (Breslin & Vedeckis, 1998). In addition, Nobukuni et al reported the
presence of three footprints on the 1C promoter, one of which was shown to bind
AP2 in HepG2 cells (Nobukuni et al., 1995). Significantly, deletion of this AP2 site
triggered a decline in promoter activity in HeLa and NIH3T3, but not in HepG2,
cells (Nobukuni et al., 1995).
Reporter constructs containing sequences associated with exons 1A1, 1A2 and 1 A3
have been shown to be active in a variety of human cell types, with the strongest
activity observed in cell lines derived from immune cells (Breslin et al., 2001). This
observation, together with the greater expression of GR exon 1 A-containing
transcripts, in particular exon 1 A3, in human T cells has been implicated in the
mechanism underlying the immune-specific up-regulation of GR levels in response
to glucocorticoids (Breslin et al., 2001). An interferon regulatory factor-binding
element has been shown to contribute significantly to basal transcription rate of exon
1 A-containing promoter constructs (Breslin et al., 2001). Furthermore, the GR 1A
promoter region was shown to contain a footprint resembling a glucocorticoid
response element that appears to bind GR(3 (Breslin et al., 2001). Interestingly,
transcription from GR exon 1A appears to be associated with mGR (Chen et al,
1999), a membrane associated/bound isoform of GR that is more strongly correlated
with glucocorticoid-evoked lymphocytolysis than the classical GR (Sackey et al.,
1997) (see section 1.2.2.1.4). Evidence gained from mGR-enriched S-49 (mouse
lymphoma) cells shows that the cellular presence ofmGR is highly correlated with
GR transcripts containing exon 1A (Chen et al., 1999). Furthermore, transfection of
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mGR-less and glucocorticoid lysis-resistant AtT-20 pituitary and HL-60 leukaemic
cells with full-length GR 1A cDNA imparted both mGR expression and
glucocorticoid lysis-sensitivity to these cells (Chen et ah, 1999).
1.3 Aims
The evidence presented in this chapter shows that glucocorticoids exert profound
effects on a variety of physiological systems. Furthermore, cellular responses to
glucocorticoids are dependent upon the actions of GR, which exists as several
different isoforms. In vitro and in vivo models show that the appropriate regulation of
GR levels in every tissue is crucial in mediating GR action. Furthermore, tissue-
specific GR levels are both permanently 'programmed' in response to the perinatal
environment and dynamically regulated in adult animals by glucocorticoids
themselves. Studies of several other members of the steroid hormone receptor family,
in which transcription is differentially driven from multiple promoters in response to
tissue-, development- and stimuli-specific factors, suggests that the multiple exon 1
structure of the GR promoter may be involved in the evidently complex regulation of
GR levels. As such, the experiments described in this thesis were designed to
investigate the role of this alternate exon 1 structure in the tissue-specific,
constitutive and auto-regulation of GR.
Previous work carried out in the laboratory showed that, while GR exons 1& and 1 io
were present in all rat tissues examined, exons including I5 and I7 showed a more
tissue-restricted pattern (see section 1.2.2.2.3.3). As such, initial RT-PCR analysis
aimed to establish 'model' cell lines, displaying specific patterns of exon 1
expression, which could then be used and manipulated in further experiments. In
addition, the expression ofmultiple alternate exons 1 implies that transcription of GR
is driven by a complex arrangement ofpromoter elements. Transient transfection
experiments in two different rat cell lines therefore aimed to elucidate potential
promoter elements involved in tissue-specific GR regulation, specifically testing
whether alternate exons 1 are driven from individual, cell-specific promoters.
65
DNasel footprinting and electrophoretic mobility shift assays were also undertaken
in order to identify putative transcription factors involved in GR regulation.
Experiments were also designed with the aim of investigating the role of individual
exon 1 splice donor sites in overall GR transcriptional regulation. As such, site-
directed mutagenesis was used to abolish selected splice donor sites and any
subsequent effects on transcriptional activity were analysed by transient transfection,
RT-PCR and sequencing techniques.
Naturally, transcriptional regulation of GR must be considered in the context of the
chromatin arrangements over the region. In this way, DNasel hypersensitive site
mapping was carried out in order to elucidate any cell-specific differences in the
chromatin structure at both specific exons 1 and the whole rat GR promoter locus.
Finally, numerous studies have shown that the most potent regulators of GR
expression are glucocorticoids themselves (see section 1.2.2.2.1). The role of the GR
promoter, specifically that of individual exons 1, in GR autoregulation was
investigated using transiently transfected cells treated with the synthetic
glucocorticoid, dexamethasone.
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2 Materials & Methods
2.1 Materials
2.1.1 General chemicals
All chemicals were obtained from VWR International Ltd or Sigma-Aldrich
Company Ltd., unless otherwise stated. Supplier's addresses are given in Appendix I.
NICK columns
Scintillation proximity assay reagent
Hybond-C nitrocellulose membrane
First Strand cDNA Synthesis Kit
Poly(dI-dC).poly(dI-dC)





Becton Dickinson UK Ltd.
Protein assay dye reagent
concentrate
Bio-Rad Laboratories Ltd.
SeaKemIM LE agarose Cambrex Bio Science Wokingham Ltd.
Agar
Caesium chloride
Low melting point agarose









High Pure PCR Product Purification
Kit
Taq DNA polymerase










Galacto Light Plus Assay Kit Tropix Ltd.
Whatman 3MM paper
Nebauer Improved Haemocytometer




Supplier's addresses are given in Appendix I.
Hyperprocessor
GeneQuant RNA/DNA Calculator
Amersham Pharmacia Biotech UK Ltd.
Beckman J2-MC centrifuge
Beckman Optima TLX ultracentrifuge
Beckman Coulter (U.K.) Ltd.
Lumat LB9501 Luminometer Berthold Technologies (U.K.) Ltd.
Agarose gel electrophoresis equipment
583 Gel Drier
Bio-Rad Laboratories Ltd.
Eppendorf Mastercycler Eppendorf AG.
Ultra-turrax TD Homogeniser IKA Labortechnik
BRL Model VI6 vertical electrophoresis
tank
Invitrogen
Heraeus Labofuge 400R Kendro Laboratory Products pic.
Kodak BioMax STS 451 vertical
electrophoresis tank
Kodak Ltd.
Seikosha video printer paper Qbiogene-Alexis Ltd.
Appligene Imager Quantum Appligene






Supplier's addresses are given in Appendix I.
[a32P] dCTP
370MBq/ml specific activity
Amersham Pharmacia Biotech UK Ltd.
2.1.4 Enzymes & antibodies
All enzymes were obtained from Promega Ltd., unless otherwise stated. Supplier's
addresses are given in Appendix I. All antibodies were obtained from Santa Cruz
Ltd.
SstI Invitrogen




RNaseA Sigma-Aldrich Company Ltd.
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2.1.5 Tissue culture reagents & equipment
Supplier's addresses are given in Appendix I.
Dulbecco's Minimal Essential
Medium (DMEM)












2ml Cryotubes Nalgene Labware
2.1.6 Solutions & buffers
DEPC dH20 0.5ml DEPC in 500ml ultrapure water. Leave for
1-24 h, autoclave.
DNA Loading Buffer 30% v/v glycerol, 0.25% w/v Orange R
DNasel Protection Buffer 50% glycerol, 50mM Tris-HCl pH 7.5, 12.5mM
MgCl2, 5mM CaCl2, 0.5mM EDTA, 375mM KC1,
20mM Spermidine, 2.5mM DTT
DNasel Stop Solution 2% SDS, lOmM EDTA (pH 8.0)
DNasel Footprinting Stop
Solution
2M NaCl, 0.1M EDTA (pH 8.0)
Freezing Medium 15% DMSO, 85% FCS
Genomic DNA Extraction
Buffer
lOmM Tris-HCl pH 8.0, 0.1M EDTA (pH 8.0),
20ug/ml RNase A, 0.5% SDS
GTE 50mM glucose, 25mM Tris-HCl pH 8.0, lOmM
EDTA
2x HBS 280mM NaCl, 50mM HEPES, 1.5mM Na2HP04.
pH to exactly 7.05 with 10M NaOH.
Hydrazine Stop Solution 0.3M NaC2H302, O.lmM EDTA (pH 8.0), 25pg/ml
tRNA
1 Ox Kinase Buffer 0.5M Tris-HCl pH 7.5, 0.1M MgCl2, 50mM DTT,
ImM spermidine, ImM EDTA (pH 8.0)
Luria-Bertoni (LB) Broth 1% w/v bactotryptone, 0.5% w/v yeast extract,
0.5% w/v NaCl. If required, ampicillin was added
to a concentration of lOOpg/ml after autoclaving.
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LB-Agar LB broth with 1.5% w/v agar. If required,
ampicillin was added to a concentration of
100p,g/ml after autoclaving and before pouring.
Luciferase Assay Buffer 40mM Tricine, 67mM DTT, 0.2mM EDTA, 2mM
MgC03, 5mM MgS04, 0.25mM coenzyme A. pH
adjusted to 7.8
Lysis Buffer 25mM Tris-HCl pH 7.8, 2mM DTT, 1% Triton X-
100, 10% glycerol
10 x MOPS 200mM MOPS acid, 50mM C2H302Na, lOmM
EDTA. pH adjusted to 7.2.
Nuclear Extract Buffer A lOmM HEPES, 1.5mM MgCl2, 10mM KC1.
0.5mM DTT and 0.5mM PMSF added just prior to
use.
Nuclear Extract Buffer C 20mM HEPES, 25% v/v glycerol, 0.42M NaCl,
1.5mM MgCl2, 0.2mM EDTA. 0.5mM DTT and
0.5mM PMSF added just prior to use.
Nuclear Extract Buffer D 20mM HEPES, 20% v/v glycerol, 0.1M KC1,
0.2mM EDTA. 0.5mM DTT and 0.5mM PMSF
added just prior to use.
Nuclei Buffer A 85mM KC1, lOmM Tris-HCl pH 7.6, 5.5% w/v
sucrose, 2mM EDTA. lOmM PMSF and 0.5mM
spermidine added just prior to use.
Nuclei Buffer B 85mM KC1, lOmM Tris -HC1 pH 7.6, 5.5.% w/v
sucrose, 2mM EDTA, 0.2% Nonidet P40. 0.5mM
spermidine added just prior to use.
Nuclei Buffer C 85mM KC1, lOmM Tris -HC1 pH 7.6, 5.5.% w/v
sucrose, 1.5mM CaCl2, 3mM MgCl2. 0.5mM
spermidine added just prior to use.
1 x PBS 1 x PBS tablet (Sigma) dissolved in 200ml dH20
to give lOmM phosphate buffer, 2.7mM KC1,
137mM NaCl
Potassium Acetate (5M acetate,
3M potassium)
245.6g KC2H3O2 dissolved in 442.5ml dH20,
57.5ml glacial acetic acid.
Prehybridisation Buffer 5 x SSC, 0.5% SDS, 5 x Denhardt's Solution (50 x
Denhardt's Solution = 5g Ficoll, 5g
polyvinylpyrrolidone, 5g BSA to 500ml with
dH20).
RNA Loading Buffer lOOpl =15pl ethidium bromide (lOmg/ml), 85pl
DNA Loading Buffer
Southern Depurination Solution 0.125M HC1
Southern Denaturation Solution 0.5M NaOH, 1.5M NaCl
Southern Neutralisation
Solution
1.5M Tris-HCl pH 7.2, 1.5M NaCl, ImM EDTA
Southern Wash Buffer I 2 x SSC, 0.1% SDS
Southern Wash Buffer II 0.5 x SSC, 0.1% SDS
20 x SSC 3M NaCl, 0.3M sodium citrate. pH adjusted to 7.0
with 10M NaOH.
70
50 x TAE 121.1 g Trizma base dissolved in 421.5ml dfLO,
50ml 0.5M EDTA, 28.6ml glacial acetic acid
lOxTBE 0.9M Tris, 0.9M Boric Acid, 12.5mM EDTA
TE Buffer lOmM Tris-HCl pH 8.0, ImM EDTA
TEN Buffer lOmM Tris-HCl pH 8, ImM EDTA, 50mM NaCl
10 x Universal Restriction
Buffer
500mM NaCl, 500mM Tris-HCl pH 8.0, lOOmM
MgCh, 60mM (3-mercaptoethanol, lmg/ml BSA
2.1.7 Oligonucleotides
All oligonucleotides were purchased from Oswel DNA service (see Appendix I),
unless otherwise stated. Locations of oligonucleotides on GR sequence are given in
Appendix II. Numbering is with respect to the translation start +1.
2.1.7.1 Oligonucleotides used in PCR
Name Sequence Comment
LUC 5'GCGTATCTCTTCATAG 3' Luciferase primer
GREx2 5'CATGGACAGTGAAACGGC 3' Rat GR exon 2 primer
GR11 5'CTTGCTGGAAGTGTCTGGGATG 3' Rat GR exon 11 primer
MGR1, 5'CTTCGTTAGAGTGTCTGGGAGGAAG 3' Mouse GR exon 11 primer
GR14 5'TTGCACCCCAAAGCAACACC 3' Rat GR exon 14 primer
(-4239 to-4219)
gri5 5'AAGAGGGTTTTGGATTCG 3 ' Rat GR exon 15 primer
(-3575 to-3557)
gri6 5'ACCTGGCGGCACGCGA 3' Rat GR exon 16 primer
(-3303 to -3287)
GRly 5'AAAGAAACTCGGTTTCCCTC 3' Rat GR exon 17 primer
(-2967 to -2947)
GR110 5'GTTGACTTCCTTCTCCGTGA 3' Rat GR exon 110 primer
(-2321 to-2301)
GRl,i 5'CGGCCTTATCTGCTAGAAGT 3' Rat GR exon In primer
(-1749 to-1729)
GR-1 5'GACCTCTTGAAGGATTTGGAG 3' Rat exon 2 forward primer
GR-2 5'GCTTACATCTGGTCTCATTCC 3' Rat exon 3 reverse primer
GAPDH-1 5'GTCGGTGTGAACGGATTTGGCCGT 3 ' Rat GAPDH forward
primer
GAPDH-2 5'CATGGCCTACATGGCCTCCAAGG 3' Rat GAPDH reverse
primer
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Rat exon 16 mutation
forward primer (-3290 to










Rat exon 1 io mutation
forward primer (-2234 to










Rat exon 111 mutation
forward primer (-1723 to








2.1.7.3 Oligonucleotides used in Electrophoretic Mobility Shift Assays


















































2.1.8 Plasmids & Constructs
pSV2L encodes the firefly luciferase gene driven by a mammalian SV40 promoter
(de Wet et al, 1987) and was used as a positive control in transient transfection
studies. pCHl 10 (Amersham Pharmacia) is a p-galactosidase expression plasmid
and was used as an internal control for transfection efficiency. pRShGR is a human
GR expression plasmid and has been described previously (Giguere et al., 1986).
pKC302 was a gift from K.E.Chapman. The rat GR competitor construct used in
quantitative RT-PCR analysis was made by J.A. McCormick and has been described
previously (Lai et al., 2003).
The following constructs, in which fragments of the rat GR promoter are fused to
luciferase reporter gene, were made by J.A. McCormick and have been described
previously (McCormick et al., 2000; McCormick, 2000): Pl5, Pl6, Pl7, Pl7a, Pl7b
and Pl7Cj Pig, PI9/10, Plio, PI 11 and P2. All constructs were based on a modified form
of pGL3-Basic (Promega), pGL3-BM (McCormick et al., 2000; McCormick, 2000).
All pVL constructs were a kind gift from V. Lyons. In the case ofpVL257, pVL258,
pVL259, pVL260, pVL261, pVL262 and pVL263, inserts were excised from P2 and
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cloned into pGL3-BM (see above and references therein, in addition to chapter 4).
Similarly, a 134bp PstI fragment (-3339 to -3205) was isolated from P2 and cloned
in the forward (pVL289) and reverse (pVL290) orientations into pGL3-BM. Finally,
a HincII/Bglll fragment containing the 134bp PstI fragment was isolated from either
pVL289 or pVL290 and cloned in both the forward (pVL287) and reverse (pVL288)
orientations into pGL3-Promoter (Promega). To construct PGbREv, a 134bp PstI
fragment (-3339 to -3205) was isolated from Pl7b and re-ligated in the reverse
orientation. In pHLM7, a Bglll/Kpnl fragment from -2931 to -2806 was isolated
from P2 and cloned into pGL3-BM. P2Mutl6, P2Mutl i0 and P2Mutl n were
synthesised by site-directed mutagenesis (section 2.2.5.4) of P2 using the appropriate
primers (section 2.1.7.2). Similarly, PlnMutlio was synthesised by site-directed
mutagenesis of P1 n.
2.1.9 Probes used in EMSAs and DNasel hypersensitive site mapping
The locations of the labelled fragments used in EMSAs and DNasel hypersensitive
site mapping are given in fig. 2.1.
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Figure 2.1 Fragments ofthe GR promoter used in EMSAs and DNasel hypersensitive
site mapping.
Diagram showing the position of fragments used in EMSAs and DNasel
hypersensitive site mapping and the restriction enzymes used to generate them.1" and
indicate regions ofpolylinker DNA derived from pGL3-BM. Recessed 3' ends that
are radioactively labelled by the Klenow enzyme are labelled with a FNs, a 130bp




























2.2.1 Maintenance of Cell Lines
A summary of the maintenance of all cell lines is given in table 2.2.1. All cell lines
were maintained in F75 flasks (Greiner) at 37°C and all media were stored at 4°C
and equilibrated to room temperature before use. Each cell line was routinely split
between 1:3 and 1:10 when confluent. To split / harvest adherent cells including
H4IIE, 2S FAZA, KNRK, PC-12 and NG108-15, each flask was washed in 10ml
serum free DMEM and treated with 2ml 1 x trypsin for 2 min at 37°C to release the
cells. 8ml DMEM with serum was added and mixed gently to give a homogeneous
suspension. Cells were then diluted as appropriate in DMEM with serum. B103 cells
are adherent but do not require the application of trypsin for release. B103 flasks
were given a sharp tap to dislodge the cells and diluted as appropriate with DMEM
plus serum. EL4 and S49 cells grow in suspension and were simply diluted as
appropriate with DMEM or RPMI plus serum.
For storage, stocks of cells were frozen and kept under liquid nitrogen. Cells from a
single confluent flask were resuspended in 3ml freezing medium and transferred in
1.5ml aliquots to cryotubes. The tubes were sandwiched in polystyrene, wrapped in
foil and places at -80°C overnight before being transferred to liquid nitrogen.
2.2.2 Gel electrophoresis
2.2.2.1 Analytical agarose gels
DNA was analysed using standard agarose gels of 0.8-2%, prepared as described in
Sambrook et al (Sambrook et al., 1989). Agarose was dissolved in 0.5 x TBE buffer
by boiling in a microwave oven, with higher percentage agarose gels used to resolve
smaller DNA fragments. The fluorescent dye ethidium bromide was used to detect
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warm solution was then poured into a gel mould including the appropriate comb
(Bio-Rad), and allowed to solidify. The solidified gel was submerged in a gel
electrophoresis tank (Bio-Rad) containing 0.5 x TBE buffer and the comb was
removed to create loading wells for the DNA samples. In order to load DNA samples
more easily and observe their progress during electrophoresis, DNA loading buffer
containing glycerol and Orange R dye was added to each DNA sample (lul loading
buffer per lOpl sample). Electrophoresis was carried out at 70-120V until the dye
front had run two thirds down the gel. DNA was visualised on an UV
transilluminator at 254nm, imaged using an Appligene Imager and printed on
Seikosha video printer paper. DNA fragment size was estimated by comparison to
lkb DNA ladder (Invitrogen).
2.2.2.2 Preparative agarose gels
To gel purify DNA fragments (e.g. for templates in radiolabelling or construction of
plasmids) the above procedure was followed with the substitution of Tow melting
point' agarose (Invitrogen). Samples were electrophoresed at 80V until the desired
fragment was resolved. DNA was visualised on an UV transilluminator at 365nm to
minimise UV damage to DNA. The required band was excised with a clean scalpel
and purified as described in section 2.2.4.5.
2.2.2.3 Agarose gels for analysis by Southern blotting
0.8% agarose gels for Southern analysis were prepared as described above using 0.5
x TBE. Electrophoresis was carried out in 0.5 x TBE at 80-100V until the dye front
had reached the end of the gel. The gel was then treated as described in section
2.2.4.11.
2.2.2.4 Denaturing agarose RNA gels
Integrity of total RNA was verified by denaturing agarose gel electrophoresis. Gel
trays, tanks and combs were scrubbed with detergent, soaked in 10M NaOH for 30
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min and rinsed with ultra-pure water before use. For a 100ml 1.2% agarose gel, 1,2g
agarose was dissolved in 88ml DEPC water by boiling in a microwave oven. The
solution was allowed to cool in a fume hood before 2ml formaldehyde and 10ml 10 x
MOPS were added and the gel was poured. The solidified gel was submerged in a gel
tank containing 1 x MOPS for 15 min prior to sample loading. Typically, 5pg of
sample RNA was used, the volume ofwhich was adjusted to lOpl with DEPC water.
Each RNA sample was denatured by adding 2.5pl formaldehyde, 2.5pl 10 x MOPS
and 10pl deionised formamide in a fume hood, before incubation at 65°C for 15 min.
2.5 pi RNA loading buffer (including ethidium bromide) was added to each of the
denatured samples before loading onto the gel and electrophoresis at 100V. RNA
was visualised on an UV transilluminator at 254nm and imaged as described
previously.
2.2.2.5 Denaturing polyacrylamide gel electrophoresis
DNcisel footprinting reactions were run on vertical denaturing polyacrylamide gels.
Glass plates were scrubbed with detergent, rinsed with water and wiped with 100%
ethanol prior to use. One side of one glass plate was siliconised by wiping
approximately 1.5ml Sigmacote over the surface. For a 10% denaturing gel 0.3mm
spacers were sandwiched between two glass plates (45cm x 35cm), clamped with
bulldog clips and sealed with 1.5% agarose (w/v in dF^O). 42g urea was dissolved in
25ml 40% acrylamide:bis-acrylamide (19:1), 10ml 10 x TBE, 600pl freshly prepared
10% ammonium persulphate and made up to 100ml with dH20. Polymerisation was
started by the addition of 125pl TEMED to the mix, which was then immediately
poured into the gel cast. The comb was inserted quickly and the gel allowed to
polymerise for at least 2h before assembly into the electrophoresis apparatus (Kodak
BioMax STS 45i). The gel was pre-run at 1500V (using a Bio-Rad Power Pac 3000)
for at least 30 min. Samples (containing formamide loading buffer) were heated at
100°C for 10 min prior to loading. Care was taken to flush out wells with buffer
immediately prior to loading, in order to remove any urea. Electrophoresis was
carried out at 1600 - 1800V (not exceeding 40mA) until the bromophenol blue
present in the loading buffer reached the bottom of the gel. For enhanced resolution
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of large DNA fragments (>100bp), a second loading of sample was applied and again
electrophoresed until the bromophenol blue reached the bottom of the gel. The gel
was then transferred to Whatman 3MM paper, covered with Saranwrap and dried
under vacuum at 80°C for 2h on a BioRad 583 Gel Drier. DNA was visualised as
described in 2.2.3.
2.2.2.6 Non-denaturing polyacrylamide gel electrophoresis
Non-denaturing polyacrylamide gel electrophoresis was used in gel mobility shift
analysis. As above, glass plates were scrubbed with detergent, rinsed and wiped with
100% ethanol prior to use. However, neither plate was siliconised. 1.5mm spacers
were sandwiched between two glass plates (17cm x 15cm), clamped with bulldog
clips and sealed with 1.5% agarose (w/v in d^O). A gel mix containing 2.5ml 10 x
TBE, 6.25ml 40% acrylamide:bis-acrylamide (19:1) (for 5% gels) and 300pl fresh
10% ammonium persulphate was made up to 50ml with dH20 and polymerisation
was initiated with 40pl TEMED. The mix was immediately poured into the gel cast
and a 20 tooth comb inserted. The gel was allowed to set for at least 2h and pre-run
at 100V for 30 min in 0.5 x TBE on a BRL model VI6 apparatus. Samples were
loaded without loading dye (lanes were numbered) and electrophoresed for
approximately 90 min at 200V. DNA loading dye was loaded into empty lanes to
check sample progression. Following electrophoresis, gels were transferred to
Whatman 3MM paper, covered with Saranwrap and dried under vacuum at 80°C for
lh on a Bio-Rad 583 gel drier. Protein-DNA complexes were visualised as described
in 2.2.3.
2.2.3 Autoradiography
Southern blots and dried gels containing 32P were exposed to either a Fujifilm
phosphorimager screen and processed on a Fujifilm FLA-2000 phosphorimager
and/or to Kodak BioMax MS-1 (maximum sensitivity) film at -80°C inside cassettes
containing two intensifying screens, which were then developed using an Amersham
Hyperprocessor.
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2.2.4 DNA and RNA techniques
2.2.4.1 RNA isolation byTRIzol extraction
RNA was isolated from frozen tissue, monolayer cells and suspension cells using
TRIzol reagent (Invitrogen). 50-100mg frozen tissue was homogenised in 1ml
TRIzol reagent in pre-chilled eppendorf tubes using an Ultra-turrax TB homogeniser
(IKA Lobortechnik). Monolayer cells were washed twice in 1 x PBS before TRIzol
was applied at 0.1ml/cm2. Suspension cells were spun at 1200rpm (Heraeus
Labofuge 400R) for 3 min at 4°C, resuspended in 10ml 1 x PBS and counted in a
Nebauer Improved Haemocytometer. TRIzol was added at lml/5-10 x 106 cells.
TRIzol solutions from all three sources were then treated with 0.2ml chloroform per
lml TRIzol, vortexed vigorously for at least 15s and incubated at room temperature
for 3 min. Solutions were spun at 12000g for 15 min at 4°C and the upper aqueous
layer transferred into fresh pre-chilled eppendorf tubes. Isopropanol was added at
0.5ml per lml TRIzol and the tubes inverted gently, before incubation at room
temperature for 5 min. RNA was precipitated by centrifugation at 12000g for 10 min
at 4°C. Pellets were washed in 75% ethanol and spun at 7500g for 5 min at 4°C.
Supernatants were removed and pellets were air-dried at room temperature for 5 min.
RNA was resuspended in 20-5Opl DEPC dTEO, its concentration measured using a
GeneQuant spectrophotometer (Pharmacia Biotech), and stored at -80°C.
2.2.4.2 Genomic DNA isolation
Isolation of genomic DNA from monolayer cells (B103 and H4IIE) was carried out
according to Blin & Stafford (Blin & Stafford, 1976). Cells were harvested from F75
flasks as described in section 2.2.1 and transferred to a pre-chilled 50ml falcon tube.
After centrifugation at 1200rpm for 5 min at 4°C (Heraeus Labofuge 400R), cells
were resuspended in 5ml cold 1 x PBS and counted using a Neubauer Improved
Haemocytometer. After a further centrifugation at 1200rpm for 5 min at 4°C, cells
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were resuspended in TE to give a concentration of 5 x 10 cells/ml. The solution was
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then transferred to an appropriate conical flask (50ml flask for 1ml cell suspension,
100ml conical flask for 2ml cell suspension etc.) and 10ml Genomic DNA Extraction
Buffer was added per ml of cell suspension. The solution was incubated at 37°C for
lh, before the addition of proteinase K (20mg/ml) to a final concentration of
100pg/ml. The suspension of lysed cells was then incubated in a water bath at 50°C
for 3h, swirling periodically. After cooling the solution to room temperature and
transferring it to a 50ml falcon tube, an equal volume of phenol/chloroform/IAA
(pH8.0) was added and gently mixed by slowly inverting the tube end over end for
10 min. The resulting emulsion was spun at 4300rpm for 15 min at room temperature
(Heraeus Labofuge 400R) to separate the two phases. The viscous aqueous phase
was carefully transferred with a wide-bore pipette (0.3cm diameter) into a fresh
falcon tube and the phenol/chloroform/IAA extraction repeated twice. After the third
extraction, 0.2 vol 10M ammonium acetate and 2 vol 100% ethanol were added and
swirled until the solution was thoroughly mixed. The resulting precipitate was
collected by centrifugation at 4300rpm for 5 min at room temperature and washed
twice in 70% ethanol. The pellet was air-dried and resuspended in 1ml TE/5 x 106
cells. Complete resuspension required 12-24h of gentle agitation of the DNA
solution on a rotating platform at room temperature. DNA concentration was
measured using a GeneQuant spectrophotometer (Pharmacia Biotech) and samples
were stored at -20°C.
2.2.4.3 DNA purification
When necessary, DNA from restriction digests, DNasel digests and DNasel
footprinting reactions was purified by phenol/chloroform extraction and ethanol
precipitation as follows. Starting with DNA solution in an eppendorf tube, an equal
amount of phenol/chloroform/IAA was added, followed by vigorous vortexing and
centrifugation at 12000g for 2 min at room temperature. The upper aqueous layer
was transferred to a fresh eppendorf tube and an equal amount of chloroform was
added. After vigorous vortexing and centrifugation at 12000g for 2 min at room
temperature, 1/20 vol 3M sodium acetate and 2 vol 100% ethanol were added. DNA
was precipitated by incubation for no more than 7 min on dry ice followed by
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centrifugation at 12000g for 10 min at room temperature. Pellets were washed in
70% ethanol, air-dried and resuspended as appropriate in dH20, TE or loading
buffer.
2.2.4.4 Restriction Digests
Single restriction enzyme digests were typically performed in a total reaction volume
of 20pl, containing 2pl 10 x restriction enzyme buffer, lpl restriction enzyme (2-
10U) and 0.5 - 15pg plasmid DNA (made up to 20pl with dH20). Reactions were
incubated at optimum temperature for l-4h. Strategies for double restriction enzyme
digests depended upon enzyme buffer compatibility. If both restriction enzymes
worked optimally in the same buffer then a standard digest as described above,
incorporating lpl (2-10U) of a second enzyme, was carried out. If no compatible
buffer could be used, the digests were performed sequentially. The enzyme with the
lower salt buffer was used in the first digest, and inactivated by heating at 65°C for
15 min. Sufficient salt to achieve the concentration required for the second digest
was then combined into the reaction and the second restriction enzyme was added.
Reactions were run on either analytical or preparative agarose gels after the addition
of DNA loading buffer (lpl loading buffer per lOpl sample).
2.2.4.5 DNA Fragment Recovery
DNA fragments required for construction of plasmids or templates for radioactive
probes were run on preparative agarose gels as described in section 2.2.2.2. Excised
bands were purified using a Roche High Pure PCR Product Purification Kit
according to the manufacturer's instructions. Samples were eluted in 15-30pl dH20
and stored at -20°C until required.
2.2.4.6 Ligation of Plasmid Vector and Insert DNA
The concentration of both vector and insert DNA was estimated by comparison with
known DNA concentrations during agarose gel electrophoresis. Ligation reactions
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were prepared in a total volume of lOpl, containing 1U T4 DNA ligase (Promega),
lpl 10 x ligation buffer and vector and insert DNA at amounts corresponding to the
appropriate molar ratio (usually 1:1). Reactions were incubated at 10°C overnight
and subsequently stored at 4°C.
2.2.4.7 Preparation of 32P-Labelled DNA Fragments for Southern Analysis
Probes for Southern analysis were generated using the Klenow fragment ofDNA
polymerase I using a Roche Random Primed Labelling Kit. Specifically, ~50ng
purified DNA fragment (made up to a volume of 9pi with dFLO) was denatured by
heating for 10 min in a glass beaker ofboiling water, then plunged immediately into
ice for 3 min. After a pulse spin, 2pl Solution 6 (random hexamers and buffer), 3pl
unlabelled nucleotides (dGTP,dATP,dTTP), 5pl [a32P]dCTP (~3000Ci/mmol) and
10U Klenow fragment (Promega) were added and the mixture was incubated for lh
at 30°C.
Unincorporated label was removed by passing the probe through a NICK column
(Amersham). NICK columns were prepared by removing storage buffer and rinsing
with 1ml TE prior to use. A further 3ml TE was allowed to drain through the column
before the probe was added. The probe volume was made up to 30pl with TE buffer
and added to the column. Two 400pl aliquots of TE buffer were then added. The
eluate of the first aliquot was discarded while that of the second was retained. 1 pi of
the second eluate was counted in 1ml liquid scintillant using a scintillation counter.
Specific activity was approximately 3500cpm/pg (assuming 70% recovery through
NICK column). Probes were denatured by heating to 100°C for 5-10 min before
addition to the hybridisation (see section 2.2.4.11)
2.2.4.8 Preparation of 32P-Labelled DNA Fragments for DNasel Footprinting
and Gel Mobility Shift Assays
Probes for DNasel footprinting reactions and gel mobility shift assays were
generated by 3'-end labelling using the Klenow fragment ofDNA polymerase I.
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Probes were synthesised such that only one end of the fragment incorporated the
label (i.e. there was only one recessed 3' end on which Klenow could act). Reactions
were carried out in a total volume of 25pl, incorporating 300ng purified DNA
fragment (made up to 14.5pl with dH20), 2.5pl 10 x Universal Restriction Buffer,
2pl unlabelled nucleotides (dGTP,dATP,dTTP) (Amersham), 5pl
[a32P]dCTP(~3000Ci/mmol) and 1 jul (10U) Klenow fragment (Promega). Reactions
were incubated at room temperature for 10 min and the enzyme inactivated by a
further incubation at 60°C for 10 min. Unincorporated label was removed using a
Roche High Pure PCR Product Purification Kit. Specifically, 300pl Binding Buffer
was added to the probe, the mixture was transferred to a Purification Column and
centrifuged at 12000g for 1 min. 500pl Wash Buffer was then added to the column
and centrifuged at 12000g for 1 min. This step was repeated with 200pl Wash
Buffer. Finally, the probe was eluted in 50pl dH20 and lpl was counted in 1ml
liquid scintillant as described previously. Specific activity was approximately
40000cpm/pmol fragment.
2.2.4.9 Preparation of 32P-I_abelled Double-Stranded Oligonucleotides for Gel
Mobility Shift Assays
Pairs of complimentary single stranded oligonucleotides were diluted to 50pmol/p.l in
TEN buffer and annealed by heating to 90°C for 10 min, followed by cooling slowly
to room temperature overnight. Complimentary oligonucleotides were labelled using
T4 DNA polynucleotide kinase in a 20pl reaction containing lOOpmol
complimentary oligonucleotides, 2pl 10 x Kinase Buffer, 2ul [y- PJATP
(~3000Ci/mmol) and 1 ju.1 (5U) T4 polynucleotide kinase (Promega). Reactions were
incubated at 37°C for lh, before the enzyme was inactivated by the addition of 80pl
TE and incubation at 68°C for lOmin. Unincorporated label was removed using a
Roche High Pure PCR Product Purification Kit as described in section 2.2.4.8.
Labelled oligonucleotides were eluted in 50pl dH20 to give lpmol/pl (assuming a
50% recovery from purification through the column) and counted using a
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scintillation counter. Specific activity was approximately 5000cpm/pmol double-
stranded oligonucleotides.
2.2.4.10 Maxam & Gilbert Sequencing Reactions
'G + A' Maxam & Gilbert sequencing reactions were carried out in conjunction with
DNasel footprinting experiments. The guanine and adenine bases of a radiolabelled
DNA fragment were modified with formic acid before cleavage with piperidine and
resolution on a denaturing polyacrylamide gel. Typically, 5pi labelled fragment was
incubated with 25pi formic acid for between 20s and 4 min and the reaction stopped
with 200pl 'hydrazine stop' buffer. DNA was precipitated by treatment with 250pl
0.3M sodium acetate and 750pl 100% ethanol before incubation on dry ice for no
more than 5 min. Following centrifugation for 5 min at 12000g, samples were
washed with 100% ethanol and air-dried at room temperature for at least 5 min.
Pellets were resuspended in 75pl 1M piperidine and incubated at 90°C for 20-30
min. Samples were then precipitated by addition of lpl tRNA (lOpg/pl) and 400pl
100% ethanol for 5 min on dry ice. After centrifugation for 5min at 12000g, samples
were again washed with 100% ethanol and air-dried at room temperature for at least
5 min. Finally, samples were resuspended in 4pl formamide loading buffer
(Promega) and heated at 100°C for 5-10 min before loading onto the gel.
2.2.4.11 Southern Blotting & Hybridisation
Southern analysis was carried out on restriction digests of genomic DNA and on
DNasel treated DNA as part ofDNasel hypersensitive site mapping (see section
2.2.10.2). For Southern analysis of genomic DNA from B103 and H4IIE cells, 15pg
DNA (see section 2.2.4.2) was digested with the appropriate restriction enzyme (see
section 2.2.4.4). Restriction digested and DNasel treated DNA samples were purified
according to section 2.2.4.3, resuspended in 20pl dF^O and run on Southern agarose
gels (see section 2.2.2.3). Following electrophoresis, Southern gels were rinsed in
dF^O and the DNA depurinated by soaking in Southern Depurination Solution with
gentle agitation on a rotating platform for 10 min. The gel was again rinsed in dF^O
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and the DNA denatured by soaking in Southern Denaturation Solution with gentle
agitation for 30 min. After a final rinse in dH20, DNA was neutralised by soaking in
Southern Neutralisation Solution with gentle agitation for 20 min. This neutralisation
step was repeated. DNA was blotted using a wick of 2 sheets of Whatman 3MM
paper in a tray of 20 x SSC. The wicks were flooded with 20 x SSC before the gel
was carefully placed on top ensuring no bubbles were trapped between the layers.
The gel was flooded with 20 x SSC and a pre-trimmed piece of Hybond-C
nitrocellulose membrane (Amersham Pharmacia) was carefully placed on top, again
ensuring no bubbles were present. Three sheets of Whatman 3MM paper, pre-cut to
size and pre-wet in 20 x SSC were then laid on top of the membrane, and the rest of
the wick was masked off with Saranwrap and parafilm to prevent 'short-circuiting'.
Finally, a stack of absorbent paper towels were placed on top of the Whatman paper
and the apparatus left overnight. Following transfer, membranes were baked between
2 sheets of Whatman 3MM paper for 2h at 80°C.
Prior to hybridisation, membranes were rehydrated in 5 x SSC at room temperature.
Subsequently, membranes were pre-hybridised in pre-warmed Prehybridisation
Buffer for at least 30 min at 65°C in tubes in a hybridisation oven. Denatured probe
(see section 2.2.4.7) was then added to the tube and hybridised for at least 16h at
65°C. After hybridisation, membranes were washed in approximately 50ml Southern
Wash Buffer I for 5 min at 65°C. Two further 10 min washes in Southern Wash
Buffer I followed. If required, membranes were subsequently washed for 10 min in
Southern Wash Buffer II, repeated as necessary. Membranes were wrapped in
Saranwrap to prevent them drying out and exposed against autoradiographic film as
described in section 2.2.3.
2.2.5 PCR Based Techniques
2.2.5.1 Exon 1 Specific RT-PCR
Reverse transcription of RNA samples was carried out using the Promega Reverse
Transcription System. Reactions were prepared using 4pg RNA and lpg of either
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oligo(dT)i5 or random primers in a total volume of 40pl according to the supplied
protocol. For each RNA sample, reactions both with and without AMY Reverse
Transcriptase were prepared in order to control for DNA contamination in the
subsequent PCR. RT products were either stored at -20°C or used immediately as
substrates for PCR.
PCR reactions were carried out using a Promega TaqBead Hot Start Polymerase kit
according to the manufacturer's instructions. Reactions included 5pi RT product and
240pmol of each 3'(exon 2/luciferase) and 5' (exon 1-specific) primer in a total of
50pl. PCR was performed on an Techne Genius Thermocycler machine according to
the following regime (each reaction was overlaid with 2 drops of mineral oil in lieu
of a heated lid):
Segment Cycles Temperature Time
1 1 95°C 4min 10s
2 34 95°C 50s
50°C 45s
72°C lmin 30s
3 1 72°C 5min
4 1 4°C Hold
lOpl of each reaction was run on an analytical agarose gel.
2.2.5.2 General RT-PCR
RT-PCR reactions were carried out as described in section 2.2.5.1, using GR or
GAPDH primer pairs as necessary.
2.2.5.3 Competitive RT-PCR
First strand cDNA synthesis for competitive RT-PCR was carried out using the
Amersham Pharmacia First Strand cDNA Synthesis kit. Either 150ng or 200ng
sample RNA was incubated with the appropriate concentration of competitor RNA in
a total volume of 8pl (made up with nuclease free water) at 65°C for lOmin and then
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immediately placed on ice. 5pl RT Buffer Mix, lpl DTT and lpl Random Hexamers
were added to each sample and the mixture incubated at 37°C for In. cDNA product
was either stored at -20°C or used immediately for PCR.
PCR was carried out in a total reaction volume of 50pl incorporating 32pl nuclease
free H20, 5pi 10 x Taq DNA polymerase buffer + 1,5mM MgCl2 (Roche), lpl dNTP
mix (lOmM, Promega), 2pl each of GR-1 primer (lOpM) and GR-2 primer (lOpM),
7.5pl RT product and 0.5pl Taq DNA polymerase (lU/pl, Roche). PCR was
performed on a Techne Genius machine according to the following regime (a heated
lid negated the need for mineral oil):
Segment Cycles Temperature Time
1 1 94°C 3min
2 30 94°C 40s
54°C 40s
72°C 40s
3 1 72°C lOmin
4 1 4°C Hold
2.2.5.3.1 Quantification of Competitive RT-PCR
10pl of each reaction was run on a standard agarose gel and analysed on a Fugi FLA-
2000 VI.0 phosphorimager using a fluorescence 473nm:O580 filter. Quantification
and comparison of DNA band intensity was carried out using A IDA version 2.0 2D
Densitometry software. Data were transferred to an Excel spreadsheet (Microsoft)
and absolute levels of sample RNA were calculated by regression analysis as
described previously (Lai, 2003).
2.2.5.4 In vitro site-directed mutagenesis
Site-directed mutagenesis of plasmid DNA was carried out using the Stratagene
QuikChange XL Site-Directed Mutagenesis Kit. Details of plasmid templates and
primers employed are given in sections 2.1.7.2 and 2.1.8. Each reaction was carried
out in a total volume of 50pl incorporating 5pl 10 x reaction buffer, 5pl plasmid
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template (lOng/pl), 1.25pl each primer (lOOng/pl), lpl dNTP (lOmM), 2pl
QuikSolution, 33.5pl dH20 and Ipl PfuTurbo DNA polymerase (2.5U/pl). Thermal
cycling was carried out on a Techne Genius machine according to the following
regime (a heated lid negated the need for mineral oil):
Segment Cycles Temperature Time
1 1 95°C lmin 30s
2 18 95°C lmin
68°C 20min
3 1 68C 7min
4 1 4°C Hold
Following thermal cycling, each reaction was incubated with lpl Dpnl restriction
enzyme (10U/pl) at 37°C for lh in order to digest the parental (nonmutated) DNA.
2.2.6 Cloning of DNA
2.2.6.1 Preparation of competent E.coli
FIB 101, a RecA strain of E.coli, was used for general cloning procedures. Competent
cells were prepared by inoculating 2ml LB with a single HB101 colony and
incubating at 37°C overnight in an orbital shaker (160rpm). A further 50ml LB was
then added to the culture and incubated at 37°C in an orbital shaker at 160rpm for
1.5-2h (until A6oo«0.4). After pouring into a pre-chilled sterile 50ml centrifuge tube,
the cells were collected using a Beckman JA-20 rotor in a Beckman J2-MC
centrifuge at 6000rpm for 5 min at 4°C. The resultant pellet was carefully
resuspended in 20ml cold 0.1M CaCl2 and incubated on ice for 0.5-2h. Cells were
again centrifuged at 6000rpm for 5 min at 4°C and resuspended in 2ml cold 0.1M
CaCl2. The resultant competent cells were either used immediately or stored on ice at
4°C for up to 3 days (with daily changes of ice). Transformation of products of site-




To transform competent HB101 cells, 200pl cells were pipetted into pre-chilled
eppendorf tubes on ice. 200-500ng DNA was added to the cells followed by
incubation on ice for 20-30 min. Cells were then heat-shocked at 42°C for exactly
50s and replaced on ice for 2-3 min. The whole reaction was then spread onto
LB/Agar/Ampicillin plates and left to air dry for approximately 10 min. Plates were
then incubated upside down overnight at 37°C.
Transformation of XL-Gold ultracompetent cells was carried out using the
QuikChange XL-Site-Directed Mutagenesis Kit (Stratagene) following the protocol
supplied. One tube of cells was thawed on ice and 45pl aliquots were placed in pre-
chilled eppendorfs. 2pl P-mercaptoethanol was added to each aliquot with gentle
mixing. Cells were incubated on ice for 10 min with gentle mixing every 2 min. 5pi
Dpnl-treated sample DNA was added to the cell aliquots and incubated on ice for 30
min. Tubes were heat-shocked in a 42°C water bath for precisely 30s and
immediately transferred to ice for 2-3 min. 0.5ml chilled LB broth was added to each
tube and incubated at 37°C for lh in an orbital shaker (140rpm). In order to prepare
LB/Agar plates for blue-white colour screening, 50pl lOmM IPTG (Promega) and
50pl 50mg/ml X-Gal (Promega) were spread over the surface and incubated face up
at 37°C for 30 min prior to plating transformations. Sample reactions were
centrifuged at lOOOrpm for 10 min and the pellet resuspended in 200pl LB. The
whole reaction was then spread on the prepared agar plates and left to air-dry for 10
min before incubating upside down overnight at 37°C.
2.2.6.3 Screening of Clones: Minipreps
Screening of transformants was carried out by small-scale preparation ofplasmid
DNA followed by appropriate restriction digests and/or sequencing. Single colonies
from transformed plates were inoculated into 1.5ml LB/Ampicillin and incubated
overnight at 37°C in a rotating oven (180rpm). Picked colonies were also patched
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onto LB/Agar/Ampicillin plates and incubated overnight at 37°C. The following
morning, cultures were poured into eppendorfs and spun for 1 min at 13000rpm. The
supernatant was removed and the pellet resuspended in lOOpl GTE. Lysis was
achieved with the addition of 200pl 0.2M NaOH/l%SDS and vigorous vortexing.
Cells were incubated on ice for 15 min before the addition of 150pl potassium
acetate (pH 4.8) and vigorous vortexing. After a further 15 min incubation on ice,
samples were centrifuged for 5 min at 13000rpm. 450pl of supernatant was removed
and added to an equal volume ofphenol/chloroform/IAA with vortexing. After a 2
min centrifugation at 13000rpm, the upper aqueous layer was removed and added to
2 vol 100% ethanol. Samples were incubated at room temperature for 5 min,
centrifuged for 5 min at 13000rpm and allowed to air-dry. Pellets were resuspended
in 50pl TE + lpl RNase A (lmg/ml).
2.2.6.4 Large scale plasmid DNA preparation: CsCI density gradient
centrifugation
Large scale plasmid DNA preparations were carried out on all novel plasmid DNA
constructs and all plasmids used in transient transfection assays. Following
transformation, single colonies were picked into 2ml LB/Ampicillin and incubated at
37°C for approximately 6h in an orbital shaker (180rpm). The cultures were then
used to inoculate 500ml LB/Ampicillin and incubated at 37°C overnight in an orbital
shaker (160rpm). Cells were collected by centrifugation in 250ml centrifuge pots at
6000rpm for 5 min at 4°C using a Beckman JA-14 rotor in a Beckman J2-MC
centrifuge. The bacterial pellet was completely resuspended in 12ml GTE (per 500ml
culture), followed immediately with the addition of 24ml freshly prepared 0.2M
NaOH/l%SDS and vigorous shaking. After a 10 min incubation on ice, 16ml cold
potassium acetate was added, shaken vigorously and the mix replaced on ice for a
further 10 min. Bacterial debris was removed by centrifugation at 6000rpm for 5 min
(as previously) and filtered through 2 layers of gauze into fresh 250ml centrifuge
pots. DNA was precipitated by adding 32ml isopropanol and incubating for 30 min at
room temperature followed by centrifugation at lOOOOrpm for 3 min. After removal
of supernatant, pellets were allowed to air-dry for at least lh. At this stage, pellets
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were resuspended in 2.2ml TE before the addition of 2.95g CsCl (to give a final CsCl
concentration of 1.67g/ml). lOOpl ethidium bromide was added in order to visualise
the DNA and the solution was carefully transferred into 3ml Beckman Quikseal
tubes. Samples were centrifuged in a TLA100.3 rotor in a Beckman Optima TLX
centrifuge at 20°C. After an initial spin at 70000rpm for 18h, banded plasmid DNA
was withdrawn through the tube wall using a needle and syringe and transferred into
a new ultracentrifuge tube. Tubes were filled with TE/CsCl (prepared by adding
lOOg CsCl to 100ml TE) and re-spun at lOOOOOrpm for 4h. Banded DNA was
withdrawn as described previously and ethidium bromide was removed by repeated
isopropanol extractions until the pink colour had completely disappeared. Salt was
removed by dialysis against 3 changes of TE for 24h at 4°C. DNA concentration was
measured using a GeneQuant spectrophotometer (Pharmacia Biotech) before storage
at -20°C.
2.2.7 Transient Transfection
2.2.7.1 Calcium phosphate precipitation method
Transient transfection by the calcium phosphate precipitation method was carried out
in B103 cells as first described by Graham & van der Eb (Graham & van der Eb,
1973). All transfections were carried out in triplicate to at least n=5 using at least two
independently prepared plasmid DNAs isolated by CsCl density gradient
centrifugation. Promoter activity was determined by luciferase expression while
transfection efficiency was controlled for by P-galactosidase activity. Cells were
harvested by centrifugation in a Heraeus Labofuge 400R at 1200rpm for 3 min
followed by resuspension in DMEM plus serum to give 2 x 105 cells/ml. 1ml of cells
were added to 60mm dishes containing 3ml DMEM plus serum and incubated at
37°C with 5% CO2 for 24h before transfection. Medium was replaced at least lh
prior to transfection and all transfection solutions were equilibrated to room
temperature before use. Two tubes were prepared for each transfection, the first
containing a total of lOpg DNA and 37pl 2M CaCf>, made up to 300li1 with dEEO,
and the second containing 300pl 2 x HBS. Control DNA solutions were as follows:
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(i) 1 Ojug pGEM3 (negative control), (ii) 5pg pSV2 luciferase (positive control) + 4pg
pGEM3 + lpg pCHl 10. In addition to reporter plasmid, each experimental DNA
solution contained lpg pCHl 10 (P-Galactosidase expression plasmid) and DNA
concentration adjusted with pGEM3 to give a total of lOpg. For transfections
involving autoregulation by GR, an expression plasmid encoding human GR,
pRShGR was included at either 10 or lOOng. Each tube of 2 x HBS was gently
vortexed while the DNA solution was added dropwise, and incubated for 30min at
room temperature. Solutions were vortexed again before dropwise addition to the
transfection plates with gentle agitation. Medium was refreshed 24h post-
transfection. Dexamethasone was added, where appropriate, at least lh post-
transfection. 'Treated' cells were given 4.6pl ImM or lOpM dexamethasone (in
ethanol) to give final concentrations of 1 x 10"6M and 1 x 10~8M dexamethasone
respectively. 'Untreated' cells were given 4.6pl ethanol. Treatments were repeated
lh after the medium was changed, 24h after transfection. 48h post-transfection, cells
were washed carefully in 1 x PBS and incubated in 300pl lysis buffer for 20 min.
Transfection dishes were scraped with rubber policemen and cell lysates were
transferred into eppendorf tubes. Cell debris was pelleted by centrifugation at
13000rpm for 2 min and assays were carried out on the cell lysates immediately.
2.2.7.2 Cationic lipid method
Transient transfection using lipofectin (Invitrogen), a cationic lipid, was carried out
in H4IIE cells. Cells were seeded at 2 x 105 cells in 4ml DMEM plus serum and
incubated for 24h before transfection at 37°C with 5% CO2. Two tubes were
prepared for each transfection, the first containing 4pg DNA adjusted to 200pl with
Opti-MEM (Invitrogen), the second containing 16pl lipofectin adjusted to 200pl with
Opti-MEM. Control transfections contained (i) 4pg pGEM3 (ii) 2pg pSV2 luciferase
+ lpg pGEM3 + lpg pCHl 10. In addition to reporter plasmid, experimental DNA
solutions contained lpg pCHl 10 and pGEM3 adjusted to give a total DNA
concentration of 4pg. Tubes were allowed to stand at room temperature for 30-45
min before being mixed together gently and incubated for a further 15 min. 1.6ml
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Opti-MEM was then added to each tube containing the lipofectin-DNA complexes.
Cells were washed with 3ml Opti-MEM before the transfection solution was gently
overlaid. Cells were incubated for 6h at 37°C after which the transfection solution
was replaced with 4ml DMEM plus serum. Cells were harvested 48h post-
transfection as described above.
2.2.7.3 Luciferase Assays
Luciferase assays were carried out in duplicate on each triplicate transfection sample,
with all solutions equilibrated to room temperature prior to use. 5pl 30mM ATP
(Sigma), lOOpl Luciferase Assay Buffer and 40pl cell lysate were combined in 5ml
Rohren tubes (Sarstedt). Luciferase activity was assayed over 10s using a Lumat
LB9501 luminometer which injected 105pl ImM beetle luciferin (Promega) into
each sample. The mean of each duplicate reading was recorded.
2.2.7.4 p-Galactosidase Assays
p-Galactosidase assays were carried out in duplicate using a Galacto-Light Plus kit
(Tropix) equilibrated to room temperature before use. Fresh Galacton Plus reagent
was diluted 1:100 in its Reaction Buffer Diluent and 67pl of the diluted solution was
added to lOpl cell lysate. Samples were incubated at room temperature for 30-45min
and P-Galactosidase activity was assayed in the luminometer as described above,
which injected 105pi Light Emission Accelerator reagent. The mean of each
duplicate reading was again recorded.
2.2.7.5 Transfection Data Analysis
The mean of each duplicate luciferase and P-galactosidase reading was entered into a
Microsoft Excel spreadsheet for analysis. The negative pGEM3 control reactions
provided background data for both luciferase and P-galactosidase assays; mean
luciferase and P-galactosidase values pGEM3 were calculated and subtracted from
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all experimental values. Promoter activity was expressed as luciferase activity/(3-
Galactosidase activity in order to control for variations in transfection efficiency
between dishes. Values were expressed relative to the appropriate control vector
(pGL3-BM or pGL3 Promoter) given an arbitrary value of 1, or, where appropriate,
relative to P2 given an arbitrary value of 100%.
2.2.8 Protein techniques
2.2.8.1 Preparation of nuclear extracts for the analysis of protein-DNA
interaction
Nuclear extracts from B103 or H4IIE cells were prepared as described by Dignum et
al (Dignam et al., 1983). The cells from 20 x F75 flasks were dislodged either by
tapping (B103) or treatment with trypsin (H4IIE) as described in section 2.2.1. Cells
were pooled and collected by centrifugation in an Heraeus Labofuge 400R at
1200rpm for 5 min at 4°C. The pellet was resuspended in 5 x packed cell volumes
(PCV) of 1 x PBS and centrifuged as before. Cells were resuspended in 5 x PCV of
pre-chilled Nuclear Extract Buffer A (NEBA) and counted using a Neubauer
Improved Haemocytometer. Following a 10 min incubation on ice, cells were spun
as before and resuspended in 2 x PCV NEBA. The solution was transferred to a pre-
chilled Dounce 1ml all-glass homogeniser and the cells lysed with 10 strokes of the
tight pestle. Lysis was confirmed by microscopic analysis (xlO magnification) and
the solution was spun as before. The supernatant was removed and the remaining
pellet was transferred to a pre-chilled sterile 50ml Beckman tube. Further
centrifugation was carried out using a Beckman JA-20 rotor in a Beckman J2-MC
centrifuge at lOOOOrpm for 20 min at 4°C. A total of 3ml Nuclear Extract Buffer C
(NEBC) per 109 cells was used to resuspend the pellet. The solution was then
transferred to a pre-chilled Dounce 1ml all-glass homogeniser and lysed by 10
strokes of the tight pestle. The suspension was transferred to a pre-chilled glass
beaker and stirred with a magnetic bead for 30 min at 4°C before centrifugation in a
Beckman J2-MC centrifuge at lOOOOrpm for 30 min at 4°C. The supernatant was
retained and dialysed against 50 x volumes ofpre-chilled Nuclear Extract Buffer D
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(NEBD) for 5h at 4°C. Following a final centrifugation in a Beckman J2-MC
centrifuge at lOOOOrpm for 20 min at 4°C, the supernatant was aliquoteci into pre-
chilled eppendorf tubes and snap frozen in liquid nitrogen. Samples were stored at -
80°C.
2.2.8.2 Estimation of protein concentration of extracts
Protein concentrations were estimated using the BioRad protein assay based on the
Bradford method. The BioRad protein assay dye reagent concentrate was diluted 1:5
with dfEO to give a working solution. A standard protein curve was constructed in
duplicate by preparing standards containing 0, 1.5, 3, 6, 9, 12 and 15pg bovine py-
globulin (made up to lOpl with dEEO) in a standard 96-well plate. A range of sample
concentrations were also prepared in duplicate (adjusted to 10pl with dh^O), and
200pl BioRad reagent was added to both controls and samples before incubation at
room temperature for 5-10 min. The plate was then inserted into a Bio-tek
Instruments EL 312e microplate bio-kinetics reader and absorbance at 570nm was
measured. A calibration curve was obtained from the standards, against which
sample protein concentrations could be calculated.
2.2.9 Analysis of Protein-DNA interactions
2.2.9.1 Gel Mobility Shift Assays
Protein-DNA interactions were analysed by gel mobility shift assays as described by
Singh et al (Singh et al., 1986). Specifically, reactions were carried out in a total
volume of 30pl incorporating 6pl 5 x Gel Mobility Shift Assay Buffer, 3pg non¬
specific DNA competitor poly (dl-dC).(dl-dC), 0-40pg protein extract and either
30fmol [32P]-labelled DNA fragment or O.lpmol [32P]-labelled double-stranded
oligonucleotide. Reactions were incubated for 15 min at room temperature prior to
"I'j
the addition of [ "P]-labelled DNA and a further 15 min prior to loading onto a non-
denaturing polyacrylamide gel (section 2.2.2.4).
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Competition gel mobility shift assays were carried out using 10- or 100-fold molar
excess of unlabelled specific or non-specific competitor fragments or
oligonucleotides. Competitors were added to gel shift reactions just prior to the
addition of [32P]-labelled DNA. Gel Mobility Supershift Assays were also
undertaken, in which antibodies to specific transcription factors were included in the
reactions and further retarded protein-DNA complexes during electrophoresis.
Specifically, 1 pg antibody was included in the pre-incubation prior to the addition of
[32P]-labelled DNA.
2.2.9.2 DNasel Protection Analysis
DNasel 'footprinting' analysis of protein-DNA binding was undertaken as described
by Galas & Schmitz (Galas & Schmitz, 1978). Reactions were prepared in a total
volume of 40pl containing 8pl 5 x DNase I Protection Buffer, lpg poly(dI-dC).(dI-
dC) and 0-50pg protein extract. Following incubation on ice for 15 min, -200000
cpm radiolabelled DNA (see section 2.2.4.8) was added. Reactions were further
incubated on ice for at least 30 min. Samples were treated with 0.2-0.5U DNasel for
exactly 1 min and reactions were stopped with lOpl DNase I Footprinting Stop
Solution. Samples were purified by phenol/chloroform extraction; 50pl
phenol/chloroform/IAA was added to each sample and vortexed vigorously for 15s.
After centrifugation at 12000g for 2 min, the upper aqueous layer was transferred to
a fresh tube and extracted with 50pi chloroform. After further vortexing and
centrifugation, the upper layer was again transferred to a fresh eppendorf tube. DNA
samples were precipitated with lpl tRNA (lOpg/pl) and 125pi 100% ethanol and
incubated on dry ice for no more than 7 min. DNA was collected by centrifugation at
12000g for 10 min at room temperature. Pellets were washed with ice-cold 100%
ethanol and air-dried for 5-10 min before resuspension in 4-8pl formamide loading
buffer (Promega). Samples were denatured for 10 min at 100°C before loading onto a
denaturing polyacrylamide gel as described in section 2.2.2.5.
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2.2.10 Analysis of Chromatin: DNasel Hypersensitive Site Mapping
2.2.10.1 Preparation of Nuclei
7 x F75 flasks of confluent H4IIE cells were used to prepare nuclei for DNasel
hypersensitive site mapping. First, the medium was aspirated and the cells were
washed twice in 1 x PBS. 3ml trypsin was applied to each flask followed by
incubation at 37°C for 2 min. After dislodging the adherent cells, 7ml FCS was
added to each flask and the mixture transferred to 2 x 50ml falcon tubes. Cells were
collected by centrifugation in an Heraeus Labofuge 400R at 1200rpm for 3 min at
4°C and carefully resuspended in a total of 5ml pre-chilled Nuclei Buffer A (NBA).
A small aliquot was removed at this stage for later comparison. In order to lyse the
cell membrane, 5ml pre-chilled NBB was added and the mixture incubated on ice for
3 min. Nuclei were pelleted by centrifugation at 1200rpm for 3 min at 4°C and
carefully resuspended in 5ml pre-chilled NBC. A further centrifugation at 1200rpm
for 3 min at 4°C was followed by resuspension in 0.5ml NBC. The presence of intact
nuclei at this stage was confirmed by comparison with the earlier, pre-lysis aliquot
under 40 x magnification. A sample of nuclei was digested in 1% SDS and
approximate DNA concentration was estimated by A260 measurement on a Shimadzu
UV-160A spectrophotometer. After dilution with cold NBC to give a solution of 10
A260 units/ml, nuclei were kept on ice and used immediately.
2.2.10.2 DNasel Treatment
lOOpl aliquots of nuclei (section 2.2.10.1) were treated with DNasel at 30, 40 and 50
U/ml for exactly 0, 1, 2, 4 and 8 min. Enzyme activity was stopped with lOOpl
DNasel Stop Solution. Each reaction was treated with 5pi RNaseA to remove RNA
and incubated with proteinase K (at a final concentration of lOOmg/ml) for 2h at
37°C. Samples were purified as described in section 2.2.4.3 and subject to Southern
analysis as described in 2.2.4.3.
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3 Analysis of GR alternate exon 1 expression in a variety of rodent cell
lines.
3.1 Introduction & Aims
Evidence discussed in Chapter 1 generated the hypothesis that the multiple exon 1
structure of the GR promoter may be involved in the tissue-specific regulation of GR
levels. This hypothesis implies that tissues show specific patterns of GR exon 1
expression.
Previous work carried out in this laboratory identified eleven potential alternate
exons 1 (termed 11, 12, I3, I4, I5, 16, h, ls,l9,lioand In) (McCormick et al., 2000),
five of which have also been described in mouse (Strahle et al., 1992; Chen et al.,
1999) and three in human (Breslin et al., 2001; Nunez & Vedeckis, 2002) (see
fig. 1.3). Further analysis demonstrated that expression of exons G and \^ was
hippocampus-specific, exon 11 expression was thymus-specific and expression of
exons If, and 110 was ubiquitous (McCormick et al., 2000; McCormick, 2000).
Correspondingly, studies of human and mouse tissues showed that exons IB and 1C
(homologous to rat exons 16 and 110 respectively) were also ubiquitously expressed,
albeit at varying levels (Strahle et al., 1992; Breslin et al., 2001; Nunez & Vedeckis,
2002).
Further to the in vivo data described above, the experiments detailed in this chapter
aimed to identify rodent cell lines in which alternate GR exons 1 are differentially
expressed. In this way, cell lines displaying specific patterns of GR exon 1
expression could be compared and manipulated with relative ease. Cell lines have the
additional advantage of cell type homogeneity, compared to the often heterogeneous
nature of tissues. A variety of rodent cell lines representing a range of tissues were
therefore screened for GR alternate exon 1 expression. In identifying cell lines that
could satisfactorily model in vivo tissues, it was also important to ensure that
absolute levels of GR were comparable. As such, a quantitative analysis of GR
mRNA in various rodent cell lines was also undertaken.
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3.2 Experimental Design
3.2.1 RT-PCR analysis of GR alternate exon 1 expression in rodent cell lines.
To investigate the cell specific expression of GR alternate exons 1, non-quantitative
RT-PCR analysis was performed on a range of rodent cell lines including H4IIE (rat
hepatoma), KNRK (rat kidney), PC 12 (rat pheochromocytoma), NG-108 (rat
glioma), EL-4 (mouse lymphoma) and S-49 (mouse lymphoma). First strand cDNA
synthesis was carried out using an oligo(dT) primer and PCR reactions were
performed using 5' primers specific for individual GR exons 1 in conjunction with a
common 3' primer complementary to GR exon 2 (section 2.1.7.1). Positive control
reactions for each primer pair were carried out on rat thymus (exon 11) and rat liver
(exons I4, I5, 16, 17, 110 and ln)-In order to control for DNA contamination ofRNA
samples, negative control reactions were also carried out for each cell sample and
primer pair, in which the reverse transcription step was carried out in the absence of
AMV Reverse Transcriptase enzyme. Where appropriate, RT-PCR reactions were
carried out in order to detect 'total' GR using 5' and 3' primers specific for exons 2
and 3 respectively. Predicted PCR product sizes are given in table 3.1.










Table 3.1 Predicted sizes ofPCR products.
3.2.2 De-methylating treatment of a cell line lacking GR expression.
The hypothesis that methylation of the GR locus is responsible for the absence of GR
expression in the B103 cell line was tested by treating cells with the de-methylating
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agent 5-aza-2'-deoxycytidine (5-Aza-CdR). If methylation has 'silenced' the GR
locus, treatment with 5-Aza-CdR should restore GR expression. Cells were therefore
grown in 60mm dishes for 24h in the presence or absence of 2pM 5-Aza-CdR.
Following extraction, RNA sample integrity was first verified by denaturing gel
electrophoresis. Subsequently, RT-PCR analysis was carried out to detect GR
mRNA, with the inclusion of appropriate positive and negative controls (as described
in section 3.2.1).
3.2.3 Quantitative RT-PCR analysis of GR expression in rodent cell lines.
Quantitative RT-PCR was carried out in order to establish model rodent cell lines
that express GR at levels equivalent to in vivo tissues. The rat GR competitor used in
these experiments has been described previously (Lai et al., 2003; section 2.1.8).
The quantitative RT-PCR strategy is based on the principle that the GR competitor
yields a truncated product (550bp) in relation to endogenous GR (630bp) when PCR
using GR-specific primers is performed. As such, reactions were carried out using a
series of known competitor concentrations combined with a constant amount of
sample RNA. At the point when the two PCR products show equal intensity, the
concentration of endogenous mRNA is equivalent to that of exogenously added
competitor (see section 2.2.5.3.1 for details of calculation method).
3.3 Results
3.3.1 All alternate exons 1 located in the CpG island region are present in all
rodent cell lines tested, but exon 1i expression is restricted to T cells.
GR exon 1-specific RT-PCR reactions were carried out on H4IIE (rat hepatoma),
KNRK (rat kidney), PC-12 (rat pheochromocytoma), NG-108 (rat glioma), EL-4
(mouse lymphoma) and S-49 (mouse lymphoma) cells. Results show that products
corresponding to the predicted sizes of all alternate exons 1 examined were
expressed in all cell lines tested (fig. 3.1). The exception was the exon 11 product,
which was restricted to the T cell lines EL-4 and S-49. It should be noted that several
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Figure 3.1 lCpG island' exons 1 are present in all rodent cell lines tested whilst exon
11 expression is restricted to cells ofthe immune system.
Representative RT-PCR using primers specific to individual GR exons 1 in
conjunction with a common GR exon 2 primer. RT reactions were performed using
4pg RNA extracted from the following cell lines: H4IIE (rat hepatoma), KNRK (rat
kidney), PC-12 (rat adrenal pheochromoctyoma), NG-108 (rat glioma), EL-4 (mouse
lymphoma) and S-49 (mouse lymphoma), which were subsequently divided between
exon 1-specific PCR reactions. Positive control reactions were carried out on rat
thymus (exon li) and rat liver (exons 11, I4, I5, \$, 17, 110 and In). Negative control
reactions were also carried out for each primer pair in each cell line using RT
reactions minus AMV reverse transcriptase. No bands were observed in the negative
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PCR products, particularly 11, appeared as a doublet. Sequence analysis showed that
these products differed in the size of a (CAG)n repeat located at the beginning of
exon 2 (J.Nixon, personal communication).
3.3.2 GR is not expressed in B103 cells
No products from individual GR exon 1 transcripts were observed when the RT-PCR
analysis described above was carried out on B103 (rat neuroblastoma) cells (data not
shown). Further RT-PCR analysis was carried out to determine if B103 cells indeed
express GR. The integrity of B103 RNA was first verified by denaturing agarose gel
electrophoresis (data not shown). Subsequently, RT-PCR reactions using primers
specific to both GR and the positive control gene GAPDH were performed. GAPDH
mRNA was present in both rat liver and B103 cells, while GR mRNA was only
detected in liver (fig. 3.2). No significant bands were observed in the negative
control reactions. B103 cells do not, therefore, appear to express GR.
3.3.3 5-aza-2'-deoxycytidine treatment does not restore GR expression in
B103 cells.
To test the hypothesis that methylation of the GR CpG island region has 'silenced'
GR expression, B103 cells were treated with the known de-methylating agent 5-aza-
2'-deoxycytidine (5-Aza-CdR). RT-PCR reactions were then performed on RNA
extracted from rat liver as well as 5-Aza-CdR treated and untreated B103 cells, using
primers specific for GR and the positive control gene GAPDH.
GAPDH mRNA was shown to be present in both untreated and 5-Aza-CdR treated
B103 cells (fig. 3.3). However, GR mRNA was not detected in untreated B103 cells,
nor was it restored following treatment with 2pM 5-Aza-CdR. The integrity of the
GR reaction was confirmed by the detection of a GR product in rat liver.
Surprisingly, in this experiment no GAPDH transcript was detected in rat liver RNA,
although it was clearly present in other experiments (e.g. figure 3.2). The reason for
the lack of GAPDH product observed in this experiment is unknown. No bands were
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Figure 3.2 GR is not expressed in B103 cells.
RT-PCR using primers specific for GR and GAPDH carried out on 4pg RNA
extracted from rat liver ('L') or B103 ('B') cells. Reactions were performed in the
presence (+) or absence (-) of reverse transcriptase (RT). lkb ladder was run in lane
M and the 1636bp, 1018bp and 506bp markers are labelled. Products corresponding
to GAPDH (lOOlbp) and GR (630bp) are also indicated.
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Figure 3.3 5-aza-2 '-deoxycytidine treatment does not restore GR mRNA expression
in B102 cells.
RT-PCR using primers specific for GR or GADPH (GP) on 4pg RNA extracted from
either rat liver or B103 cells grown in the presence or absence of 2pM 5-aza-2'-
deoxycytidine (Aza). Reactions were performed in the presence (+) or absence (-) of
reverse transcriptase (RT). lkb ladder was run in lane M and the 1636bp, 1018bp and
506bp markers are labelled. Products corresponding to GAPDH (1001 bp) and GR
(630bp) cDNAs are also indicated.
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observed in any of the negative control reactions. It appears, therefore, that treatment
with the de-methylating agent 5-Aza-CdR does not restore GR expression in B103
cells.
3.3.4 Competitive RT-PCR analysis of GR expression in H4IIE, 2S FAZA and
PC-12 cells.
Measurement of absolute GR mRNA levels in rat liver as well as H4IIE (rat
hepatoma), 2S FAZA (rat hepatoma) and PC-12 (rat pheochromocytoma) cells was
carried out using competitive RT-PCR. Representative RT-PCR results showed the
presence of both 630bp and 550bp products, produced from endogenous and
competitor GR RNA respectively, in all samples (fig. 3.4A, rat liver; B, 2S FAZA;
C, H4IIE; D, PC-12). H4IIE cells were found to express GR mRNA at a
concentration of 2.4 x 107 copies/pg total RNA, very similar to the levels of 2.5 x 107
copies/pg total RNA detected in rat liver (fig. 3.4E). In addition, 2S FAZA and PC-
12 cells were shown to express GR levels of 8.5 x 105 and 1.7 x 106 copies/pg total
RNA respectively.
3.4 Discussion
Experiments described in this chapter aimed to identify rodent cell lines that could
satisfactorily model GR expression observed in vivo tissues. Specifically, overall
levels of GR mRNA and patterns of alternate GR exon 1 expression were
investigated. Results described here showed that in all cell lines tested, including
H4IIE (rat hepatoma), KNRK (rat kidney), PC-12 (rat pheochromocytoma), NG-108
(rat glioma), EL-4 (mouse lymphoma) and S-49 (mouse lymphoma) cells, products
corresponding to GR exons I4, I5, U, I7, 110 and In were present. It should be noted
that variability in detection of the 14 product may be due to its general low
abundance. Previous work has shown that exon l4-containing transcripts are
relatively rare (McCormick et al., 2000; Freeman, 2003). Consistent with this, the
exon 14 transcript could be detected in all cell lines under RT-PCR conditions in
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Figure 3.4 Competitive RT-PCR measurement ofGR mRNA levels in rat liver,
2S FAZA, H4IIE and PC-12 cells.
Representative gels showing competitive RT-PCR analysis using GR-specific
primers on 150ng or 200ng RNA extracted from rat liver (A), 2S FAZA (B), H4IIE
(C) and PC-12 (D) cells. RT reactions were supplemented with a synthetic GR
competitor at levels between 1.6 x 10"11 and 1.5 x 10"12 moles as shown. Products of
630bp and 550bp, generated by endogenous and competitor RNA respectively, are
labelled. Panel E shows the absolute levels of endogenous GR mRNA for each cell
type. Calculations were performed as described in section 2.2.5.3.1.
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Cell Type Moles/ug total RNA No. copies/ng total RNA
Rat Liver 4.2 x 10"17 2.5 x 107
2SFAZA 1.4 x 10"18 8.5 x 105
H4IIE 4.0 x 10"17 2.4 x 107
PC-12 2.8 x 10'18 1.7 x 106
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which more RNA template was included or the number of amplification cycles was
increased (data not shown).
It was interesting that a consistent relationship between the intensities of alternate
GR exon 1 products was observed in most samples. Products corresponding to exons
110, In and 16 showed the greatest intensities in all cell lines tested, which might be
expected from the higher levels of exons U and 110 previously observed in rat tissues
(McCormick et al., 2000; McCormick, 2000). While it must be remembered that
PCR is a non-quantitative technique, these data suggest that absolute levels of
alternate exons 1 may vary between tissues. Nevertheless, all alternate GR exons 1
located in the CpG island region were expressed to some degree in all cell lines
tested. In theory, RT-PCR can detect a single mRNA transcript present in a sample
and is therefore a more sensitive technique than RPA. As such, while transcripts
corresponding to the 'minor' exons 14, 15, 17 and In were below the limit of
detection of the RPA analysis carried out by McCormick et al, (McCormick et al.,
2000), they were readily identified by the more sensitive RT-PCR technique used in
these experiments. Indeed, further RT-PCR analysis carried out in this laboratory has
identified all 'CpG island' alternate exons 1 in all rat tissues tested (Freeman, 2003).
These results are consistent with data gained from mouse cells and tissues showing
that expression of the 'CpG island' exons IB, 1C, ID and IE (homologous to rat
exons 16, 1 io, Is and ln respectively) is ubiquitous (Strahle et al., 1992; Chen et al.,
1999). Similarly, human GR exons IB and 1C (equivalent to 16 and 110) have been
detected in all human cell lines investigated, including Jurkat (T-cell ALL), HeLa
(cervical carcinoma), HepG2 (hepatoma), IM-9 (B-cell lymphoma), CEM-C7 (T-cell
lymphoblasts), HL-60 (myeloid leukaemia), MCF-7 (breast carcinoma), 786-0
(kidney carcinoma), SJSA (osteosarcoma), HI299 (lung carcinoma) and WI-38
(fibroblasts) (Breslin et al., 2001; Nunez & Vedeckis, 2002). Work carried out in this
laboratory has also identified human homologues to the rat GR exons 14, 15, 17, lg, I9
and In (Reynolds, 2002). It would be interesting to determine if, as the current
evidence suggests, these additional exon 1 variants are ubiquitously expressed in
human cells and tissues.
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It appears therefore that cells do not operate an 'all-or-nothing' policy with regards to
expression of the GR 'CpG island' exons. Rather, transcription is initiated at all CpG
island exons 1 in all cells. Regulation of GR does not occur as a result of switching
the transcription of alternate exons 1 'on' or 'off. If the GR CpG island exons do
indeed play a role in the regulation of GR, it must be through adjustment of their
relative levels.
Exon li-containing mRNA is not expressed in H4IIE, KNRK, PC-12 or NG-108
cells but is present in the lymphoma cell lines EL-4 and S-49. In contrast to the exon
I4 reaction, the li product was repeatedly only detected in lymphoma cells, despite
alterations to RT-PCR parameters. In accordance with previous work, it appears that
rat exon 11 expression is restricted to cells of the immune system (McCormick et al.,
2000; Freeman 2003). In contrast to the CpG island alternate exons 1, it may be the
case that expression of exon 11 which is located ~30.2kb upstream of exon 2, is
subject to regulation by a tissue-specific promoter.
Studies carried out in human cells have shown that alternative splicing events
generate three different exon 1A (homologous to rat exon li)-containing transcripts,
1A1, 1A2 and 1A3 (Breslin et al., 2001). It should be noted that, despite presumably
sharing a common promoter, the expression of only one variant, 1 A3, was restricted
to cells of the immune system. In contrast, exons 1 Al and 1A2 were both detected in
cell lines representing a variety of human tissues (Breslin et al., 2001). Similarly,
RPAs demonstrated that exon 1A mRNA was present at low levels in a range of
mouse tissues (Chen et al., 1999). Work is currently being undertaken in this
laboratory to investigate if rat tissues also express the three exon 11 variants and, as
such, should establish if the exon lj region is associated with a tissue-specific
promoter.
While glucocorticoid exposure is usually associated with down-regulation of GR
expression, one report showed that exon 1A1-, 1A2- and 1 A3- containing transcripts
were up-regulated in CEM-C7 (human ALL) cells following hormone treatment
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(Breslin et al., 2001). The same report suggested that expression of exon 1A
facilitates up-regulation of GR in T cells, causing them to undergo programmed cell
death or apoptosis. It is interesting to note that cells such as EL-4 and S-49, shown in
these experiments to express exon 1], also expressed all other alternate exons 1
examined. This corresponds to data reported for human T cells and mouse thymus, in
which exons IB, 1C, and (in mouse), ID and IE (homologous to rat exons 15 and In
respectively) were also detected (Chen et ah, 1999; Breslin et ah, 2001). Speculation
into the functional consequences of exon 11 expression must therefore consider that
exon 11-containing transcripts form only a proportion of total GR mRNA. Indeed,
previous RPAs showed that transcripts containing exon 1] were present at -25% in
rat thymus, although the proportion of exon 11 expression in specific thymus cell
subtypes was not addressed (McCormick, 2000).
In light of previous work showing the ubiquitous expression of GR (Ballard et ah,
1974) it was surprising to identify a cell line, B103 (rat neuroblastoma), in which GR
was absent. There are several possible causes for the lack of GR expression in B103
cells. One hypothesis tested in this study was based on work carried out by
Antequera et al which showed that in cell lines, de novo methylation can occur at the
CpG islands of genes that are non-essential in culture (Antequera et ah, 1990). Many
studies have shown an inverse correlation between transcriptional activity of a gene
and the presence of CpG methylation (reviewed in Bird, 1984). In order to
investigate ifmethylation was indeed 'silencing' GR expression in the B103 cell line,
cells were treated with the de-methylaling agent, 5-aza-2'-deoxycytidine (5-Aza-
CdR). This treatment has previously been shown to restore the expression of several
genes in cultured cells (Harris, 1984). Results described here show that 5-Aza-CdR
treatment did not restore GR expression in B103 cells. Thus, methylation of the GR
locus does not appear to be responsible for the lack of GR expression in this cell line.
However, it should be noted that the efficacy of 5-Aza-CdR treatment was not
controlled for in this experiment. It cannot, therefore, be ruled out that the lack of GR
mRNA expression in treated B103 cells is due to the 5-Aza-CdR not achieving the
desired de-methylation effect.
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An alternative possibility for the lack of GR mRNA expression in B103 cells is a
mutation, most probably a deletion, at the GR locus. This could be tested by
Southern or PCR analysis of B103 genomic DNA. Whatever the cause behind the
lack of GR mRNA expression, it is interesting to note that cells in which this
'housekeeping' gene is absent are clearly viable. COS-1 (green monkey kidney) cells
and the parallel cell line CV-1 have previously been shown to lack detectable GR
protein, although the cause of the absence has not been identified (Giguere et ah,
1986). Similarly, HepG2 (human hepatoma) cells have been shown to express
functional GR but at a level too low to stimulate glucocorticoid-responsive gene
transcription (Baumann, et ah, 1990). Given the enormous number of GR-responsive
genes and their involvement in normal development and physiological homeostasis,
it is surprising that cells in which functional GR expression is either minimal or
absent are perfectly viable. With regard to the B103 cell line, it effectively forms a
neural GR 'knock-out' and could therefore be used to investigate any cell-specific
downstream implications of a lack of GR expression.
It should also be remembered that glucocorticoids tend to be anti-proliferative in
most, but not all, tissues (Crocker et ah, 1998; Sakai et ah, 1999; Almawi & Tamirn,
2001). It is therefore conceivable that a lack of GR expression might be
advantageous in cultured cells, where frequent passaging selects for rapid growth and
proliferation. It was previously assumed that the housekeeping roles of GR required
its expression in virtually every cell. However, these results suggest that cell lines in
which GR has been lost may be more common than expected.
Finally, quantitative analysis of GR mRNA levels in rat liver as well as 2S FAZA
(rat hepatoma), H4IIE (rat hepatoma) and PC-12 (rat pheochromocytoma) cells
showed H4IIE cells to express GR at levels most similar to rat liver. Furthermore, the
levels of GR mRNA detected in rat liver and H4IIE cells during these experiments
(2.5 x 104 and 2.4 x 104 copies/ng total RNA respectively) were comparable with the
value of 18.65±6.85 x 10" copies/ng total RNA previously reported for rat liver
(Zhang & Byrne, 2000). Interestingly, these experiments showed that the 2S FAZA
hepatoma cell line expressed GR at levels ~30-fold less than both rat liver and
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H4IIEs. 2S FAZAs are therefore another example of a cell line in which GR levels
are considerably lower than expected, perhaps again suggesting that culture
conditions might select against high GR expression.
The aim of these experiments was to identify a model cell line in which the observed
GR levels were comparable to those found in vivo, and, in this respect, the H4IIE
result is encouraging. However, it should be noted that competitive RT-PCR results
for all samples were subject to considerable variability and the results presented here
should be viewed with caution. Representative results are shown in figure 3.4 but
several more reactions, in which the results did not reach sufficient statistical power,
were carried out for each cell line. The relative rarity of the GR transcript is reflected
in the small quantities of both endogenous and competitor mRNA involved in these
reactions. Such low template RNA levels may have contributed to the observed
variability in this study and further experiments to increase 'n' are required.
To conclude, these experiments demonstrated that exon li was the only GR alternate
exon 1 to show tissue-specific expression, being restricted to cells of the immune
system. In contrast, all exons 1 located in the CpG island region were expressed in all
rodent cell lines tested. In addition, the rat neuroblastoma cell line, B103, was shown
to be viable in the total absence of GR mRNA expression. However, methylation of
the GR locus did not appear to be responsible for the lack of GR expression in these
cells. Finally, the absolute level of GR mRNA detected in H4IIE (rat hepatoma) cells
was shown to be comparable with that observed in rat liver. This result, together with
RT-PCR data showing the presence of all alternate exons 1 examined, suggested that
H4IIE cells are a good model for rat liver and, as such, they were selected for use in
further experiments.
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4 Investigation of promoter elements involved in rat GR regulation.
4.1 Introduction & Aims
Results described in the previous chapter showed that all alternate GR exons 1 of the
CpG island region were detected in all rodent cell lines examined, indicating that
cells do not operate an 'all-or-nothing policy' with regard to expression of these
exons 1. However, the alternate exon 1 structure of the GR CpG island region may
still play a role in tissue-specific regulation; it may be the case that alternate exons 1
are driven by multiple promoters showing differential activity between cell types.
However, while the 3' ends of all identified exons 1 have been precisely mapped,
most of the exact 5' transcription starts remain undefined. The GR promoter lacks
any notable TATA or CAAT boxes, or even a consensus Initiator sequence (Zong et
al., 1990; Encio et al., 1991; Gearing et ah, 1993). Consistent with this, 5'RACE-
PCR and primer extension analyses of rat and human GR have shown that the
transcription starts of most alternate exons 1 are heterogeneous (Zong et ah, 1990;
Gearing et ah, 1993; McCormick et ah, 2000). All these factors have increased the
difficulty in identifying exon 1-associated promoters.
Previous work has established that the CpG island region of GR exhibits significant
promoter activity in human, rat and mouse cells (Strahle et ah, 1992; Nobukuni et ah,
1995; McCormick et ah, 2000; Breslin et ah, 2001; Nunez & Vedeckis, 2002).
Several of these studies explored the possibility that alternate exons 1 are associated
with individual, tissue-specific promoters. Work carried out in this laboratory
demonstrated that promoter activity associated with rat exon 17 is neural-specific
(McCormick et ah, 2000). In addition, RPA analyses of selected mouse tissues and
cells have shown variability in the absolute levels of exons IB and 1C (Strahle et ah,
1992). A series of reporter constructs in which the human GR promoter was fused
within exon 1C, identified a region shown to bind the transcription factor AP2,
which, when deleted, caused a cell-specific decline in promoter activity (Nobukuni et
ah, 1995). Nunez & Vedeckis also showed that luciferase reporter constructs
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containing sequences proximal to either human GR exons IB or 1C exhibited
differential promoter activity between Jurkat (T-cell ALL) and HepG2 (hepatoma)
cells, but not HeLa cells (cervical carcinoma) (Nunez & Vedeckis, 2002).
Furthermore, Breslin et al showed no difference in the activity ofpromoter IB
between IM-9 (B lymphoma), CEMC-7 (T-cell lymphoblast), Jurkat, HeLa cells,
with higher activity in WI-38 (fibroblast) cells than IM-9 cells but not significantly
different to the other cell lines (Breslin et ah, 2001). However, there were significant
difference in the activity of promoter 1C between all the cell lines (Breslin et al.,
2001).
The work described in this chapter was designed to (i) explore the hypothesis that
alternate rat GR exons 1 are driven by individual promoters showing tissue-specific
activity and (ii) further elucidate elements of the CpG island region involved in GR
regulation. A series of constructs, in which various fragments of the rat GR CpG
island region were fused to a luciferase reporter gene, were transiently transfected
into two rat cell lines, B103 (neuroblastoma) and H4IIE (hepatoma). These cell lines
were chosen based on previous work showing that B103 cells exhibit a neural-
specific pattern of GR exon 1 promoter activity (McCormick et al., 2000), while
results described in chapter 3 showed that H4IIE cells provide a physiologically
relevant model for GR expression in rat liver.
4.2 Experimental Design
4.2.1 Transient Transfections
In order to investigate promoter activity over the GR CpG island region, a variety of
constructs, in which elements of the GR promoter were fused to a luciferase reporter
gene, were transiently transfected into B103 and H4IIE cells. The 3' GR deletion
series used in these experiments, in which the 3' ends of individual rat GR exons 1
were fused directly to a luciferase reporter gene, has been described previously
(McCormick et al., 2000; McCormick, 2000). While all members of the series share
the same 5' end, the luciferase fusion in each construct abolishes the splice acceptor
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site normally present at the beginning of exon 2. As such, only the fused exon
contributes to luciferase activity; all upstream transcripts are spliced at their
respective donor sites, but in the absence of a suitable acceptor site, are unlikely to
give rise to functional luciferase activity. The 3' deletion series can therefore be seen
to measure only the promoter activity associated with each individual exon 1. In
contrast, the exon 2 splice acceptor site is retained in the 'P2' construct, which
therefore reflects the activity of the whole promoter region.
A 5' deletion series of the GR promoter, constructed by V.Lyons, was also used in
transient transfection experiments. Constructs in this series retain the same 3' end
fused to luciferase, and were therefore used to assess the combined activity of
multiple exons 1. In addition, a 5' deletion series of the Pl7 construct was used to
localise a 134bp PstI fragment associated with neural-specific promoter activity and
has been described previously (McCormick, 2000). To investigate any enhancer
properties associated with the region, a further construct, in which the orientation of
the 134bp PstI fragment was reversed (PCbREv), was also synthesised.
To investigate the contribution to overall promoter activity made by the 134bp PstI
fragment, a series of constructs carrying internal deletions within P2 was synthesised
by V. Lyons. Finally, potential promoter and enhancer properties of the 134bp PstI
fragment were further investigated using plasmids constructed by V. Lyons in which
the fragment was cloned in both orientations into a promoterless vector (pGL3-BM)
and a vector containing a heterologous promoter (pGL3-Promoter).
4.2.2 DNasel footprinting analysis of the exon 17 region.
In order to identify trans-acting proteins that may bind to the exon 17 region, DNasel
nuclease protection assays were undertaken. This assay works on the simple
principle that a sequence-specific DNA binding protein protects the nucleotides
involved in DNA binding from enzymatic digestion by DNasel, leaving a 'footprint'
(Galas & Schmidt, 1978). Experiments used two 32P probes, FA and FB, which were
generated from the 134bp PstI fragment (fig.2.1). Each probe was uniquely labelled
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at one end and on one strand only. A further 32P-labelled probe, Fc, corresponding to
the 274bp Pstl/Bglll fragment located immediately downstream of the 134bp Pstl
region, was also used (see fig.2.1).
4.2.3 Electrophoretic Mobility Shift Assays of the 134bp Pstl region
Electrophoretic Mobility Shift Assays (EMSAs) were used to further investigate the
nature of protein-DNA interactions in the 134bp Pstl region. This assay separates
radioactively labelled 'free' DNA from protein-DNA complexes by non-denaturing
polyacrylamide gel electrophoresis. The appearance of a DNA fragment with altered
mobility (a 'shift') is therefore indicative ofprotein binding. The inclusion of an
antibody specific to the bound protein can cause further retardation of the complex
during gel electrophoresis, known as a 'supershift'. In addition to the labelled
fragments described in 4.2.2, double stranded oligonucleotides representing both
known transcription factor binding sites as well as specific segments of the 134bp
Pstl fragment were also used. Competition EMSAs, in which the ability of
unlabelled fragments or oligonucleotides to compete with the labelled probe for
binding to protein extracts, were also carried out to determine the specificity of
interactions in protein-DNA complexes.
4.3 Results
4.3.1 Promoter elements of the rat GR CpG island
4.3.1.1 High neural cell specific promoter activity is associated with P17.
A 3' deletion series of the rat GR CpG island region was transfected into two rat cell
lines, B103 (neuroblastoma) and H4IIE (hepatoma), in order to investigate cell-
specific promoter activity associated with alternate exons 1 (fig. 4.1). The P2
construct, which represents the whole promoter, showed the highest activity in both
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Figure 4.1 High neural cell specific promoter activity is associated with PI 7.
Transient transfection analysis of a 3' deletion series of the rat GR promoter.
A: Diagram showing the design of the 3' deletion series, in which each construct is
fused to a luciferase reporter gene. All constructs have the same 5' end but differ at
the 3' end. The 3' end of P2 is fused to luciferase within exon 2 while all other
constructs are fused within known exons 1. Restriction enzyme sites used to engineer
the construct series are also indicated.
B: Transient transfections carried out in H4IIE (rat hepatoma) and B103 (rat
neuroblastoma) cells. The activity of all constructs is expressed relative to P2
nominally set at 100%. n=3-12 (2 independent plasmid DNA preparations), values
represent means +SEM. Data were subject to two way ANOVA analysis before post-
hoc comparison using Student's t-test. denotes a significant difference from
empty vector in the same cell line (p<0.05). ). 'f' denotes a significant difference
from the same construct in the other cell line (p<0.05).
C: Transient transfection data compiled from H4IIE and B103 transfections shown in
fig 4.IB with previous results for HepG2 (human hepatoma), C6 (rat glioma) and
B103 (rat neuroblastoma) cells (McCormick et al., 2000). The activity of all
constructs is expressed relative to a P2 value nominally set at 100%. n=3-12 (2
independent plasmid DNA preparations); values represent means +SEM. Data were
subject to two way ANOVA analysis before post-hoc comparison using Fisher's
LSD test. denotes a significant difference from both empty vector and the same
construct in hepatoma cell lines (p<0.05). 'f' denotes a significant difference from
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cell lines (p<0.001) (fig. 4.IB). No construct, apart from P2, showed significant
promoter activity in H4IIE cells. In contrast, Pl6, Pl7 and PI 10 all showed
significantly higher activity than empty vector in B103 cells (p<0.05).
However, data gained for B103 cells, while confirming the pattern of exon 1-
associated promoter activity previously observed (McCormick et al., 2000;
McCormick 2000), were the result of only one transient transfection experiment
(carried out in triplicate). As such, results from the current study were compiled with
previous data obtained in this laboratory (McCormick et al., 2000; McCormick,
2000) (fig. 4.1C). The pattern of activity of the constructs was broadly similar in all
cell lines. Again P2 shows significantly higher activity than all other constructs in all
cell lines (p<0.01). In B103 cells, Pl7 shows significantly increased activity relative
to all other constructs (p<0.001). In C6 cells PI9/10 and Pl7 are significantly higher
than empty vector (p<0.05), with Pl7 significantly higher than all other exon 1
constructs apart from PI9/10 (p<0.01). Finally, in HepG2 cells, PI9/10 is significantly
higher than empty vector (p<0.01), and all other exon 1 constructs apart from Pl6
and Pl7 (p<0.05). The activity of Pl7 is significantly higher in the neural cell lines
B103 and C6 than in the hepatoma cell lines H4IIE and HepG2 (p<0.01). The high
promoter activity associated with Pl7 appears therefore to be neural specific. No
other construct showed cell-type specific promoter activity.
4.3.1.2 Two regions of the GR promoter account for the majority of activity in
B103 cells.
While the 3' deletion series of the GR promoter tested activity associated with
individual exons 1, a 5' deletion series was used to investigate the combined activity
of multiple exons 1 (fig. 4.2). All constructs in the series showed significant activity
relative to empty vector in B103 cells (p<0.001) (fig. 4.2B). Results show that while
a deletion from -4878 to -3912 (pVL259) resulted in a significant decrease in
promoter activity of -40% relative to P2 (p<0.001), a further deletion to -2806
(pVL257) caused no additional decrease in activity. Furthermore, while removal of a
fragment from -4878 to -2535 (pVL258) caused a decrease in promoter activity of
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Figure 4.2 Two regions ofthe GR promoter accountfor the majority ofactivity in
B103 cells.
Transient transfections of a 5' deletion series of the GR promoter in B103 (rat
neuroblastoma) cells.
A: Diagram showing the design of the 5' deletion series in which each construct is
fused to a luciferase reporter gene. All constructs have the same 3' end but differ at
the 5' end. The 3' end of each construct is fused to luciferase within exon 2.
Restriction enzymes sites used to engineer constructs are also shown.
B: Transient transfections carried out in B103 cells. The activity of all constructs is
expressed relative to P2 nominally set at 100%. n=16-21 (2 independent plasmid
DNA preparations); values represent means ±SEM. Results were subject to analysis
by Student t-test. denotes a significant decrease from P2 (p<0.001). 'f denotes a






































-80% relative to P2, an additional deletion to -1770 produced no further reduction.
As such, two regions, the first between -4878 and -3912 (R^) and the second
between -2806 and -2535 (R2), each account for -40% of P2 promoter activity in
B103 cells.
4.3.1.3 The 134bp region responsible for neural cell specific P17 promoter
activity is orientation dependent.
Previous work (McCormick, 2000), together with data presented in section 4.3.1.1,
showed an association between the PI7 construct and neural-specific promoter
activity. Further investigations were carried out using a 5' deletion series of PI 7
transiently transfected into B103 and H4IIE cells (fig. 4.3). No exon l7-associated
construct showed significantly higher activity than empty vector in H4IIE cells (fig
4.3B). Once again, in B103 cells Pl7 activity was significantly higher than that of
empty vector (p<0.001) and Pl7 in H4IIE cells (p<0.001). Pl?a, in which a 881bp
fragment is deleted from the 5' end of PN, showed a -30% increase in promoter
activity relative to PI7 in B103 cells (p<0.05). Similarly, PI7b, in which a further
216bp fragment is deleted from the 5' end of PI7, showed an increase of-56% in
promoter activity relative to Pl7 (p<0.01). Importantly, deletion of an additional
134bp fragment from Pl7c caused a -90% decrease in promoter activity relative to
PI7 (p<0.001). It appears, therefore, that this 134bp PstI fragment is necessary for the
high neural cell specific promoter activity associated with PI7.
Potential enhancer properties of the 134bp PstI fragment were investigated using a
construct based on PI7b in which the region was reversed (Pl7bREv)- Interestingly, the
activity of PNbREv was identical to that of Pl7C, demonstrating that the 134bp PstI
fragment is inactive in the reverse orientation (fig 4.3B).
4.3.1.4 The 134bp PstI fragment does not act as a classical enhancer
In order to confirm results presented in 4.3.1.3, in which the 134bp PstI fragment
failed to show the orientation-independent activity associated with a traditional
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Figure 4.3 The 134bp region responsiblefor neural-specific P17 promoter activity is
orientation dependent.
Transient transfection analysis of the 5' deletion series of Pl7 in B103 (rat
neuroblastoma) and H4IIE (rat hepatoma) cells.
A: Diagram showing design of the PI 7 5' deletion series. All constructs, apart from
P2, share the same 3' end, but differ at the 5' end. The 3' end of P2 is fused to
luciferase within exon 2 while all other constructs are fused within exon I7. Pl7bREV
is a modified form of Pl7b in which the 134bp PstI fragment is reversed. Restriction
enzyme sites used to engineer the constructs are also shown.
B: Transient transfections carried out in B103 and H4IIE cells. The activity of all
constructs is expressed relative to P2, nominally set at 100%. n=l 1-18 (2
independent plasmid DNA preparations), values represent means ±SEM. Data were
subject to two way ANOVA analysis before post-hoc comparison using Fisher's
LSD test. denotes significant difference in construct activity between cell lines
(p<0.001). 'f' denotes significant increase in activity from PI7 (p<0.05).
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enhancer, the activity of the fragment was tested in a heterologous promoter vector,
pGL3-Promoter (Promega). The 134bp PstI fragment failed to show significant
activity in either the forward (pVL287) or reverse (pVL288) orientation in either
B103 or H4IIE cells, confirming that it does not act as an enhancer in either cell line
(fig 4.4).
4.3.1.5 The 134bp PstI fragment acts as an orientation dependent promoter.
Promoter properties associated with the 134bp PstI fragment were investigated using
constructs in which the fragment was cloned in both orientations into a modified
form of the promoterless vector pGL3-Basic (pGL3-BM). The fragment showed
significant promoter activity in the forward orientation (pVL289) in both B103 and
H4IIE cells (p<0.001) (fig. 4.5). Furthermore, the activity of the fragment was over
2-fold greater in B103 than in H4IIE cells (p<0.001). In contrast, no significant
activity was observed in the reverse orientation in either cell line. Indeed, reversal of
the 134bp PstI fragment caused a significant decrease in activity relative to empty
vector in H4IIE cells (p<0.001). The 134bp PstI fragment therefore only confers
promoter activity in the forward orientation, and is significantly more active in B103
than H4IIE cells.
4.3.1.6 Deletion of the 134bp PstI fragment from P2 causes a cell-specific
decrease in activity.
A series of internal deletion constructs was used to investigate the contribution of the
134bp PstI fragment to the overall promoter activity of P2 (fig. 4.6). Deletion of the
134bp PstI fragment from P2 (pVL261) caused a significant decrease in promoter
activity in B103, but not H4IIE cells (p<0.01) (fig. 4.6B). Deletion of a -3339 to -
1770 region, which included the 134bp PstI fragment, from P2 (pVL262) reduced
activity to levels not significantly different from empty vector in both cell lines.
Interestingly, a deletion of-3205 to -1770 from P2 (pVL263), in which the 134bp
PstI fragment is restored, also failed to show significant promoter activity in either
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Figure 4.4 The 134bp PstIfragment does not act as an enhancer.
Transient transfections of constructs in which the 134bp PstI fragment was cloned in
both the forward (pVL287) and reverse (pVL288) orientations into the heterologous
promoter vector, pGL3-Promoter. Experiments were carried out in FI4IIE (rat
hepatoma) and B103 (rat neuroblastoma) cells. The activity of all constructs is
expressed relative to empty vector nominally set at 1. n=6-12 (2 independent plasmid
DNA preparations), values represent means ±SEM. Data were subject to two way







Figure 4.5 The 134bp PstIfragment acts as an orientation dependent promoter.
Transient transfections of constructs in which the 134bp PstI fragment was cloned in
the forward (pVL289) and reverse (pVL290) orientations into pGL-3BM.
Experiments were carried out in H4IIE (rat hepatoma) and B103 (rat neuroblastoma)
cells. The activity of all constructs is expressed relative to empty vector nominally
set at 1. n=13-18 (2 independent plasmid DNA preparations), means ±SEM. Values
were subject to two way ANOVA analysis before post-hoc comparison using
Fisher's LSD test. denotes a significant difference from empty vector (p<0.01).








Figure 4.6 Deletion ofthe 134bp PstIfragmentfrom P2 causes a cell-specific
decrease in promoter activity.
Transient transfections ofPstI internal deletion constructs in H4IIE (rat hepatoma)
and B103 (rat neuroblastoma) cells. A: Diagram showing the design of the PstI
internal deletion constructs. All constructs have the same 5' and 3' ends but carry
different internal PstI fragment deletions. The activity of all constructs was
expressed relative to P2 nominally set at 100%. n=12-26 (2 independent plasmid
DNA preparations), values represent means ±SEM. Data were subject to two way
ANOVA analysis before post-hoc comparison using Fisher's LSD test. denotes a
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cell line. Therefore, following a deletion of-3205 to -1770 from the GR promoter,
the presence of the 134bp PstI fragment does not 'rescue' promoter activity in either
cell line.
4.3.1.7 There is no difference in activity between GR promoter constructs
representing either -4878 to -3339, -1770 to -9 or both.
Comparison of constructs Pig (fig. 4.1C), pVL260 (fig. 4.2B) and pVL262 (fig.
4.6B) allows investigation of the contribution of two regions, -4878 to -3339 and -
1770 to -9, to overall promoter activity (fig. 4.7). Pie possesses -4878 to -3339 only,
pVL260 possesses -1770 to -9 only and pVL262 possesses both. Interestingly, there
is no significant difference between the activities of any of the constructs.
4.3.2 Protein-DNA interactions involving the 134bp PstI fragment
4.3.2.1 B103 and H4IIE nuclear extracts protect a 'footprint' on the 134bp
PstI fragment from DNasel digestion.
Sites and proteins involved in the neural-specific promoter activity of the 134bp PstI
fragment were initially investigated by DNasel footprinting. Experiments using the
radiolabeled Fb fragment, which encompasses the 134bp PstI region, identified a
footprint (FP1) at the 3' end of the fragment, produced by both B103 and H4IIE
nuclear extracts (fig. 4.8). Due to the location of this footprint at the 3' end of the
fragment, it was difficult to delineate its 3' boundary using the corresponding M+G
sequencing reaction. However, the protected sequence consists of at least ten
nucleotides between -3230 and -3220 and most probably extends for a further five
or six nucleotides in the 3' direction. Comparison of this region with the
TRANSFAC database suggested that the footprint might contain a putative AP2
transcription factor binding site (fig 4.8C).
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Figure 4.7 There is no difference in activity between GR promoter constructs
representing either -4878 to -3339, -1770 to -9 or both.
Compiled results of transient transfections of 3 constructs of the GR promoter in
B103 (rat neuroblastoma) cells taken from data presented in figs 4.2, 4.3 and 4.7.
A: Diagram showing the design of the constructs. pVL262 (-4878 to -3330 plus -
1761 to 0) and pVL260 (-1770 to 0) share the same 3' ends which are fused to
luciferase within exon 2. In contrast, the 3' end of Pl6 (-4878 to -3330) is fused to
luciferase within exon 16. Restriction enzymes sites used to engineer constructs are
also shown.
B: Transient transfections carried out in B103 cells. The activity of all constructs is
expressed relative to P2 nominally set at 100% (not shown). n=16-21 (2 independent
plasmid DNA preparations); values represent means ±SEM. Data were subject to
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Figure 4.8 B103 and H4IIE nuclear extracts protect a 'footprint' on the 134bp PstI
fragmentfrom DNasel digestion.
DNasel protection analysis of the 134bp PstI fragment FB, using B103 and FI4IIE
nuclear extracts. A and B represent successive loadings of the same reactions; the
dotted arrow indicates the continuation of the sequence. Lane 1, no added protein;
lane 2, lOpg B103 extract (Bj); lane 3, 50pg B103 extract (B2); lane 4, 8pg H4IIE
extract (Hi); lane 5, 48pg H4IIE extract (H2). Brackets indicate the region of DNA
protected from DNasel digestion. Arrows indicate nucleotides hypersensitive to
DNasel.
C: Diagram of the GR promoter showing the FB fragment including the 134bp PstI
fragment (shown in red) and the short linker sequences (shown in black) present in
the vector. The enzymes used to generate FB are shown; the radiolabeled end is
marked with The location and sequence of the footprint is also shown. Capital
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The Fa fragment, which was radiolabeled at the opposite end and on the opposite
strand to FB, was used to determine the extent of the footprint on the other strand.
However, results of 2 independent experiments showed a weak footprint at the
corresponding site that was only detectable by densitometric analysis (fig 4.9). The
integrity of B103 and H4IIE nuclear extracts was controlled for in parallel
experiments in which FP1 was detected on the FB fragment.
4.3.2.2 B103 extract, but not recombinant AP2 protein, protects a 'footprint'
on the 134bp Pstl fragment from DNasel digestion.
To determine if AP2 protein was indeed binding to FP1, further DNasel protection
analysis of the FB fragment was carried out using B103 nuclear extract and
recombinant AP2 protein. However, while results confirmed the formation of FP1
with B103 extract, AP2 protein failed to induce the same region of protection (fig.
4.10).
4.3.2.3 No DNasel footprint is formed on the 274bp Pstl/Bgll fragment of the
GR promoter with B103 or H4IIE nuclear extracts.
To further investigate protein-DNA interactions over the exon 17 region, DNasel
protection analysis was carried out using the Fc fragment. Fc represents the 274bp
Pstl/Bgll region immediately downstream from the 134bp Pstl fragment (fig. 4.1 IB).
As such, Fa and Fc together comprise the region present in construct Pl7b, which
showed high promoter activity in B103 cells. No detectable regions ofDNasel
protection were observed on the Fc fragment (fig. 4.11 A, B). Again, the integrity of
B103 and H4IIE nuclear extracts was positively controlled for in parallel
experiments in which a footprint was observed on the FB fragment.
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Figure 4.9 No DNasel 'footprint' is seen on the complementary strand ofthe 134bp
PstIfragment with B103 or H4IIE nuclear extracts.
A. DNasel protection analysis of the complementary 134bp PstI fragment FA, using
B103 and H4IIE nuclear extracts. Lane 1, G+A Maxam & Gilbert sequencing
reaction; lane 2, no added protein; lane 3, 10pg B103 extract (Bi); lane 4, 50pg B103
extract (B2); lane 5, 8pg H4IIE extract (Hi); lane 6, 48pg H4IIE extract (H2). Dashed
brackets indicate the area complementary to the footprinted region observed on FB.
B: Diagram of the GR promoter showing the Fa fragment including the 134bp PstI
fragment (shown in red) and the short linker sequences (shown in black) present in
the vector. The enzymes used to generate FA are shown; the radiolabeled end is
marked with The location and sequence of the putative footprint is also shown.
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Figure 4.10 B103 extract, but not recombinant AP2protein, protects a 'footprint' on
the 134bp PstIfragmentfrom DNasel digestion.
DNasel protection analysis of the 134bp PstI fragment Fb, using B103 nuclear
extract and recombinant AP2 protein. A, B and C represent successive loadings of
the same reactions. Lane 1, no added protein; lane 2, lOpg B103 extract (Bi); lane 3,
50pg B103 extract (B2); lane 4, 3.8pg AP2 protein (Ai); lane 5, 7.6pg AP2 protein
(A2). Brackets indicate regions of DNA protected from DNasel digestion. Arrows
indicate nucleotides hypersensitive to DNasel.
148
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Figure 4.11 No DNasel 'footprint' is seen on the 274bp Pstl/Bgllfragment of the GR
promoter with B102 or H4IIE nuclear extracts.
DNasel protection analysis of the 274bp Pstl/Bgll fragment Fc, using B103 and
H4IIE nuclear extracts. A: Lane 1, G+A Maxam & Gilbert sequencing reaction; lane
2, no added protein; lane 3, 75pg B103 extract (B2); lane 4, 25pg FI4IIE extract (H2).
B: Diagram of the GR promoter showing the location of the Fc fragment.
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4.3.2.4 Factors in B103 and H4IIE nuclear extracts bind to the 134bp Pstl
fragment.
Further to the DNasel footprinting experiments described above, protein-DNA
interactions involving the 134bp Pstl fragment were investigated by electrophoretic
mobility shift assays (EMSAs). Factors present in both B103 and H4IIE cell extracts
were shown to bind to the Fb fragment, with complex formation roughly proportional
to nuclear extract concentration (fig 4.12). Three complexes were formed between
the Fb fragment and B103 nuclear extract, with a further complex observed with
H4IIE nuclear extract. Based on this data, nuclear extract concentrations of25pg and
15pg for B103 and H4IIE, respectively, were used in further EMSAs.
Specificity of H4IIE and B103 nuclear protein binding to the 134bp Pstl fragment
was investigated by competitive EMSA. Using both extracts, a 100-fold excess of
unlabelled Fb fragment successfully competed for binding to the labelled Fb probe at
the upper 2 complexes, while the lower complexes remained unaffected (fig. 4.13;
compare lanes 4 and 12 with 2 and 10). In contrast, a 100-fold excess of unlabelled
non-specific competitor, Fns, did not compete with the labelled probe for binding at
any complex (fig. 4.13; compare lanes 6 and 14 with 2 and 10). It appears, therefore,
that B103 and H4IIE protein binding at the upper 2 complexes is sequence specific,
while binding at the lower complexes is not.
4.3.2.5 Factors in B103 and H4IIE nuclear extracts, including a Sp1-related
protein, form specific complexes with the 134bp Pstl fragment.
Supershift analysis, in which antibodies against candidate transcription factors were
included in EMSAs, were used to identify the protein(s) responsible for specific
binding of the 134bp Pstl fragment. The Spl antibody caused a supershift in the
DNA-protein complex formed with both B103 and H4IIE nuclear extracts (fig. 4.13;
compare lanes 7 and 15 with lanes 2 and 10). However, it should be noted that not all
the protein-DNA complex formed with either B103 or H4IIE extract was
supershifted with the addition of the Spl antibody. In contrast, no supershift was
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Figure 4.12 Factors in B103 and H4IIE nuclear extracts bind to the 134bp PstI
fragment.
EMSA using the 134bp PstI fragment, Fb, and either B103 or H4IIE nuclear extracts.
30fmol [32P]-labelled FB was incubated with 2pg (lanes 2,7), 5pg (lanes 3,8), 10pg
(lanes 4,9), 20pg (lanes 5,10) or 40pg (lanes 6,11) B103 or H4IIE extract. Lane 1






Figure 4.13 Factors in B103 and H4IIE nuclear extracts, including a Spl-related
protein, form specific complexes on the 134bp PstIfragment.
EMSA using the 134bp PstI fragment, FB, and either B103 or H4IIE nuclear extracts.
30fmol [32P]-labelled FB was incubated with 25pg B103 or 15pg H4IIE nuclear
extract in the absence or presence of 10- or 100-fold molar excess of unlabelled
specific competitor DNA FB (lanes 2,3,11,12) or unlabelled non-specific competitor
DNA Fns (lanes 5,6,13,14), or in the presence of lpg antibody against Spl(As),
Egrl(An) or Phospho-Statl (Ac). Lane 1 contained no nuclear extract. Filled and un¬
filled arrows indicate specific and non-specific protein-DNA complexes respectively.
A dotted arrow indicates a super-shifted complex.
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observed following the inclusion of antibodies against either Egr-1 (fig 4.13; lanes 8
and 16) or the negative control Phospho-Statl (fig 4.13; lanes 9 and 17). Results
suggest, therefore, that Spl or an antigenically-related protein present in both B103
and H4IIE extracts binds to the FB fragment.
4.3.2.6 Factors in B103 and H4IIE nuclear extracts bind to an oligonucleotide
corresponding to the 'footprinted' region of the 134bp Pstl fragment.
The DNasel footprinting data described in 4.3.1.1 showed binding at FP1 with both
B103 and FI4IIE nuclear extracts. In order to confirm this, EMSAs were performed
using a radiolabelled synthetic oligonucleotide, Of, representing the sequence
protected in FP1. In addition, a further labelled oligonucleotide, 0Mf, in which the
putative AP2 binding site was abolished (see section 2.1.7.3), was also used. Figure
4.14 shows that factors present in B103 extract formed two complexes with Of, with
binding at the lower complex being more intense than at the upper. The same two
complexes were formed between FI4IIE extract and 0F, although the upper complex
is even less intense in this case. Analysis of the gel also suggests the possibility of
binding at a further upper complex, although longer exposure of the gel did not
increase the intensity of these bands. A 75-fold molar excess of unlabelled 0F
successfully competed with the labelled Of probe for binding at the two lower
complexes formed with B103 extract, while the same excess of unlabelled Omf did
not. In contrast, an excess of both unlabelled Op and Omf oligonucleotides
successfully competed with the labelled Of probe for binding to H4IIE extract.
However, it should be noted that the same complexes were also formed between
factors present in both B103 and H4IIE nuclear extracts and the mutant
oligonucleotide, 0Mf. Furthermore, antibodies against Spl, Egr-1 and the negative
control, Phospho-Statl, did not induce a supershift in either labelled oligonucleotide
or with either nuclear extract.
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Figure 4.14. Factors in B103 and H4IIE nuclear extracts bind to an oligonucleotide
corresponding to the 'footprinted' region ofthe 134bp PstIfragment.
EMSA using Of and Omf oligonucleotides (corresponding to the correct and mutated
sequence of the footprinted region of the 134bp PstI fragment respectively) and
B103 or H4IIE nuclear extract. O.lpmol [32P]-labelled Of or Omf was incubated with
25pg B103 or 15pg H4IIE nuclear extract in the absence or presence of 75-fold
molar excess of unlabelled Of (lanes 3,9) or Omf (lanes 4,10), or in the presence in
lpg Spl(As), Egrl(An) or Phospho-Statl (Ac) antibodies. Solid arrows indicate
protein-DNA complexes. The faint bands observed at the top of the gel did not
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4.3.2.7 Factors in B103 and H4IIE nuclear extracts bind to an oligonucleotide
encoding a consensus Sp1 binding site.
Further to the supershift of complexes between the FB fragment and B103 and H4IIE
extract induced by an antibody against Spl (fig 4.13), EMSAs were carried out using
radiolabelled oligonucleotides containing either a consensus (Os) or mutant (Oms)
Spl binding site. Both B103 and H4IIE nuclear proteins formed three complexes
with Os (figure 4.15; lanes 2-11), but only two with Oms (figure 4.15; lanes 13-16).
With both cell extracts, protein binding at the upper complex was successfully
competed by a 60-fold excess of Os (figure 4.15; lanes 5 and 10), but not by a 60-
fold excess 0Ms (figure 4.15; lanes 6 and 11). It therefore appears that binding
between either cell extract and Os at the upper complex is specific, while binding at
the lower complexes is non-specific.
The inclusion of a Spl antibody induced a weak supershift in the DNA-protein
complex formed with both B103 and H4IIE nuclear extracts (figure 4.15; lanes 3 and
8). In addition, the presence of Spl antibody caused the intensity of the shifted
complex to decrease relative to the zero antibody reactions (figure 4.15; lanes 2 and
7). Together these observations provide evidence of sequence-specific Spl or Spl-
related protein binding activity in both cell extracts.
4.3.2.8 Factors in B103 and H4IIE nuclear extracts bind to oligonucleotides
encoding both consensus and mutant AP2 binding sites.
Although DNasel protection analyses failed to show binding of recombinant AP2
protein at FP1, results were confirmed by EMSAs using radiolabelled
oligonucleotides containing either a consensus (0A) or mutant (0Ma) AP2 binding
site. Oa formed one complex with B103 nuclear extract, while two complexes were
formed with H4IIE nuclear extract (fig.4.16). Using B103 extract, an excess of
unlabelled 0A successfully out-competed the labelled 0A probe for binding. This was
also the case for H4IIE, where competition for binding at the upper complex was
stronger than at the lower. In addition, unlabelled Oma successfully competed for
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Figure 4.15. Factors in B103 and H4IIE nuclear extracts bind to an oligonucleotide
encoding a consensus Spl binding site.
EMSA using oligonucleotides encoding consensus (Os) and mutant (Oms) Spl
binding sites and either B103 or H4IIE nuclear extracts. O.lpmol [32P]-labelled Os or
0Ms was incubated with 25pg B103 or 15pg H4IIE nuclear extract in the absence or
presence of 60-fold molar excess of unlabelled Os (lanes 5,10) or Oms (lanes 6,11),
or in the presence of lpg Spl(As) or Phospho-Statl (Ac) antibodies. Filled and un¬
filled arrows indicate specific and non-specific protein-DNA complexes respectively.
A dashed arrow indicates a super-shifted complex. A longer exposure of the
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Figure 4.16 Factors in B103 and H4IIE nuclear extracts bind to oligonucleotides
encoding both consensus and mutant AP2 binding sites.
EMSA using oligonucleotides encoding consensus (0A) and mutant (Oma) AP2
binding sites and either B103 or H4IIE nuclear extracts. O.lpmol [32P]-labelled 0A or
Oma was incubated with 25jug B103 or 15pg H4IIE nuclear extract in the absence or
presence of 60-fold molar excess of unlabelled 0A (lanes 3,8) or Oma (lanes 4,9), or
in the presence in lpg AP2 (Aa) or Phospho-Statl (Ac) antibodies. Solid arrows
indicate specific protein-DNA complexes. A longer exposure of the bracketed region
containing the shifted complexes is also shown.
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binding at the B103/Oa complex, but this was not the case for either of the two
H4IIE/Oa complexes. However, once again, complexes were formed between both
B103 and H4IIE nuclear extracts and the mutant oligonucleotide, Oma- The inclusion
of an AP2 antibody did not induce a significant supershift or reduction in intensity of
the protein-DNA complex using either Oa or Oma with either cell extract.
4.3.2.9 Binding between B103 and H4IIE nuclear extracts and Fb is not
competed by either Sp1 or Egr1 consensus oligonucleotides.
To further investigate binding specificity of the FB fragment, competition EMSAs
were carried out using unlabelled oligonucleotides representing Spl (Os and Oms)
and Egrl (Oe and Ome) binding sites as well as FP1 (0F and Omf)- Complexes
formed between H4IIE nuclear extract and FB were not competed by a 30-fold molar
excess of unlabelled Of, Omf, Ob or Ome (fig-4.17). Similarly, complexes formed
between B103 nuclear extracts and FB were not competed by an excess of unlabelled
Os- However, there was a loss of free DNA in reactions including B103 extracts and
excesses of Oms, Oe and Ome- The reason for this is unclear, although it appears that
a portion of the complexes remained in the well during electrophoresis. As such, it is
difficult to assess if 0Ms, 0B and Ome, do indeed compete for binding between B103
extracts and Fb, although results using H4IIE extract and those shown in fig 4.15
suggest this is unlikely.
4.4 Discussion
The experiments described in this chapter were designed to (i) explore the hypothesis
that alternate GR exons 1 are driven by individual promoters showing tissue-specific
activity and (ii) further investigate elements of the CpG island region involved in GR
regulation. With regard to objective (i), transient transfections using the 3' deletion
series of P2, which measures the promoter activity associated with each individual
exon 1, showed that PI7 was the only construct to show tissue-specific activity.
Specifically, Pl7 activity was higher in B103 (rat neuroblastoma) and C6 (rat glioma)
cells than in H4IIE (rat hepatoma) or HepG2 (human hepatoma) cells. Experiments
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Figure 4.17 Binding between B103 and H4IIE nuclear extracts and Fr is not
competed by either Spl or Egrl consensus oligonucleotides.
EMSA using 134bp PstI fragment, FB, and either B103 or H4IIE nuclear extracts.
30fmol [32P]-labelled FB was incubated with 25pg B103 or 15pg H4IIE nuclear
extract in the absence or presence of 30-fold molar excess of unlabelled consensus
Spl oligonucleotide Os (lane 3), mutant Spl oligonucleotide Oms (lane 4), consensus
Egr-1 oligonucleotide Oh (lanes 5,10), mutant Egr-1 oligonucleotide 0Me (lanes
6,11), or the 134bp PstI fragment 'footprinted' oligonucleotides Of and Omf (lanes
8,9). Based on data shown in fig 4.12, filled and un-filled arrows indicate specific
and non-specific protein-DNA complexes respectively.
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using the 5' deletion series of PI 7 confirmed that a 134bp PstI fragment is necessary
for high neural-specific activity. Deletion of this fragment from P2 caused a
significant decrease in activity in B103, but not H4IIE cells, suggesting that the
134bp PstI fragment makes a significant contribution to overall P2 activity in neural
cells only. The neural-specific high promoter activity of this fragment was found to
be orientation-dependent. Under the accepted definition of an enhancer as 'a DNA
element that increases transcription in a position- and orientation-independent
manner' (Gill, 2001), the directionality of the 134bp PstI fragment rules out a
classical enhancer role. In addition, the fragment did not activate a heterologous
promoter in either orientation, confirming that this region does not show any
enhancer properties. Instead, the fragment was shown to be an orientation-dependent
promoter that was significantly more active in B103 than H4IIE cells.
DNasel footprinting analysis of the 134bp PstI fragment (FB) reproducibly identified
a region near the 3' end of the fragment that was protected by both B103 and H4IIE
nuclear extracts. Confusingly, DNasel footprinting analysis of the same 134bp PstI
fragment, labelled on the opposite strand (FA), showed only very weak protection at
the site corresponding to the previously identified footprint. The possible causes for
this discrepancy is discussed in more detail later.
Sequence analysis showed the footprinted region to contain a putative AP2
transcription factor binding site. However, DNasel footprinting analyses using
recombinant AP2 protein did not demonstrate the same region ofprotection. While it
should be noted that no positive control for the integrity of the AP2 protein was
included, further evidence against a role for AP2 was provided by EMSAs.
Specifically, while complexes were formed between factors present in both B103 and
H4IIE nuclear extracts and a synthetic oligonucleotide containing FP1, an
oligonucleotide in which the putative AP2 site present in FP1 was mutated was also
shown to bind to both extracts. There are three possible explanations for this
observation: (i) the putative AP2 site is not responsible for the observed binding; (ii)
the mutation has created a new transcription factor binding site; or (iii) the binding is
non-specific and occurs as a result of the high concentrations of nuclear extract used
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(15-25pg). In addition, while both B103 and H4IIE nuclear extracts bound to an
oligonucleotide containing a consensus AP2 binding site, complexes were also
formed on an oligonucleotide in which the AP2 site was mutated, suggesting that
either the complexes were non-specific or binding did hot involve the mutated
nucleotides. Furthermore, complexes formed between B103 or H4IIE extracts and
the consensus AP2 nucleotide were not supershifted upon the inclusion of an
antibody against AP2, suggesting that the observed complexes did not contain AP2
protein. The balance of evidence therefore suggests that AP2 binding is not
responsible for FP1.
Initial sequence analysis of the 134bp PstI fragment showed it to encode an Egr-1
(synonymous with NGFI-A) transcription factor binding site. Previous work has also
shown that increases in hippocampal GR mRNA following environmental
enrichment of infant rats correlates with increased NGFI-A mRNA (Olsson et al.,
1994; Meaney et ah, 2000). The higher relative abundance of exon 17-containing
transcripts in rat hippocampus and the high neural-specific promoter activity of the
134bp PstI fragment led to the hypothesis that up-regulation ofNGFI-A following
perinatal programming might cause an up-regulation of exon 17 transcription,
consequently leading to an overall rise in GR mRNA levels (Meaney et ah, 2000).
However, DNasel footprinting experiments and EMSAs using both B103 and H4IIE
nuclear extracts showed no evidence of NGFI-A binding at its putative site or
anywhere else on the fragment. Further results have suggested that, in this instance,
the NGFI-A site responsible for up-regulation of GR is located further downstream
from the 134bp PstI fragment (Meaney M., personal communication). This site
resides in the region corresponding to Fc, although DNasel footprinting studies
carried out during this investigation did not show any evidence of binding between
B103 nuclear extracts and the Fc fragment. However, on the basis of data presented
here, the Fc complementary strand should also be tested.
Several pieces of evidence suggested that Spl or an Sp-1 related transcription factor,
present in both H4IIE and B103 nuclear extracts, binds to the 134bp PstI fragment in
a specific manner. Specifically, the inclusion of an antibody against Spl caused a
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supershift in complexes formed between FB and both H4IIE and B103 nuclear
extracts. In addition, both H4IIE and B103 extracts were shown to form specific
complexes with a synthetic Spl consensus oligonucleotide. However, it is notable
that an excess of unlabelled consensus Spl oligonucleotide did not compete with the
labelled FB fragment for binding to B103 extract. Considering the GC-rich nature of
the whole region, including the 134bp PstI fragment, perhaps evidence showing
binding by Spl or a Sp-1 related protein was to be expected. As such, while Spl
binding appears to be specific, whether this is at a high enough affinity to be relevant
in vivo remains unconfirmed.
It should be noted that time constraints did not permit the repitition of several band
shift experiments shown here. The specificity of potential binding over the 134bp
PstI region should therefore be confirmed by further experiments in which
consistent, rerproducible band shifts are observed.
It is interesting to note that the DNasel footprinting experiments of the 134bp PstI
fragment mirror the directionality observed in transient transfection studies; activity
and binding of this fragment appear to be completely orientation-specific. Given that
the physical properties of transcription factor binding protect both strands from
DNasel digestion, regardless of whether contacts are made on only one strand (Gill,
2001), the presence of a DNasel footprint on only one strand of this fragment is
puzzling. The integrity of B103 and H4IIE nuclear extracts used in experiments with
Fa was controlled for in parallel experiments in which protection was observed on
fragment FB, ruling out degradation ofprotein as a source of the discrepancy. Recent
studies have shown that protein-DNA binding is often extremely dynamic, whereby a
binding protein continually 'hops' on and off its binding site (Becker et al., 2002;
Maruvada et al., 2003). These experiments only capture a 'snapshot' ofbinding over
the fragment and naturally the more dynamic the binding, the greater the difficulty in
observing a footprint. It is therefore conceivable that interactions in this region may
be too dynamic to leave a strong footprint, although it is unclear why binding should
be more easily detectable on one strand than its complement.
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However, it is conceivable that protection would only be seen on one strand if the
sequence in question were 'unwound'. This would be the case ifRNA polymerase II
was bound and active on this fragment and would also explain the directionality of
its promoter activity. If this region does indeed represent a region at which
directional transcription is initiated, the presence of factors involved in the RNA
polymerase II transcription machinery would be predicted. Unfortunately, EMSAs
that included an antibody against TFIID, a protein complex known to be involved in
the transcription initiation complex, showed no supershift in the protein-DNA
complex with either H4IIE or B103 cell extracts (data not shown). However, TFIID
is a large complex of proteins (Gill, 2001) and as such is relatively easily degraded. It
may therefore be the case that the protein extracts used in the experiments described
here might not have been of sufficient quality to maintain the integrity of the TFIID
complex.
Significantly, the protein binding observed at the 134bp PstI fragment is not specific
to the neural cell line B103, but is also seen with H4IIE (hepatoma) extract. As such,
the experiments described here do not provide a candidate neural-specific protein
whose binding accounts for the high neural-specific activity of this region. It may be
the case that post-transcriptional mechanisms account for the high neural-specific
activity of PI 7, PI 7a and PI 7b- For instance, exon U-associated transcripts may be
more stable or more easily translated in neural cells. Similarly, if the region does
indeed contain a transcription initiation site, it may be that the start site is simply
more active in B103 than H4IIE cells, although the reason for this remains unclear.
With regard to objective (ii), transient transfection data provided some further
insights into the functional elements involved in transcriptional activity of the GR
promoter region. In all cell lines tested, P2, which represents the whole CpG island
promoter region, showed the highest activity. The low promoter activity associated
with most alternate exons 1 must therefore combine to produce high overall activity.
To further investigate this, the total cumulative activity of all constructs in the 3'
deletion series was calculated in the four cell lines (table 4.1). The values for B103,
C6, HepG2 and H4IIE cells are 148%, 124%, 102% and 42% respectively. The
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cumulative activity of all CpG island exon 1 constructs therefore accounts for at least
all of P2 activity (set at 100%) in B103, HepG2 and C6 cells, but not in H4IIE cells.
The fact that the cumulative activity of individual exons 1 exceeds that of P2 in B103
and C6 cells also suggests that there might be an upper limit to total (P2)
transcription rate over the region. In addition, the apparent additive activity of
individual exons 1 indicates that there is little 'promoter competition', i.e. initiation
of transcription at one exon does not prevent initiation at another.






Table 4.1 Combinedpromoter activity ofthe 3' deletion constructs.
Table showing the combined promoter activity of transiently transfected constructs
of the 3' deletion series (PI5, PU, PI7, Pis, PI9/10, PI 10 and PI 11). Values were
calculated from the means of each transiently transfected construct in each cell line
and are expressed as a percentage of total P2 activity (nominally set at 100%).
The difference between the cumulative activity of individual exons 1 and overall P2
activity in H4IIE cells is puzzling. It may be the case that, in the H4IIE line, the
exons are working synergistically. Alternatively, the result may reflect the different
technique used to transiently transfect H4IIE cells (cationic lipid method) compared
to the other cell lines (calcium phosphate method). However, levels of P2 in relation
to empty vector are not significantly different in H4IIE cells to those seen in B103 or
C6 cells, which makes differences caused by transfection technique unlikely.
The lack of significant promoter activity associated with Pl6 and PI 10 was surprising
given the predominance of exon 16 and 110 containing transcripts in all tissues tested
(Strahle et al., 1992; McCormick et ah, 2000) Strahle at al used RPA analysis to
carry out quantification of mouse GR transcripts IB and 1C (corresponding to rat
exons and lio respectively), in mouse liver, brain, S49 (mouse T lymphoma) and
WEHI-7 (mouse T lymphoma) cells (Strahle et al., 1992). They detected a
comparatively stronger signal for IB in liver relative to other cells and tissues, and
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observed several 1C transcripts (indicating variable transcription start sites) which
were present at varying levels in all samples. They therefore concluded that
transcription of exons IB and 1C is driven by individual promoters showing cell-
specific activity. However, it should be noted that while IB and 1C expression levels
were compared between tissues, the pattern of IB versus 1C expression within
tissues was not shown. It may simply be the case that levels of exons IB and 1C are
both higher in mouse liver relative to other tissues and cells. In this way, exons IB
and 1C may not be differentially driven by tissue-specific promoters; rather
transcription at both exons is simply higher in cells that express high levels of GR.
Data gained for PI6 and Plio also contrast with evidence showing that luciferase
reporter constructs containing sequences proximal to either human GR exons IB or
1C (homologous to rat exons H and 110 respectively) exhibited significant promoter
activity in several human cell lines (Nobukuni et al., 1995; Breslin et ah, 2001;
Nunez & Vedeckis, 2002). Breslin et al showed no difference in the activity of
promoter IB between IM-9 (B-cell lymphoma), CEMC-7 (T-cell lymphoblast),
Jurkat (human T), HeLa cells (human cervial carcinoma), with higher activity in WI-
38 (fibroblast) cells than IM-9 cells but not significantly different to the other cell
lines (Breslin et ah, 2001). In contrast, there were significant differences in the
activity of promoter 1C between all the cell lines (Breslin et ah, 2001). However,
similar to the case described above, the activity of promoter IB and 1C constructs
was compared between and not within tissues. In this way, the relative contribution
of these promoters to activity within specific cell lines was not addressed.
Nunez et al have reported data showing that the IB and 1C promoters exhibit
differential activity within cell types (Nunez & Vedeckis, 2002). While there was no
difference in activity between the two constructs in HeLa or Jurkat cells, the
promoter activity of 1C was significantly higher than IB in HepG2 cells (Nunez &
Vedeckis, 2002). With regard to the IB promoter, footprints have been reported at
one GATA, three YY1 and four Spl transcription factor binding sites (Breslin &
Vedeckis, 1998) (Nunez & Vedeckis, 2002). In addition, the relative contribution of
these binding sites has been shown to be tissue-dependent. Specifically, deletion of
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the three YY1 sites has been shown to lead to a decrease in promoter activity in
HepG2 and Jurkat cells, but not in HeLa cells (Nunez & Vedeckis, 2002).
Conversely, deletion of all four Spl sites caused a significant down-regulation in
promoter activity in HeLa cells, but not in HepG2 or Jurkat cells (Nunez &
Vedeckis, 2002). However, it should be noted that the resolution of the DNasel
protection data presented by Nunez et al, in which they claim to identify four
footprints corresponding to one GATA and three Spl transcription factor binding
sites, is relatively poor (Nunez & Vedeckis, 2002). Similarly, in several of the
EMSAs, lanes corresponding to 'labelled fragment only' are empty; thus preventing
comparison between DNA alone and potentially shifted complexes. Furthermore,
addition of an antibody against GATA-3 failed to induce a supershift in the protein-
DNA complex, and supershifts were only seen with the addition of an antibody
against Spl. Similar to the work presented here, it might be expected that evidence of
Sp-1 binding might be observed at such a GC-rich sequence, particularly at high
concentrations of nuclear extracts (Nunez et al do not report the concentration of
HeLa extract used in their experiments). The physiological relevance of these Spl
sites therefore remains to be seen.
With regard to promoter 1C, previous studies have identified five putative Spl sites,
although their contribution to overall and tissue-specific GR regulation has not been
investigated (Breslin & Vedeckis, 1998). In addition, Nobukuni et al reported the
presence of three footprints on the 1C promoter, one ofwhich was shown to bind
AP2 in HepG2 cells (Nobukuni et al., 1995). Significantly, deletion of this AP2 site
triggered a decline in promoter activity in HeLa and NIH3T3 cells, but not in the
HepG2 cells in which binding had been observed (Nobukuni et al., 1995). The
relevance of this transcription factor to GR regulation in HepG2 or indeed any other
cell line therefore remains unconfirmed.
Despite the relative lack of clarity with regard to the transcription factors involved in
regulating transcriptional activity over the GR promoter, particularly at sequences
associated with exons IB and 1C, the balance of evidence provides some interesting
implications. Most significantly, it appears that tissue-specific GR expression is not
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regulated by exclusively tissue-specific transcription factors. Instead, transcriptional
activity is driven by ubiquitously expressed factors such as YY1 and Spl.
Furthermore, while deletion of the four YY1 sites from the whole human GR
promoter resulted in a -60% decrease in activity (Breslin & Vedeckis, 1998), their
deletion from the isolated IB promoter caused only a -30% reduction (Nunez &
Vedeckis, 2002). This finding suggests that the contribution made by these
regulatory elements may be dependent upon their context within the whole promoter,
i.e. there is inter-dependence between interactions at different regulatory elements.
As such, isolation of these regulatory elements may not give an accurate picture of
their overall contribution to promoter activity. If this is the case, then differences in
the size and relative positions of fragments used in transient transfection assays may
create marked differences in their activities. This may explain the apparent
discrepancy between the promoter activities of the Pl6 and PI io constructs used in
these experiments and the IB and 1C constructs used by others.
This contextual dependence may also explain why the contribution of the 134bp PstI
fragment is significantly higher within the Pl7b construct than when isolated in a
promoterless vector. Similarly, regulatory regions that are not present in the Pl6 and
PI io constructs may contribute to the transcriptional activity at exons U and 1 io,
hence the predominance of these GR mRNA isoforms in rat tissues (McCormick et
al., 2000; McCormick, 2000). However, an alternative possibility, in which post-
transcriptional mechanisms may act to specifically stabilise exon 16- and lio-
containing GR mRNA isoforms, should also be mentioned. While transcriptional
activity at each exon 1 is relatively similar in all cells, transcripts containing specific
5' leader sequences may be subject to differential, tissue-specific degradation, thus
giving rise to characteristic patterns of GR mRNA isoforms, in which exon 16- and
lio-containing transcripts predominate. This could be investigated by assaying the
rate of degradation of transcripts containing alternate 5' leader sequences. Indeed,
GR/GFP minigene constructs have already been synthesised in this laboratory and
could be used for this purpose.
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It is interesting that further investigation of the elements involved in regulating
activity of the rat GR promoter supported this idea of contextually dependent
regulatory regions. Experiments using the 5' deletion series identified two regions,
Ri (-4878 to -3912), and R2 (-2806 to -2535), that together accounted for 80% of
total P2 activity in B103 cells. Ri incorporates exon I4 while R2 includes exonslg and
19. Interestingly, the -3912 to -2806 deletion, which includes exons 15, 16 and 17,
appears to have no effect on promoter activity. As such, the loss of the region
represented by PI7, which has previously been shown to be highly active in B103
cells, does not produce any further decrease in activity over and above that occurring
as a result of the -4878 to -3912 deletion. This suggests that the contribution of the
I7 promoter element, specifically the 134bp PstI fragment, may be relatively small in
the context of the whole promoter. Consistent with this, while the 134bp PstI
fragment was important in the context of Pl7b, its deletion from P2 resulted in a
significant, but relatively small decrease in overall promoter activity.
The position-dependent nature of regulatory elements in the GR promoter is also
supported by comparison of results in B103 cells for pVL262 (an internal PstI
deletion construct), Pl6 (from the 3' deletion series) and pVL260 (from the 5'
deletion series). The activity of two regions from -4878 to -3339 and -1770 to -9
can be assessed by comparison of data for these three constructs. Interestingly, there
is no significant difference in activity between any of the constructs. In addition, the
5' deletion series showed that the -4878 to -3912 region accounted for 40% of P2
activity, although pVL262, in which -4878 to -3339 is present, is not more active
than pVL260, in which it is absent. Regional promoter activity therefore appears to
be dependent upon correct positioning within the whole promoter.
To conclude, the PI7 construct was unique in showing tissue-specific promoter
activity in neural cells. This result complements previous data showing the presence
of 1-/-containing GR transcripts in rat hippocampus (McCormick et al., 2000). A
134bp PstI fragment was shown to be responsible for high neural-specific activity,
although no neural specific protein-DNA interactions were observed over the region.
Therefore, with the exception of 17, it appears that the alternate exons 1 that are
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located in the CpG island region of the rat GR promoter are not driven by individual
tissue-specific promoters. As such, regulatory elements appear not to be associated
with individual exons 1 but are instead located over the whole GR promoter region.
Furthermore, these elements do not appear to operate in isolation but are inter¬
dependent upon each other. Hence, the activity of regional promoter elements is
dependent upon their correct positioning within the whole GR promoter region.
Together with evidence showing that all exons 1 residing within the CpG island
region are expressed in all tissues, it appears that tissue-specific regulation of GR
mRNA levels does not primarily occur through the selective regulation of
transcriptional activity at individual exons 1.
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5 Investigation of the roles of exon 1-associated splice donor sites and
chromatin structure in rat GR regulation.
5.1 Introduction & Aims
The work described in the previous two chapters investigated the hypothesis that
alternate exons 1 located in the rat GR CpG island region are associated with tissue-
specific regulation. However, results showed that all alternate exons 1 tested were
ubiquitously expressed, and only one exon (I7) appeared to be associated with a
tissue-specific promoter. The balance of evidence therefore suggests that the
selective activity of alternate exons 1 does not provide a mechanism for the tissue-
specific regulation of GR. In light of this, alternative roles of this unusual and highly
conserved structure were investigated.
Results presented in chapter 4 indicated that relatively insignificant regional
promoter activity over the CpG island region combines additively to generate high
overall activity. This suggests that the multiple exon 1 structure of GR might play a
role in ensuring the high constitutive expression of this important housekeeping
gene. As such, transcription can be thought of as initiating from multiple preferential
sites (giving rise to multiple exons 1), but selection of individual start sites is
relatively unimportant. In this way, transcription initiation over the whole CpG island
region might combine to generate high and constitutive GR expression.
Under this hypothesis, the role of the splice donor site would be minimal. If
transcription is initiating indiscriminately over the GR CpG island region, splicing
should simply occur at the most proximal suitable donor site. There are also some
significant implications for chromatin structure. This hypothesis implies that the GR
CpG island region occupies an extended area of transcriptional activity and, as such,
should be accompanied by a corresponding region of'open' chromatin. Thus, the
aim of experiments described in this chapter was to elucidate the role of the alternate
CpG island exons 1 in the constitutive regulation of GR. Specifically, the role of the
splice donor site and the chromatin conformation of the region were investigated.
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5.2 Experimental Design
5.2.1 Site-directed mutagenesis of splice donors sites at exons 16, 110 and
111 within P2.
The role of exon 1-associated splice donor sites in GR regulation was assessed using
constructs in which various splice donor sites were abolished. Site-directed
mutagenesis of P2 was used to engineer GT to AC mutations in the splice donor sites
at exons 16, 1 io and In, generating the constructs P2Mutl6, P2Mutl]0 and P2Mutln
respectively. In addition, a GT to AC mutation at the exon lio splice donor site was
engineered within Pin, resulting in PlnMutlio- Transient transfection analysis in
B103 cells was undertaken to investigate the effect of the mutations on promoter
activity.
The effect of each mutation on splicing activity was assessed by RT-PCR and
sequence analysis of RNA extracted from transfected cells. To this end, each
transient transfection was performed using six replicates, with three dishes used for
promoter activity assays and three dishes used to prepare RNA. Following RT-PCR,
reactions were performed using 5' primers specific for individual exons 1 (15, 16, 17,
lio and GO in conjunction with a common 3' primer complementary to luciferase
(section 2.1.7.1). Predicted product sizes are given in table 5.1. Positive control
reactions for each primer pair were carried out using RNA from cells transfected
with intact P2 plasmid. In order to control for DNA contamination of RNA samples,
negative control reactions, in which AMV Reverse Transcriptase enzyme was
omitted from the reverse transcription step, were carried out for each RNA sample
and primer pair.






Table 5.1 Predicted sizes ofP2 alternate exon 1 RT-PCR products
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5.2.2 DNasel hypersensitive site mapping of the GR promoter locus.
The chromatin structure at the GR promoter locus was investigated by DNasel
hypersensitive (HS) site mapping. This technique is based on the principle that
chromatin in an 'open' conformation is more sensitive to enzymatic digestion by
DNasel than 'closed' chromatin. Specifically, relatively small areas of open
chromatin, usually coinciding with active promoter or enhancer elements, give rise to
sites that are hypersensitive to digestion by DNasel. Nuclei preparations of selected
cells or tissues are treated with increasing concentrations ofDNasel, genomic DNA
is isolated and subsequently restricted using an enzyme yielding a fragment that
encompasses the whole region under investigation. This is known as the 'parent'
fragment and DNasel digestion at sites of hypersensitivity generates smaller
'daughter' fragments. After Southern blotting of the digested DNA and hybridisation
with a radiolabeled probe, the relative sizes of 'parent' and 'daughter' bands are
calculated to map regions of hypersensitivity.
Nuclei were isolated from H4IIE (rat hepatoma) cells and digested with three
different concentrations ofDNasel enzyme (30u/ml, 40u/ml and 50u/ml) for four
different lengths of time (1, 2, 4 and 8 min). Genomic DNA was isolated before
treatment with Hindlll to give a 3641 bp parent fragment encompassing the whole of
the GR CpG island region. A 'zero' reaction, which was not exposed to DNasel, was
also retained. In addition, DNA purified from DNasel-treated H4IIE nuclei was
digested with Sail, generating a large 30.1kb parent fragment, which encompassed
the previously mentioned 3641bp Hindlll region. Southern blotting was carried out




5.3.1 Mutagenesis of splice donor sites at exons 16, 110 and 1n in the P2
construct does not significantly decrease promoter activity.
The role of the exon 1-associated splice donor sites was investigated using constructs
in which the splice donor sites at exons 16, 110 and 111 were mutated within the P2
plasmid. The resulting constructs (P2Mutl6, P2Mutl 10 and P2Mutl n respectively)
were transiently transfected into B103 (rat neuroblastoma) cells. Transient
transfections of the PI 1 iMutl 10 construct, in which the exon 110 splice donor site of
the Pin plasmid was mutated, were also carried out. None of the mutated P2
constructs show significantly different activity to intact P2 (fig 5.1). In addition,
there was no significant difference in activity between PI nMutlio and Pin.
Mutation of splice donor sites, including those at the most abundant transcripts 16
and 110, therefore appears to have no effect on GR promoter activity.
5.3.2 Longer transcripts are associated with GR exons 1 at which the splice
donor sites are mutated.
The effect of each mutation on splicing activity was investigated using RT-PCR and
sequence analysis. RT-PCR reactions were carried out on RNA extracted from B103
cells transfected with P2, P2Mutl6, P2Mutlio and P2Mutln, using 5' primers
specific for individual exons 1 (15, U, 17, 110 and In) in conjunction with a common
3' primer complementary to luciferase. Reactions using RNA from cells transfected
with intact P2 clearly generated products of the predicted size corresponding to
exons I5, 1(>, I7, 110 and In (fig. 5.2). No bands were observed in negative control
reactions performed without reverse transcriptase (data not shown). The exon 1 ]0
product was absent from RNA of cells transfected with P2Mutli0, but all other exon
1 products were present at the predicted sizes. Interestingly, RT-PCR analysis of
RNA from cells transfected with P2Mutl6 showed a 290bp U product that was larger
than predicted. Further RT-PCR analysis using the U primer produced an additional
476bp product (fig. 5.2B). The 290 and 476bp PCR products were each sub-cloned
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Figure 5.1 Mutagenesis ofsplice donor sites at exons 16, 110 and In in P2 does not
decrease promoter activity.
Transient transfection analysis in B103 (rat neuroblastoma) cells of a series of
constructs in which the splice donor sites at exons U, lio and In were individually
mutated within P2. The activity of all constructs is expressed relative to P2
nominally set at 100%. n=12-19 (2 independent plasmid DNA preparations), values












Figure 5.2 Longer transcripts are associated with GR exons 1 at which the splice
donor sites are mutated.
Representative gels showing RT-PCR analysis of RNA extracted from transfected
B103 cells. Positive control reactions were carried out on RNA extracted from cells
transfected with intact P2. Negative control reactions were also carried out for each
primer pair using RT reactions minus AMV reverse transcriptase. No bands were
observed in the negative controls (data not shown). marks products of a larger
size than predicted, lkb ladder was run in lane M, and the 298bp band is indicated.
A: Results from RNA of B103 cells transfected with constructs including P2 and
variants ofP2 in which the splice donor sites at exons N, lio and In are mutated.
Reactions used 5' primers specific to individual exons 1 (15, 16, 17, No and Ni) in
conjunction with a common 3' primer specific to luciferase. 'I' and II' mark products
detected in the exon Ni reaction using RNA from P2Mutln transfected cells.














into pGEM-Teasy and sequenced. Sequence analysis confirmed that these longer
products are spliced from GT donor sites located downstream of the mutated site, at -
3001 and -2815 (fig.5.3). All other exon 1 products were detected at their predicted
sizes.
Similarly, at least three longer exon 111 products were detected in RNA extracted
from cells transfected with P2Mutl n. The longest and shortest of these transcripts
(labelled I and II on fig 5.2) were sub-cloned into pGEM-Teasy and sequenced.
Product I is spliced from a downstream splice donor site at -990 (fig. 5.4), while II
corresponds to a full-length, unspliced transcript spanning the exon In and luciferase
primer sites (data not shown).
5.3.3 A 3.6kb Hindlll fragment encompassing the CpG island region shows
general DNasel sensitivity.
Analysis of chromatin conformation was investigated by DNasel hypersensitive site
mapping. Genomic DNA was purified from DNasel-treated H4IIE nuclei and
restricted with Hindlll to generate a 3641bp fragment encompassing the GR CpG
island region (fig. 5.5A). The 3641bp 'parent' band can be seen to disappear with
increasing DNasel concentration (fig. 5.5B). Interestingly, the disappearance of the
parent band is not accompanied by the appearance of any 'daughter' bands, which
would correspond to sites ofDNasel hypersensitivity. As such, there appear to be no
nuclease hypersensitive sites within the 3641 bp Hindlll fragment, rather the whole
region is generally sensitive to DNasel digestion.
5.3.4 A 30.1 kb Sail fragment of the GR promoter contains a ~3kb 'daughter'
band.
Results described above showed that the 3 641 bp Hindlll fragment of the GR
promoter showed general sensitivity to DNasel digestion. In order to determine the
boundaries of this sensitive region, DNasel hypersensitive site mapping was carried
out on genomic DNA purified from ZWa.se/-treated H4IIE nuclei and restricted with
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Figure 5.3 Sequence oflonger transcripts generated by the P2Mutl(, mutation.
Sequence of the GR promoter showing exons U, I7 and 18 and the downstream splice
donor sites used in the event of a mutation at the If, splice donor sites. Exon 1
sequences present in 5'RACE-PCR clones identified by McCormick et al are
underlined and labelled (McCormick et al., 2000). The GT to AC mutation at the 16
splice donor site is marked in red. The downstream splice donor sites of products
identified by RT-PCR of RNA from B103 cells transfected with P2Mutl6 are shown






















Figure 5.4 Sequence oflonger transcripts generated by the P2Mutl / j mutation.
Sequence of the GR promoter showing exon In and the downstream splice donor
site used in the event of a mutation at the In splice donor site. The exon In sequence
present in 5'RACE-PCR clones identified by McCormick et al is underlined and
labelled (McCormick et al., 2000). The GT to AC mutation at the In splice donor
site is marked in red. The downstream splice donor site used to generate a product
identified by RT-PCR of RNA from B103 cells transfected with P2Mutln is shown
in blue and marked with a triangle. A further product corresponded to the full,


























Figure 5.5 A 3.6kb Hindlllfragment encompassing the CpG island shows general
DNasel sensitivity.
Strategy (A) and results (B) ofDNasel hypersensitive site mapping carried out on
H4IIE nuclei. Nuclei were treated with 30U/ml, 40U/ml and 50U/ml DNasel for 0, 1,
2, 4 and 8 min. Genomic DNA was purified before Hindlll-restriction, Southern
blotting and hybridisation to a Sphl/Hindffl radiolabeled probe (labelled PA). The
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Sail. This digestion generated a 30.1kb fragment that extended from the beginning of
exon 2 to close to exon 11 and therefore encompassed the whole HinclIII region (fig.
5.6A). A 30.1kb parent band can be seen in the 'zero' DNasel reaction but is absent
from all DNasel-treated reactions (fig. 5.6B). A 'daughter' band of ~3kb can be seen
in three DNasel-treated lanes (2, 6, 10), and is particularly strong in lane 10. Two
further diffuse bands, one larger and one smaller than 3kb can also be seen in lanes
2,6 and 10.
5.4 Discussion
The experiments described in this chapter were designed to investigate the role of
alternate exons 1 in the constitutive regulation of GR. It was hypothesised that
relatively indiscriminate transcription initiation over the whole CpG island combines
to generate high GR expression. As such, the role of exon 1-associated splice donor
sites was investigated. Specifically, the proposal that, following initiation, transcripts
simply splice at the most proximal donor site was tested. This hypothesis also
implies that a large region of transcriptionally active DNA extends over the GR
promoter. This region should therefore be accompanied by a large area of 'open'
chromatin; a proposal that was tested by DNasel hypersensitive site mapping.
RT-PCR analysis of RNA extracted from B103 cells transfected with P2 confirmed
that all exons 1 examined were present at their predicted sizes. This confirmed that
all exon 1 transcripts identified in vivo can be detected in this in vitro system. The
identification of longer products associated with mutations at the splice donor sites of
exons U and In also gives rise to several interesting implications. It appears that
RNA polymerase II and its associated splicing machinery by-passes the mutation and
continues to a donor site further downstream. Following sequence analysis showing
that all splicing conformed to the GT/AC rule (Black, 2003), it was originally
assumed that, after moving past the mutation, the splicing machinery would simply
utilise the next suitable donor site. However, results from experiments in which the
16 site was mutated show that this was not always the case. Whilst the splicing
machinery generated products that were spliced at -3001 and -2815, no product was
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Figure 5.6 A 30.1kb Sailfragment ofthe GR promoter contains a ~3kb 'daughter'
band.
Strategy (A) and results (B) ofDNasel hypersensitive site mapping carried out on
H4IIE nuclei. Nuclei were treated with 30U/ml, 40U/ml and 50U/ml DNasel for 0, 1,
2, 4 and 8 min. Genomic DNA was isolated before ^//-restriction, Southern blotting
and hybridisation to a Sphl/Hindlll radiolabeled probe (PA)- lkb ladder was run in
lane M and the 2036bp and 510bp bands are indicated. marks bands generated by
cleavage at potential DNasel hypersensitive sites. A solid arrow marks the 30. lkb
parent fragment and a broken arrow indicates a ~3kb daughter band.
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generated from splicing at -2916, the mapped I7 donor site. It is unclear why this
splice donor site, which generates the 17 transcript identified in both tissues and cell
lines, is not utilised. However, it may be that the product generated by splicing at the
I7 donor site is, in this case, inherently unstable and therefore rapidly degraded.
The absence of a longer exon 110 transcript in RNA extracted cells transfected with
P2Mutl 10, is also puzzling. It may be that the mutant 110 product(s) is too large to
amplify successfully under the PCR conditions used. However, use of the exon 111
splice donor site in this instance would generate a product of 677bp, considerably
smaller than the 800bp and 1650bp products successfully detected as a result of the
111 mutation. Once again, it is possible that the longer transcripts may be inherently
unstable and therefore rapidly degraded.
The splice donor sites identified during the experiments described above have never
been detected in previous RT-PCR or 5'-RACE-PCR analyses in either cells or
tissues. Initial 5'RACE-PCR data identified clones containing overlapping exons,
e.g. a clone termed 14 5 was spliced from a donor site located between those mapped
for exon 14 and 15 (McCormick, 2000), but it would appear that the vast majority of
splicing occurs at the mapped donor sites. It is interesting that, following mutation of
one such 'consensus' site, splicing occurs at more than one alternative. The 'cryptic'
splice donor sites uncovered by the mutations are therefore considerably 'weaker'.
Sequence analysis of the mapped 'consensus' sites at exons 14, 15, 16, I7, I9, 110 and
In revealed no obvious splicing enhancer elements (Dominski & Kole, 1994;
Selvakumar & Helfman, 1999; Tian & Kole, 2001), although it is interesting to note
that five of the sites contained the sequence c/gAGGT, while two contained AGT. In
contrast, the sequences of the three 'cryptic' donor sites identified were more
heterogeneous.
Results also showed that mutation of exon 1 splice donor sites, including those at the
predominant exons 16 and lio, had no effect on overall promoter activity. This
finding provides further intriguing implications. The splice donor site mutations give
rise to transcripts with significantly longer 5' leader sequences, which might
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conceivably adopt different secondary structures, yet high luciferase activity is
maintained. The influence exerted by 5' leader sequences and their associated
secondary structure on mRNA stability and translational efficiency is well
documented (Kozak, 1991; Preiss & Hentze, 1999; van der Velden & Thomas,
1999). However, these data suggest that the length of the GR 5' leader sequence has
no functional influence on protein expression. This is admittedly an artificial system
in which luciferase, rather than GR protein, is synthesised, yet if a primary function
of these alternate exons 1 is to influence GR protein levels through differential
mRNA stability, localisation or translation, we might expect to observe an effect.
DNasel hypersensitive site mapping was carried out to determine if the entire exon 1
region occupies an area of transcriptionally active and therefore 'open' chromatin.
Results indicated that a 3.6kb Hindlll fragment, encompassing the whole CpG island
region, is sensitive to digestion by DNasel, with no accompanying sites of
hypersensitivity. The lack of hypersensitive (HS) sites in a region known to be highly
transcriptionally active was surprising. However, it should be noted that chromatin
can exist in several different states (Romberg, 1977). The extremes of chromatin
conformation are exemplified by the inert nucleosomal chromatin associated with
bulk transcriptionally inactive DNA and the nuclease HS sites that occur at
promoters from which the nucleosomes have been displaced (Tazi & Bird, 1990;
Cuadrado et al., 2001). However, between the extremes there is an intermediate level
of chromatin stmcture that is associated with transcribed sequences (Tazi & Bird,
1990). Chromatin of this kind is defined by moderately enhanced DNasel sensitivity
of its constituent DNA, usually over an extended region (Weintraub & Groudine,
1976). CpG islands are known to involve modification of nucleosomal histones (in
particular, histone acetylation), absence of histone HI, presence ofnon-histone
proteins and under-methylation of the DNA sequence (Tazi & Bird, 1990). These
factors act to prevent higher order folding of chromatin at CpG islands, leading to a
disorganised 'beads-on-a-string' nucleosomal stmcture. This kind of structure,
typical of a CpG island, may be responsible for the long-range DNasel sensitivity
observed over the GR promoter. However, it must be stressed that the structural
'openness' of chromatin is a relative issue and all chromatin is DNasel sensititive to
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some degree. The DNAsel sensitivity of the Hindlll fragment of GR can only be
expressed relative to a control fragment from another gene. This control must be
carried out in order to confirm the sensitivity of this region.
Further DNasel hypersensitive site mapping was carried out to elucidate the
boundaries of this sensitive region. Experiments showed that a large 30.1kb Sail
'parent' fragment extending from exon 1] to exon 2 yielded a ~3kb 'daughter' band
following DNasel treatment. Increased DNasel exposure subsequently caused this
~3kb band to disappear. The probe used to detect this daughter band was located
>25.2kb and 4.5kb away from the 5' and 3' Sail sites respectively. As such, both
ends of the ~3kb fragment must be generated by DNasel. It is extremely likely that
this ~3kb fragment corresponds to the entire 3.6kb Hindlll fragment shown
previously to exhibit general nuclease sensitivity. In this way, hypersensitive sites
marking the ends of the ~3kb region were identified by low concentrations of
DNasel (~50U/ml). This region, which must overlap with (and probably corresponds
to) the 3.6kb Hindlll fragment, shows general DNasel sensitivity and is therefore
degraded following increased nuclease exposure (>60U/ml). It is possible that both
hypersensitive sites lie outside the 3.6kb Hindlll fragment, hence the absence of a
'daughter' band in experiments using the 3.6kb Hindlll 'parent' fragment. Similarly,
if a hypersensitive site is present, its location must be extremely close to one of the
Hindlll restriction sites. The resulting 'daughter' band would either be too small to
allow successful identification or too similar in size to the parent band to be
sufficiently distinguished.
The observation of the 3kb DNasel sensitive band is the product of a single
experiment and must therefore be viewed with caution. It is possible that the band is
a product of exogenous enzyme activity and further experiments are therefore needed
to verify its existence. Unfortunately, it was extremely difficult to optimise the
DNasel hypersensitive site mapping technique. The CpG island region of the GR
promoter is obviously extremely GC rich, which can lead to problems during the
denaturation and hybridisation steps of the Southern blotting protocol. GC-rich DNA
regions are often described as 'sticky', and can therefore cause high levels of non-
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specific binding during hybridisation with a radiolabeled probe. Unfortunately, very
high levels of 'background' hybridisation, due to non-specific binding, rendered
many blots uninformative. In addition, on several occasions hybridised blots were
completely blank, which may have been due to incomplete denaturation of this
'sticky' GC-rich region.
The original intention of the DNcisel hypersensitive site mapping experiments was to
compare the chromatin conformation of the GR locus in different cell types,
specifically the B103 (rat neuroblastoma) and the H4IIE (rat hepatoma) cell lines.
However, results discussed in Chapter 4 show that B103 cells do not endogenously
express GR and were therefore unsuitable for this analysis. Time constraints imposed
by the technical difficulties described above meant further experiments in alternative
cell lines could not be carried out. However, elucidation of the chromatin structure at
the GR locus in different cell types is an important part of investigations into GR
regulation, and should be pursued. In particular, comparison of the non-CpG island
exon 11 region between expressing and non-expressing cells would be extremely
interesting. Previous studies have shown sites ofDNasel hypersensitivity at the 1A
promoter region in WEHI-7 T-lymphoma, but not LTK", cells (Strahle et al., 1992).
We might therefore speculate that the CpG island region, which is ubiquitously
active, is in 'open' chromatin conformation in all cell types, while a tissue-specific
hypersensitive site at exon 11 restricts its expression to T cells only.
The data presented here indicates that splice donor site selection has no impact on
overall GR promoter activity, as well as demonstrating that the CpG island region
occupies an extended area of transcriptionally active chromatin. These findings are
consistent with the hypothesis of relatively indiscriminate transcription initiation
over the whole region, which combines to generate high overall expression.
However, this raises the question ofwhy expression is generated by the combined
activity of several 'weak' promoters, rather than one 'strong' promoter. There are
many genes whose 'housekeeping' roles require their guaranteed expression in every
cell type at all times, regardless of the typical pool of transcription factors present. It
is conceivable that one single promoter may simply not be able to accommodate all
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the necessary elements for truly ubiquitous expression. This hypothesis is supported
by work carried out on the housekeeping gene Hft9 showing that its promoter binds
different factors depending on the tissue in which it is expressed. As such, cell type-
specific combinations of tissue-specific and ubiquitous binding factors act to
guarantee Hft9 expression in every cell (Stapleton et al., 1993).
There is also the intriguing possibility that a gene in which transcription is initiated at
several sites, generating transcripts differing only in their 5'-leader sequence, might
be rendered less vulnerable to mutations in promoter sites. This would obviously be
of enormous benefit to a housekeeping gene whose expression must be guaranteed in
every cell. In this light, heterogeneity of transcription initiation at the GR CpG island
might simply be a robust mechanism to ensure ubiquitous expression. Furthermore,
CpG islands are generally believed to be under a greater mutational pressure relative
to the rest of the genome because of their dual role as promoters and DNA
replication origins (Delgado et al., 1998; Antequera & Bird, 1999; Cuadrado et al.,
2001). Maintaining ubiquitous GR expression in the face of this large mutational
burden may therefore require the protection of multiple redundant promoters.
There are several reported cases of genes containing both a promoter that confers
ubiquitous expression and an alternative promoter with a more restricted spatial or
temporal expression pattern. As mentioned in section 1.2.2.2.3.2, the human
phobilinogen deaminase (PGBD) gene exemplifies this situation, displaying a CpG
island-embedded promoter that is active in all tissues and an alternative promoter,
located 3kb downstream, which is active only in erythroid cells (Chretien et al.,
1988). The human STAT5B gene, which belongs to the Signal Transducer and
Activators of Transcription family of transcription factors, employs a similar
mechanism in which constitutive and tissue-specific activity is driven by promoters
located in and out of a CpG island respectively (Ambrosio et al., 2002). It is not
difficult to apply this system to the regulation of GR, in which constitutive
expression is driven by multiple promoters in the CpG island region, while the
upstream exon 11 promoter is tissue-specific.
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The results described in this chapter are consistent with the hypothesis that the CpG
island multiple exon 1 structure plays a major role in the constitutive expression of
GR. As such, an extended region of 'open' chromatin facilitates heterogeneous
transcription initiation over the whole CpG island region. The presence of multiple
transcription initiation sites allows the GR promoter to exhibit a great deal of
resistance to mutation, even if the disruption is not 'random' but directed at the splice
donor sites crucial in maintaining 'normal' exon 1 structure. The resulting multiple
exon 1 structure of the GR promoter ensures robust, high throughput and constitutive
expression of this essential housekeeping gene.
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6 Investigation of the role of the GR promoter and its constituent
alternate exons 1 in rat GR autoregulation.
6.1 Introduction & Aims
Work described in the previous three chapters investigated the complex rat GR
promoter and its associations with tissue-specific and constitutive GR regulation.
However, an investigation into GR regulation must also consider the most potent
regulators of GR expression: glucocorticoids themselves. There is a wealth of
evidence showing that regulation of GR by glucocorticoids is a GR-mediated
response, with repression predominating in most cells and tissues (section 1.2.2.2.1)
The experiments described in this chapter were designed to investigate the effect of
the synthetic glucocorticoid, dexamethasone, on the rat GR promoter. In particular,
the hypothesis that individual GR exons 1, or discrete elements of the promoter, are
differentially regulated by dexamethasone was investigated. Previous work carried
out in vivo has suggested that glucocorticoid-induced repression of GR reaches a
'ceiling', after which increased glucocorticoid exposure causes no further decrease in
GR expression (Sapolsky et al., 1984). In this way, it was hypothesised that specific
exons 1 may be targets for autoregulation, while others act to maintain GR
expression, even at high glucocorticoid levels.
6.2 Experimental Design
To investigate potential autoregulation of the GR promoter, the P2 construct was
transiently transfected into B103 cells that were then treated with either vehicle or
the synthetic glucocorticoid dexamethasone. Results described in chapter 3 showed
that B103 cells do not endogenously express GR. Two different masses of the
pRShGR expression plasmid, lOng and lOOng, were therefore co-transfected in all
transfections. One hour post-transfection, cells were treated with vehicle (0.1%
ethanol), 10~8M or 10~6M dexamethasone. The higher dose has frequently been used
in both in vivo and in vitro experiments, while the lower dose is closer to the Kd of
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dexamethasone for GR and is therefore more physiologically relevant. Unlike
previous transfection experiments, cell medium was not changed 24h post-
transfection and cells remained in the 'transfection' medium until harvesting.
6.3 Results
6.3.1. P2 activity is decreased following 48h dexamethasone treatment.
Results showed a significant decrease in P2 activity in all dexamethasone-treated
transfections (fig. 6.1). In addition, experiments in B103 cells, which do not
endogenously express GR, showed that dexamethasone had no effect on P2 activity
in the absence of a co-transfected GR expression plasmid, pRShGR (data not
shown). This confirms that autoregulation of the GR promoter is dependent upon GR
itself. Using lOng co-transfected pRShGR, there was a significant decrease in
activity between 10~8M and 10~6M dexamethasone treatment. However, using lOOng
co-transfected GR plasmid, there was no significant difference in activity between
dexamethasone concentrations. Similarly, using 10* M dexamethasone, there was a
significant decrease in activity with lOOng relative to lOng co-transfected GR
plasmid. Finally, using 10"6M dexamethasone, there was no significant difference in
activity between groups co-transfected with either lOng or lOOng pRShGR.
The decrease in P2 activity following dexamethasone treatment confirmed the
presence of elements in the promoter that may be subject to autoregulation. lOOng
pRShGR and 10"6M dexamethasone were shown to cause the greatest reduction in P2
activity, and were therefore chosen for further transient transfection experiments.
6.3.2 Transfections using a 5' deletion series of the GR promoter identified a
region subject to down-regulation by dexamethasone.
The 5' deletion series of P2 was transiently transfected into B103 cells in order to
localise the dexamethasone-sensitive region (fig. 6.2). No significant difference in
activity was observed between vehicle and 10* M dexamethasone-treated empty
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Figure 6.1 P2 activity is decreasedfollowing 48h dexamethasone treatment.
Transient transfection analysis of P2 in B103 (rat neuroblastoma) cells. Vehicle-
treated P2 activity was nominally set to 100% and the activity of all other groups is
expressed relative to this value. n=7-10 (2 independent plasmid DNA preparations),
means ±SEM. Values were subject to Student t-test analysis. '*' denotes a significant
difference from vehicle-treated P2 activity (p<0.05). 'f' denotes a significant
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Figure 6.2 Transfections using the 5' deletion series ofthe GR promoter identified a
region associated with down-regulation by dexamethasone.
A: Diagram showing the design of the 5' deletion series in which each construct is
fused to a luciferase reporter gene. All constructs have the same 3' end but differ at
the 5' end. The 3' end of each construct is fused to luciferase within exon 2.
Restriction enzymes sites used to engineer constructs are also shown. marks
constructs showing a significant difference between dexamethasone-treated activity
and vehicle-treated activity (p<0.001).
B: Transient transfections carried out in B103 (rat neuroblastoma) cells co-
transfected with lOOng pRShGR and treated with either vehicle (0.1% ethanol) or 10
6M dexamethasone. The activities of all constnicts are expressed relative to a
vehicle-treated P2 value nominally set at 100%. n=9-21 (2 independent plasmid
DNA preparations), values represent means ±SEM. Data were subject to analysis by
Student t-test. denotes a significant difference between dexamethasone-treated












































vector (fig. 6.2B). All observed repression is therefore attributable to the cloned
fragment. Dexamethasone treatment caused significant decreases in the activity of
pVL259 (-3912 to -9) and pVL257 (-2806 to -9), but not pVL258 (-2535 to -9) or
pVL260 (-1770 to -9). Constructs in which repression was observed therefore share a
common dexamethasone-sensitive region between -2806 and -2535.
6.3.3 Dexamethasone significantly decreases the activity of all constructs in a
3' deletion series of the GR promoter.
Transient transfections of the 3' deletion series of P2 were undertaken to further
localise the region of dexamethasone-sensitivity (fig. 6.3). Again, dexamethasone
treatment had no significant effect on empty vector activity (fig. 6.3B). In contrast,
P2 and all other constructs in the 3' deletion series showed a significant decrease in
activity with dexamethasone treatment. As such, a region between -4878 and -3339,
present in all constructs, appears to be dexamethasone-sensitive.
6.4 Discussion
Experiments described in this chapter investigated the effects of the synthetic
glucocorticoid dexamethasone on the rat GR promoter. Results also indicated that the
extent of repression was dependent upon both the amount of co-transfected pRShGR
expression plasmid and dexamethasone concentration. Interestingly, at the highest
amount ofpRShGR (lOOng), there was no difference in P2 activity between 10~8M
and 10"6M dexamethasone treatment groups. Similarly, at the highest concentration
of dexamethasone (10"6M), increased amounts of co-transfected pRShGR caused no
further decrease in promoter activity. It appears, therefore, that both GR and
glucocorticoid concentration are limiting in their effect on GR promoter activity.
Transient transfections using a 5' deletion series of P2 showed that dexamethasone-
associated repression was lost following deletion of the region between -2806 to -
2535. To investigate this further, the -2806 to -2535 region was cloned into a
modified form of pGL3-Basic. The resulting construct (pHLM7) was then
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Figure 6.3 Dexamethasone significantly decreased the activity ofall constructs in a
3' deletion series ofthe GR promoter.
A: Diagram showing the design of the 3' deletion series, in which each construct is
fused to a luciferase reporter gene. All constructs have the same 5' end but differ at
the 3' end. The 3' end of P2 is fused to luciferase within exon 2 while all other
constructs are fused within known exons 1. Restriction enzyme sites used to engineer
the construct series are also indicated. marks constructs showing a significant
difference between dexamethasone-treated activity and vehicle-treated activity
(p<0.05).
B: Transient transfections carried out in B103 (rat neuroblastoma) cells, co-
transfected with lOOng pRShGR and treated with either vehicle (0.1% ethanol) or 10"
6M dexamethasone. The activities of all constructs are expressed relative to a
vehicle-treated P2 value nominally set at 100%. n=l 1-12 (2 independent plasmid
DNA preparations), values represent means ±SEM. Data were subject to analysis by
Student t-test. denotes a significant difference between dexamethasone-treated















































transfected into B103 cells and subject to either vehicle or dexamethasone treatment.
Unfortunately, in this set of transfections, dexamethasone failed to induce a
significant decrease in P2 activity. There was therefore no positive control for
dexamethasone efficacy. Several different batches of dexamethasone were tested but
none caused the reduction in P2 activity seen in previous experiments. The reason for
this failure remains elusive.
Results also demonstrated that all constructs tested in the 3' deletion series of P2
(specifically PI9/10, PI8, PI7 and Pl6) were down-regulated by dexamethasone. These
constructs share a common region between -4878 and -3339, suggesting that this
area contains elements associated with dexamethasone sensitivity. However,
transient transfections involving shorter constructs in the 3' deletion series, such as
Pl5 and Pl4, are required to further localise this region. Together, data from the 5'
and 3' suggest that two regions of P2, from -4878 to -3339 and from -2806 to -2535
are associated with dexamethasone repression (summarised in fig. 6.4).
However, it must be remembered that the luciferase fusion in each of the 3' deletion
constructs abolishes the splice acceptor site normally present at the beginning of
exon 2 (see section 4.2.1). As such, only the fused exon contributes to luciferase
activity; all upstream transcripts are predicted to be spliced at their respective donor
sites but, in the absence of a suitable acceptor site, are unlikely to give rise to
functional luciferase activity (fig. 6.5A). The region between -4878 and -3339 that is
common to all 3' deletion constructs must therefore exert a repressive effect on
transcription from downstream initiation sites in response to dexamethasone (fig.
6.5B). In this way, the region can be thought of acting as a 'repressor'; factors
binding in this region can be seen to have a negative effect on the activity of
downstream promoters in a manner similar to the positive effect associated with
'enhancers'.
Previous work using constructs in which the human GR promoter was fused directly
to a CAT reporter gene showed dexamethasone-associated repression when
transfected into CV-1 cells (Govindan et al., 1991). The area of dexamethasone
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Figure 6.4 Two regions ofP2, -4878 to -3339 and-2806 to -2535, appear to be
dexamethasone-sensitive.
Diagram showing the 5' and 3' deletion series used in transient transfection
experiments to localise regions of dexamethasone-sensitivity. Common regions
























Figure 6.5 The dexamethasone-sensitive region ofP2 between -4878 and-3339 must
exert downstream effects.
A: Diagram showing the 3' deletion series used in transient transfection experiments
to localise regions of dexamethasone sensitivity. Arrows indicate putative
transcription initiation sites; those which do not give rise to functional luciferase
activity are crossed out. 'LUC' represents the luciferase gene, fused to each 3'
deletion construct within a known exon 1.
B: Diagram depicting the putative region of dexamethasone-sensitivity, with arrows
representing its possible downstream effects.
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sensitivity was mapped between -750 and -250 relative to the transcription start at
exon 110 (Govindan et al., 1991) and therefore corresponds roughly to the region
between -3156 and -2656 on the rat GR promoter. This region overlaps with the
region of dexamethasone sensitivity between -2806 and -2535 localised during this
investigation. Interestingly, a novel protein present in MCF-7 cell extracts, termed
GRF-1, was shown to bind to this region (Leclerc et ah, 1991a; Leclerc et al.,
1991b). However, while GRF-1 mRNA was shown to be up-regulated in rat liver
following dexamethasone treatment, this was not found to be the case in the MCF-7
cell line from which the protein was isolated (Warriar et al., 1996). In addition, this
result is contradicted by several studies showing that homologous down-regulation of
GR mRNA and protein appears to be independent ofprotein synthesis, since it
occurs in the presence of cylcohexamide (Okret et al., 1986; Burnstein et al., 1994).
The latter observation implies that activated GR does not induce expression of a
factor that subsequently represses GR transcription. Thus, the inhibitory actions of
activated GR must occur through direct interactions of either the (i) protein-protein
or (ii) protein-DNA variety. With regard to possibility (i), it may be that activated
GR recruits a factor(s) that directly inhibits GR transcription, or binding by activated
GR prevents a factor(s) from maintaining GR transcription. Investigation of
possibility (ii) is hindered by the heterogeneous nature of negative GRE elements
(see section 1.2.1.5). However, two sequences have been found in the human GR
promoter, in the region between -2838 and -1476 (relative to the translation start)
that are homologous to the nGREs found in the promoter of the POMC gene (Drouin
et al., 1989; Schaaf & Cidlowski, 2003). While it remains to be seen if this region is
involved in human GR autoregulation (Schaaf & Cidlowski, 2003), it is interesting
that it roughly corresponds to the -2806 to -2535 dexamethasone sensitive region
suggested by these experiments, although the exact sequences are not conserved.
Further investigation to confirm interactions between GR and sequences in this
region are required to confirm the presence ofputative nGRE sequences. It should
also be noted that sequence analysis of the -4878 to -3339 region, which was also
associated with dexamethasone repression in these experiments, did not identify any
similar nGRE elements.
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However, further analysis of the transfection data suggested an alternative
interpretation. Interestingly, the reduction in activity exerted by dexamethasone in
the 5' series appears to be proportional to construct length (fig. 6.6A). That is, the
longer the construct, the greater the repression. The exon 2 splice acceptor site lies
upstream of the luciferase fusion in all constructs of this series. Thus, each construct
reflects the total activity associated with all included exons. The deletion of exons
therefore appears to be proportionally associated with a decrease in the extent of
dexamethasone down-regulation. This interpretation suggests that the mechanism of
autoregulation does not act at discrete sites on the promoter, but occurs in a manner
dependent upon the number of alternate exons 1 available. In this way, repression of
the two shortest constructs, pVL258 and pVL260, might simply be below the limit of
detection of the transient transfection technique. The power of the transient
transfection technique is enhanced by experiments in which the potential regulation
associated with a region is 'transferred' or mutated. However, mutation is impossible
without more exact knowledge of the location of any potential regulatory region and
there would be little benefit in transferring the regions contained in pVL258 and
pVL260 into an alternative promoterless vector. Nevertheless, while these
experiments may not be sufficiently powered to reliably detect significance at these
small levels of GR repression, changes of this magnitude may exert considerable
physiological influence.
Results from the 3' deletion series transfection data also conform to this alternative
interpretation. If, as discussed above, there are two dexamethasone-sensitive regions,
constructs in which both are present should show significantly greater repression.
However, repression of PI9/10, which possesses both proposed dexamethasone-
sensitive regions, is not significantly greater than that of Pl8, Pl7 or PI6. Instead,
dexamethasone exerts a similar repressive effect of-50% on the activity of all
constructs in the 3' deletion series (fig. 6.6B). The 3' deletion series measures the
transcriptional activity associated with each individual exon 1, and as such,
dexamethasone can be thought of as exerting the same effect, to the same extent, on
the promoter activity associated with each exon 1. If the extent of autoregulation
depends upon the number of alternate exons 1 available; all 3'
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Figure 6.6 Patterns ofdexamethasone repression in the 5' and 3' deletion series of
P2.
Graphs showing dexamethasone repression of the 5'(A) and 3' (B) deletion series of
P2. Values represent the percentage repression in promoter activity associated with
dexamethasone. The value for P2 was generated from all experiments shown in figs.
6.1, 6.2 and 6.3 (n=36).
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deletion constructs, in which only the fused exon contributes to activity, should, and
do, exhibit the same extent of dexamethasone repression.
The mechanism that might cause dexamethasone repression to occur in a manner
dependent upon the number of alternate exons 1 available is unclear. If correct, such
a mechanism would be limited by either the number of transcription initiation sites
available or the number of transcripts bearing different 5' leader sequences. The first
possibility is unlikely because, while only members of the 5' series show variable
repression, both deletion series possess a variable number of transcription initiation
sites (albeit without the formation of viable transcripts in the 3' series). The second
possibility evokes a post-transcriptional mechanism in which the presence of GR
transcripts bearing a larger number of different 5' leader sequences somehow permits
greater repression. However, it should be noted that speculation is limited by the fact
that any post-transcriptional regulation is acting on luciferase, rather than GR
mRNA. It must also be remembered that any putative mechanism of down-regulation
must occur without, as previously mentioned, any de novo protein synthesis. As
such, activated GR must act directly to effect any transcriptional or post-
transcriptional changes.
Previous work has shown that autoregulation of GR can occur at a post-
transcriptional level. While some groups have failed to observe any change in GR
mRNA stability with glucocorticoids (Rosewicz et al., 1988; Dong et al., 1988),
Burnstein et al described a greater than 2-fold increase in GR mRNA degradation
following dexamethasone treatment (Burnstein et al., 1994). It would be interesting
to investigate associations between multiple 5' leader sequences and GR mRNA
stability after steroid treatment. Indeed, GR minigene constructs have been
synthesised in this laboratory in order to address this question.
Transient transfection experiments using GR expression vectors under the control of
either the Rous sarcoma virus (Burnstein et al., 1991) or human metallothionein-IIa
(Alksnis et al., 1991) promoters, also showed a decrease in GR mRNA after steroid
treatment, again suggesting a post-transcriptional mechanism of autoregulation.
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However it should be noted that, in these instances, autoregulation occurs in the
absence of any 5' leader sequences, although evidence does indicate the involvement
of the 3' untranslated region (Okret et ah, 1986).
Evidence indicates that autoregulation of GR operates at multiple levels, affecting
both mRNA and protein. Transcription rate (Dong et al., 1988) (Rosewicz et al.,
1988), mRNA stability (Burnstein et al., 1994), and protein degradation (Mclntyre &
Samuels, 1985) have all been implicated in mediating the glucocorticoid response.
Given that autoregulation of GR is influenced by factors including tissue-specificity
(Kalinyak et al., 1987), stage of cell cycle (Cidlowski & Cidlowski, 1982), degree of
cellular differentiation and aging, perhaps the existence ofmultiple levels of control
is unsurprising. The work described in this chapter showed that the transcriptional
activity of the whole CpG island region, rather than individual exons 1, was down-
regulated by dexamethasone. As such, the observation that down-regulation of GR
expression reaches a 'ceiling', after which further glucocorticoid treatment causes no
further decrease, cannot be explained by the selective down-regulation of one or
more alternate exons 1, leaving the other exons to maintain a basal level of GR
expression. Therefore, in the same way that tissue-specific regulation of rat GR does
not appear to occur through the selective promoter activity of one or more exons 1,




The work described in this thesis was designed to investigate the functional
relevance of the rat glucocorticoid receptor (GR) promoter region. Specifically, the
involvement of the multiple exon 1 structure of the GR promoter in tissue-specific,
constitutive and auto-regulation was studied.
The importance of maintaining appropriate GR levels in every cell has been well-
documented (see section 1.2.2.2). Similarly, the complex regulation of the GR gene,
in which levels vary both between and within tissues, has been the subject of much
investigation. The GR promoter shows a great deal of complexity, consisting of
multiple exons 1 that are alternatively spliced onto a common exon 2. However, an
in-frame translational stop codon downstream of the splice acceptor site in exon 2
means that the sequence of the translated protein is unaffected by the first exon. As
such, all GR transcripts encode a common protein, but differ in their 5' leader
sequence. While most of the alternate exons 1 are located within a -3.2 kb region
containing two CpG islands, exon R lies ~30.2kb upstream of exon 2. This multiple
alternate exon 1 structure naturally suggests itself as a possible mechanism for
providing complex GR regulation.
It is conceivable that tissue-specific patterns of alternate exon 1 expression might
provide a means by which transcriptional regulation of GR is exerted in response to
cell-specific factors. This hypothesis implies that alternate exons 1 are expressed in a
tissue-specific manner. RPA analysis carried out in this laboratory showed that,
while exon 16 and Ro-containing transcripts predominated and were present in every
rat tissue examined, transcripts containing exons 15 and 17 were only detectable in
hippocampus (both at -8%) (McCormick et ah, 2000). However, the more sensitive
RT-PCR analysis used in this investigation showed that all alternate GR exons 1
located in the CpG island region (R, 15, R, R, Ro and Ri) were expressed in all
rodent cell lines tested.
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These data are consistent with further RT-PCR analysis carried out in this laboratory,
in which all 'CpG island' alternate exons 1 were detected in all rat tissues tested
(Freeman, 2003). Similarly, studies of human GR have shown exons IB and 1C
(homologous to rat exons 16 and lio respectively) to be ubiquitously expressed
(Breslin et ah, 2001; Nunez & Vedeckis, 2002). Mouse GR exons IB, 1C, ID and IE
(the last two being homologous to rat exons 15 and 111 respectively) have also been
detected in every mouse tissue tested (Strahle et al., 1992; Chen et al., 1999).
This contrasts with results showing that expression of exon 11, which lies outside the
CpG island region, ~30.2kb upstream of exon 2, is tissue-specific. Previous RPA
analysis showed that exon 11-containing transcripts were found exclusively in rat
thymus, where they accounted for -25% of total GR mRNA (McCormick et al.,
2000; McCormick, 2000). RT-PCR analysis of rodent cells lines carried out during
this investigation confirmed that exon 11 expression was only detectable in the
mouse T cell lines S-49 and EL-4. These data are consistent with RT-PCR results
carried out rat tissues, which also showed that exon 11 expression was restricted to
the thymus (Freeman, 2003). However, studies in mouse showed that the 1A
transcript was present in all tissues investigated (Chen et al., 1999). Furthermore,
three alternate 1A transcripts, termed 1A1, 1A2 and 1A3 have been described for
human GR and while expression of 1 A3 appears to be restricted to cells of the
immune system, 1 Al and 1A2 are ubiquitously expressed (Breslin et al., 2001).
Further investigation of GR exon 11 regulation, particularly with regard to whether
alternate 11 variants are conserved in the rat, is required and is currently being
undertaken in this laboratory.
It appears therefore that cells do not operate an 'all-or-nothing' policy with regard to
expression of the GR exons 1 residing within the CpG island region. Rather,
transcription is initiated at all 'CpG island' exons 1 in all cells. Regulation of GR
does not occur as a result of switching the transcription of alternate exons 1 'on' or
'off. If the GR 'CpG island' exons do indeed play a role in the regulation of GR, it
must be through adjustment of their relative levels.
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In this way, the multiple alternate exons 1 of the CpG island region might be driven
by multiple promoters that show differential activity between cell types. As such,
transient transfection experiments involving constructs in which fragments of the rat
GR promoter were fused to a luciferase reporter gene were carried out in B103 (rat
neuroblastoma) and H4IIE (rat hepatoma) cells. B103 cells were chosen based on
previous work showing that a construct associated with the exon I7 exhibited neural-
specific promoter activity (McCormick et al., 2000; McCormick, 2000). In addition,
H4IIE cells were found to express both alternate exons 1 and total GR mRNA at
levels comparable with rat liver. The P2 construct, which represented the whole of
the rat GR promoter, showed the highest activity in both cell types. Transient
transfections using a 3' deletion series of the GR promoter, designed to measure the
activity associated with each individual exon 1 (McCormick et ah, 2000;
McCormick, 2000), confirmed that PI7 was the only construct associated with cell-
specific promoter activity, being restricted to neural cells.
A 5' deletion series of PI7 identified a 134bp Pstl fragment necessary for high
neural-specific promoter activity. Furthermore, deletion of this fragment from P2
caused a neural-specific decrease in promoter activity. Interestingly, the high activity
associated with this fragment was lost in the reverse orientation, suggesting a lack of
classical enhancer properties. Consistent with this, the fragment did not activate a
heterologous promoter, but did show orientation-specific activity within a
promoterless vector, which was higher in B103 than EI4IIE cells. This directionality
was also observed during DNasel protection experiments, in which both B103 and
H4IIE extracts protected a footprint near the 3' end of the 134bp PstI fragment,
which was detectable on one strand only. Comparison of the protected sequence with
the TRANSFAC database showed it to encode a putative AP2 site. However, further
DNasel protection and EMSA analyses failed to provide evidence of AP2 binding.
While EMSAs did show evidence that Spl or an Spl-related protein, present in both
B103 and H4IIE cell extracts, bound to the 134bp PstI fragment, it remains to be
determined if this binding is of sufficiently high affinity to be physiologically
relevant. Importantly, the observed binding was not specific to B103 cells and
therefore did not provide a candidate factor that might be responsible for the high
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neural-specific activity of this region. The directionality of the observed binding also
remains unexplained. It may be the case that the 134bp PstI fragment contains a
transcription initiation region that is more active in neural cells, although EMSAs
showed no evidence of TFIID-specific binding (TFIID is a component of the
initiation complex).
Interestingly, apart from I7, no other exon 1 was associated with cell-specific
promoter activity. Indeed, PI7 and PI9/10 were the only constructs to show significant
promoter activity in any cell type. In light of evidence showing that exon 16- and 110-
containing transcripts account for the vast majority of GR mRNA (McCormick et al.,
2000; McCormick, 2000), the lack ofpromoter activity associated with Pl6 and PI ]0
was particularly surprising. This result also contrasted with previous work showing
significant promoter activity associated with the human GR exons IB and 1C
(homologous to rat exons U and lio respectively) (Breslin et al., 2001; Nunez &
Vedeckis, 2002). Indeed, DNasel footprinting, EMSAs and deletion analyses have
implicated binding of transcription factors including YY1, Spl and AP2 in the tissue-
specific promoter activity of exons IB and 1C (Nobukuni et al., 1995; Breslin et al.,
2001; Nunez & Vedeckis, 2002). The published data regarding potential cis-
regulatory elements of the GR promoter suggest that tissue-specific expression of
alternate GR exons 1 is not controlled by the action of tissue-specific transcription
factors. Rather, combinations of ubiquitously expressed transcription factors, e.g.
YY1 and Spl, act to control activity over the whole promoter, including that
associated with exons IB and 1C. For instance, in HeLa cells, deletion of three YY1
sites from the IB promoter causes only a 30% loss in activity, while a substantial
decrease in activity is observed following deletion of all four Spl sites (Nunez &
Vedeckis, 2002). In contrast, the elimination of the same three YY1 sites results in a
dramatic reduction in promoter activity in both HepG2 and Jurkat cells (64 and 77%
respectively), while deletion of the Spl sites appears to have no effect (Nunez &
Vedeckis, 2002 ).
However, these data also suggest that the relative contribution of these regulatory
elements is context-dependent. For example, while deletion of the four YY1 sites
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from the isolated IB promoter resulted in only a -30% decrease in activity in HeLa
cells (Nunez & Vedeckis, 2002), their deletion from a construct representing the
whole GR promoter led to a -60% reduction in activity (Breslin & Vedeckis, 1998).
This indicates that transcription from alternate exons 1 may be dependent upon their
context and position within the whole promoter, suggesting that isolation of discrete
fragments may not provide an accurate picture of the regulatory elements involved.
In this way, differences in the size and relative position of constructs representing
promoters 16 and 1 io in this study and the IB and 1C constructs used by Nunez et al
(Nunez & Vedeckis, 2002) and Breslin et al (Breslin & Vedeckis, 1998) may explain
the discrepancy in observed activities.
The suggestion that regulatory regions are context-dependent also has implications
for results relating to the activity of the 134bp PstI fragment. Transfection data
showed that the contribution of this fragment generated significantly higher activity
in the context of PI 7b than when isolated in front of a promoterless vector. It is
therefore possible that binding at the 134bp PstI fragment might be enhanced by
regulatory elements located outside the region. The contrast between the insignificant
promoter activity associated with Pl6 and Plio found during this investigation and
the predominance of exon U and 1 io-containing transcripts reported in rat tissues
(McCormick et al., 2000; McCormick, 2000) may also be explained by this
contextual dependence. That is, regulatory elements present in the whole promoter,
but not present in Pl6 or PI io, may increase the transcriptional activity of exons %
and 1 io.
The idea that activity of discrete elements in the GR promoter is dependent upon
their relative position and context within the whole region was enhanced by the
findings of experiments using the GR 5' deletion series. Results showed that while
the loss of sections between -4878 to -3339 and -1770 to -9 caused significant
decreases in activity in B103 cells, the presence of these regions in other constructs,
including Pl6 and pVL262, was not associated with significant activity. It therefore
appears that these regions are necessary, but not sufficient for high GR promoter
activity in B103 cells.
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The balance of evidence gained from this study and others therefore suggests that
transcription from alternate GR exons 1 is not directed by discrete exon 1-associated
promoters that act in isolation. Instead, transcriptional activity at alternate GR exons
1 is dependent upon regulatory interactions over the whole promoter. As such, a
model can be proposed in which individual exons 1 are not accompanied by
individual promoters; rather, transcription is initiated from multiple preferential sites
(giving rise to multiple exons 1) that lie within a large promoter 'region' (fig.7.1).
Under this model, the selection of individual exon 1 transcription initiation sites is
not of primary importance. Instead, transcription initiation at alternate exons 1 is
simply a consequence of the combined activity of regulatory elements positioned
over the whole promoter.
Several pieces of evidence gained during this investigation support this model. Under
this hypothesis, the splice donor sites associated with each exon 1 are of minimal
importance; the transcript is simply spliced at the next suitable donor site following
the initiation point. Consistent with this, transient transfections of P2 constructs
carrying mutations at the splice donor sites of either exons 1 io or 1 n, followed by
RT-PCR and sequence analysis, identified longer transcripts that were indeed spliced
at donor sites downstream of the mutations. Furthermore, mutagenesis of these sites
was not associated with any decrease in promoter activity.
If relatively indiscriminate transcription initiation is indeed occurring over the whole
CpG island region, this extended area of transcriptional activity should be
accompanied by a corresponding region of'open' chromatin. Accordingly, DNasel
hypersensitive site mapping identified a ~3kb region of transcriptionally active
chromatin, bounded by hypersensitive sites, that extended over the whole CpG island
region.
However, while transcriptional regulation of GR may not occur through the selection
of individual exon 1 transcription initiation sites, there are several advantages in
driving transcription from multiple start sites, particularly with regard to ensuring
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Figure 7.1 Alternative models ofGR promoter activity over the CpG island region.
Diagram showing two alternative models ofpromoter activity over the GR CpG
island region. Both exon 2 and exon li, which lies ~30.2kb upstream of exon 2, are
indicated. Mapped splice donor sites are marked with a triangle.
A: Each alternate exon 1 (shown in grey) is accompanied by an individual promoter
(shown in white). Transcription from each individual promoter is indicated by a
corner arrow.
B: The promoter 'region' is shown in white, within which transcription from multiple
initiation sites (labelled with wavy arrows) gives rise to multiple exons 1 (shown in
grey). Larger arrows are used to indicate transcription initiation from the two most







constitutive expression of this essential housekeeping gene. The data described here
present the intriguing possibility that GR expression, in which transcription is
indiscriminately initiated at several sites, might be rendered less vulnerable to
mutations. The mutagenesis experiments performed during this study show that the
GR promoter exhibits a great deal of resistance to mutation, even if the disruption is
not 'random' but directed at the splice donor sites crucial in maintaining 'normal'
exon 1 structure. This robustness would obviously be of enormous benefit to a
housekeeping gene such as GR, whose expression must be guaranteed in every cell.
Furthermore, the dual role of CpG islands as promoters and DNA replication origins
causes them to be under a greater mutational pressure than the rest of the genome
(Delgado et al., 1998; Antequera & Bird, 1999; Cuadrado et al., 2001). As such,
maintaining ubiquitous GR expression in the face of this large mutational burden
may require the protection of multiple sites of transcription initiation.
I therefore suggest that the primary function of alternate GR exons 1 within the CpG
island region is not one of tissue-specific regulation, but rather a way of ensuring
constitutive GR expression. In this way, individual exons 1 are not accompanied by
individual promoters that are selectively regulated in different tissues. Instead, tissue-
specific regulation occurs through interactions over the whole promoter 'region',
giving rise to characteristic exon 1 expression patterns. Furthermore, it appears that
after characteristic patterns of GR exon 1 expression are 'set' in different tissues, up-
or down-regulation of GR transcription does not act selectively at individual exons 1,
but on this pattern as a whole.
This proposal is supported by results gained from investigations into autoregulation
of the GR promoter. Strikingly, all constructs in the 3' deletion series, which
measures the activity associated with each individual exon 1, showed the same
degree of repression. It appears, therefore, that autoregulation does not operate by
repressing the expression of one or more individual exons 1 while leaving the others
unaffected, or indeed by down-regulating individual exon 1 activity to different
extents. This finding has been confirmed by in vivo work carried out in this
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laboratory, in which in situ hybridisation analysis of rat liver showed that individual
GR exons 1 were not selectively down regulated in dexamethasone-treated animals
(Freeman, 2003). Furthermore, RPA analyses of liver taken from dexamethasone-
treated rats showed that characteristic 'patterns' of GR exon 1 expression are
maintained following down-regulation (Freeman, 2003).
The number of characterised genes containing multiple promoters has increased
rapidly over the last decade. Many studies have speculated on the advantages gained
by such a transcriptional system, with the prevailing view that transcription from
multiple promoters permits additional flexibility in the control of gene expression
(Ayoubi & Van De Ven, 1996). In this way, multiple promoter regions can be seen to
provide all the regulatory elements needed for tissue- and/or development-specific
expression, as well as allowing responsiveness to hormonal and/or nutritional
stimuli. This was thought to be the case for GR, in which each alternate exon 1 was
supposed to be driven by an individual promoter, thus providing the required
flexibility of GR expression. However, results presented in this thesis provided an
alternative hypothesis. Under this model, the CpG island region of the GR promoter
occupies an extended area of active chromatin in which transcription occurs at
heterogeneous transcription initiation sites that give rise to multiple alternate exons
1. These alternate exons 1 are not accompanied by individual discrete promoters but
rather form part of a large promoter 'region'. As such, cells do not express specific
combinations of alternate exons 1; instead, all exons 1 are expressed in all cells.
Combinations of ubiquitous transcription factors, most probably including YY1 and
Spl, act at regulatory elements located over the whole promoter region to drive this
heterogeneous transcription. Tissue-specific levels of GR transcriptional activity are
regulated by these ubiquitous transcription factor combinations, which do not act
selectively at specific exons 1, but may produce tissue-specific 'patterns' of relative
exon 1 expression. This combined activity means that regional regulatory elements
are position- and context- dependent with regard to the whole promoter region.
Regulation of GR promoter activity is therefore not dependent upon the selection of
individual exon 1 transcription start or, indeed, splice donor sites. Similarly,
autoregulation of GR transcriptional activity does not occur in an exon 1-specific
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manner but instead dampens activity over the whole promoter region. However,
while selection of alternate exon 1 transcription initiation sites may not be of primary
importance to the tissue-specific or auto-regulation of GR, the multiple exon 1
structure does ensure that promoter activity is especially robust to mutations and thus
ensures the constitutive expression of this vital housekeeping gene.
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Cambrex Bio Science Wokingham Ltd., 1 Ashville Way, Wokingham, Berks.,
RG41 2PL, U.K.
Eppendorf AG, Barkhausenweg 1, 22331 Hamburg, Germany
Greiner Bio-One Ltd., Brunei Way, Stroudwater Business Park, Stonehouse, Glos.,
GL10 3SX, U.K.
IKA Labortechnik, IKA-Werke GmbH & Co. KG, Janke & Kunkel-Str. 10, D-
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Invitrogen, Ichinnan Business Park, 3 Fountain Drive, Paisley, PA4 9RF, U.K.
Kendro Laboratory Products Pic., Stortford Hall Park, Bishhop's Stortford, Herts.,
CM23 5GZ, U.K.
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Appendix II: The rat GR promoter sequence
The sequence of 5'-DNA flanking exon 2 of the rat GR gene is shown below.
Numbering is with respect to the translation start, +1. Underlined sequence in red
indicate exon 1 sequences found in 5'-RACE PCR clones amplified from
hippocampal GR mRNA. In the case of exon 16 (which was not represented
among the 5'-RACE clones), the red underlined nucleotides are those present in
the published rat cDNA sequence (Miesfeld, 1984). Blue sequences represent
primers used in GR exon 1 specific PCR reactions.The start of exon 2 is at -13.
Adapted from McCormick et al., 2000.
- 4 6 0 0 tagtataggttttccttcttgaggtatcaagcttctattcctttgccaagatggctgccctggatcccatggaggtagcgaccgtgcggcatctctgccc
- 4 5 0 0 aaggagcccgcttacagtcacgttctccccgtgcaaagcggacgatacattgggcagcctttaagcttttcatccaagaaagaacgactcgggtttgacg
- 4 4 0 0 ccaaagagcacctttgccaagatggtgaccgtgcggcgtcactgctctttaccaagatggcggcgagggacttccggcacgcgcttccccaatcagggat
- 4 3 0 0 ctccaagaggtcaggcagaggagaccgcccttggagtcgaagtgcggcgcgagccgcttctgccgcccgccgcgggagggcatgaggtggagtcatggcc
-4200 acctccgctctaatcagaagtgccaagcgctggc'acct'gtgggggagcaaaagttacttc'cttgcaccccaaagcaacaccgtaacacctttcccggagt
-4100 cccccaaatcctagcctatqgcatgaggtagaggggcacggtcccggcgtcgccccagcctgcctaacacagaggacacccgaggggcaggtactgcgcg
- 4 0 0 0 gccgcacagtcaccctacgcccctttcctgtcctagggggaccggccatgtgtttctcttggagacccggggactcgtattgggcacagctggacggagc
- 3 9 0 0 taaaagctgacgttttaaagatgcatgtttttgttttatttggagggacagaggggtccctggaacccagaaagctgagcaaggcaccgagcctggagca
- 3 8 0 0 gcaaatgtcaagattcgggggaggggcctccgcggggagcttggatgctggccccgaagggggtggaaggagaggtcaggagtttgggtaagaggagggc
-3 7 0 0 ggacttcagcagcaacttactattcggtctgcaacttgcttctaggcctgcacacaccccctcccgccccgcaaggcttccttaatcacaattttttttt
- 3 6 0 0 taagtgcaaagaaacccagctctctgagagggttttgcattcggcatgcaacttcctccgagtgtgagcgcgctggcaggcggggagggagcggtggggg
- 3 5 0 0 ttgaacttggcaggcggcgcctcctgctgccgccgccgccgccgcctctcagactcggggaagagggtgggggacgatcggggcgcgggggagggtgggt
- 3 4 0 0 tctgctttgcaacttctcccggttgcgagcgagcgcgcgcgcggcggcggcggcggcggctgcagacggggccgcccagacgctgcgggggtgggggacc
- 3 3 0 0 tggcggcacgcgagtccccccccgggctcacagtatgtatgcgctgaccctctcctctgcgctcccctccccaggcctccccagagggcgtgtctgcagt
- 3 2 0 0 cctgccccgagagcaagcggccagggctctgcggcaccgtttccgtgccatcctgtagcccctctgctagtgtgacacacttcgcgcaactccgcagttg
-3100 gcgggcgcggaccacccctgcggctctgccggctggctgtcaccctcgggggctctggctgccgacccacggggcgggctcccgagcggttccaagcctc
- 3 0 0 0 ggagctgggcgggggcgggagggagcctgggagaagagaaactaaagaaactcggtttccctcccaqgccaggtcggcacccgctgccgcactttttctc
- 2 9 0 0 gttccttgggtggggaaaggcgaagccgcgggccccagcgaggcgatgccctgagccgcgggcttgcaggcgccgtcggggccgggctggcgggtaccgc
- 2 8 0 0 gcgctgggagaaaagagggcgagggccacgggcgcccttgcagttgccgacagtcgccaacaggttgcaccgttccccgcggccgcgcggcccctcgggc
- 2 7 0 0 ggggagcggccgggggtggagtgggagcgcgtgtgtgcgagtgtgtgcgcgccgtggcgccgcctccgcccgcccctcgctcggtcccgctcgcctgccg
- 2 6 0 0 cggc'cgggcggccc'tttcgc'gtgtc'cgcgc'tccc'c'cc'cctcccctcc'gcctcctccattttgcgagctcgagtcagtgcctggagcccgagtcgccgccc
- 2 5 0 0 gcccgtcggggacggattctaagtgggtggaacaagacgccgcagccgggcggcgcggcgccgggacgggggacgcgcgcgggagacgggagcggcgcgg
-2400 gggcccggcttgtcagccgggaacgggtgactttcagcgctaggggctctcccctcccccatggagaagagggggcgactgttgacttccttctccgtga
-2300 cacgcgcgcctcccgcgtccgcacgccgacttgtttatctggctgcggtgqgagccgcgagcgggcgagcgcgcqggtgctgaggtgagcgggggctggg
- 2 2 0 0 cgagcgggcgagcggggccggcccgcgctgaggtgagccggactgggcgcgctcccctaggggctcggcaccgggggcggccggacttggcaaacttttg
- 2100 ccagcccggggttgggggtggaggctggcgagggcagggtgacggtgacgaaagggccttggcggtgacagcgctggcgcttcctctccccgcaccgcca
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